Abstract
ATTD 2022 Invited Speaker Abstracts A‐1 ATTD 2022 Oral Presentation Abstracts A‐23 ATTD 2022 E-Poster Viewing Abstracts A‐80 ATTD 2022 Read By Title A‐235 ATTD 2022 Abstract Author Index A‐238
ATTD 2022 Invited Speaker Abstracts
PLENARY ‐ PREVENTION AND CURE OF TYPE 1 DIABETES (PART 1)
CAN WE ARREST TYPE 1 DIABETES?
University Hospitals Leuven, Endocrinology, Leuven, Belgium
After 100 years of insulin therapy, our insights in the pathogenesis of type 1 diabetes (T1D) have evolved and using the combination of genetic risk and presence of autoantibodies in the blood has allowed us to progress in the prediction of risk. Consortia worldwide are exploring the value of novel biomarkers and evaluate interventions targeting arresting progression of beta‐cell destruction in people with newly diagnosed T1D or in those at risk of T1D. In Europe, the IMI2‐funded projects INNODIA and INNODIA HARVEST focus on novel biomarker discovery and the consortium is executing 4 clinical trials in people with newly diagnosed T1D. An overview of activities, as well as the evolution of novel therapies for prevention and arrest of T1D will be discussed.
PLENARY ‐ ARTIFICIAL INTELLIGENCE AND PERSONALIZED MEDICINE IN DIABETES CARE
BIG DATA IN DIABETES CENTERS AND HOSPITALS – WHAT DO WE DO WITH IT?
Children's Mercy Kansas City, Pediatric Endocrinology, Kansas City, United States of America
Diabetes centers, healthcare systems, and individuals with diabetes generate many types of data about diabetes‐related outcomes and about self‐management behaviors, comorbid medical conditions, and clinical care‐related events. Yet only a small fraction of these data are used by clinicians regularly for decisionmaking. Risk‐based management protocols can help diabetes centers to improve both the quality and cost‐efficiency of care. These protocols may be driven by biomarkers of risk extracted or derived from electronic health records, diabetes self‐management devices (or the cloud services that receive their data), and digital patient reported outcomes platforms; protocols may alternately be driven by forecasting of negative outcomes via Artificial Intelligence/Machine Learning approaches. The participation by diabetes centers in Learning Health Networks, with data sharing to a central data repository, can accelerate Big‐Data‐driven quality‐improvement of care delivery. The presenter will review examples of risk‐based management approaches using each technique, including novel biomarker‐based risk indices like the 6 Habits of self‐management, the Diabetes Care Index, and the Risk Indexes for Poor Glycemic Control and for Diabetic Ketoacidosis (RI‐PGC and RI‐DKA, respectively). The presenter will further examine the current state of algorithms and AI/ML to manage population health in diabetes clinics, including a population health dashboard to reduce deterioration in glycemic control in the post‐diagnostic period for type 1 diabetes, a precision medicine project for type 2 diabetes incorporating multiple ‐omics biomarkers, and the Rising T1DE Alliance, which seeks to implement multiple ML models to predict outcomes in clinical care, and to test remote patient monitoring along with multiple digital and behavorial health interventions to improve those predicted outcomes via a risk‐based management approach.
PLENARY ‐ ARTIFICIAL INTELLIGENCE AND PERSONALIZED MEDICINE IN DIABETES CARE
TELEHEALTH USE ACROSS THE LIFESPAN WITH DIABETES
Harvard Medical School, Joslin Diabetes Center, Boston, United States of America
The COVID‐19 pandemic required the urgent deployment of a telehealth approach to deliver diabetes care across regions and across the lifespan. A number of observational studies have documented the use of telehealth in people with type 1 and type 2 diabetes from childhood through the older adult population. While the pandemic brought multiple inconveniences to all of us, it permitted health care delivery systems and providers to utilize remote care delivery in a previously unprecedented manner. As a result, a number of these observational studies have a demonstrated that provision of telehealth services maintained needed care processes and some studies have even demonstrated either maintenance or potential improvement in glycemic outcomes. Data from the Joslin Diabetes Center offer observational information on how telehealth was deployed either via telephone or video modalities in various age groups. In addition, these data help us to evaluate the utility of telehealth services in different segments of the population living with diabetes, for example, according to age or modality of their diabetes treatment. Finally, telehealth services provided opportunities even to initiate diabetes treatment in those newly diagnosed and to implement changes in diabetes management for those with established diabetes, including the implementation of advanced diabetes technologies. These issues will be discussed in the symposium.
PARALLEL SESSION ‐ UPDATE ON GLUCOSE AND KETONE MONITORING
NEWER CONTINUOUS GLUCOSE MONITORING SYSTEMS
1Barbara Davis Center for Childhood Diabetes, Endocrinology, Aurora, United States of America, 2University of Colorado Denver, School Of Medicine, Aurora, United States of America
“
PARALLEL SESSION ‐ UPDATE ON GLUCOSE AND KETONE MONITORING
IMPLANTABLE GLUCOSE AND KETONE MONITORING
University Hospital Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Endocrinology‐diabetology‐metabolism, Antwerp, Belgium
Living with type 1 diabetes (T1D) is challenging as it requires intensive monitoring of glucose levels, nutritional intake and physical activity, and correct titration of insulin in order to obtain near‐normal glucose levels. The Endocrine Society has proposed real‐time continuous glucose monitoring (RT‐CGM) as the gold standard for people with T1D. RT‐CGM devices display interstitial glucose levels around the clock and are designed to set off alarms to warn people when glucose levels are trending too high or too low. The evolution in pump and CGM technology has led to the development of hybrid closed loop (HCL) systems where basal insulin delivery is automatically guided by sensor glucose values using an algorithm. CGM and HCL systems have demonstrated improvements in HbA1c, time spent in hypoglycaemia, hospitalisations for severe hypoglycaemia or ketoacidosis, and quality of life. However, there are still some shortcomings with currently available CGM devices. Firstly, currently available sensors rely entirely on continuous glucose measurements and do not provide an alert for high ketone levels or impending diabetic ketoacidosis (DKA). Monitoring ketones is also advised for sick‐day management, but in reality many at‐risk patients do not have ketone test strips at home. Production of ketone bodies may occur as a result of insulin deficiency (e.g. in case of pump failure or inadequate bolus dosing), sickness, insufficient intake of carbohydrates (very low calorie diet), or sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐i) therapy. Continuous ketone monitoring (CKM) may facilitate earlier detection of ketones, thereby possibly reducing hospitalisations for DKA in high‐risk patients. The first‐in‐human results obtained in 12 volunteers of a CKM device were published in 2021 by Alva et al. The electrochemical sensor used wired enzyme to measure β‐hydroxybutyrate (BHB), the major pathologic analyte. This sensor delivered a linear response over the 0‐8 mM range with good accuracy and stability, both in vitro and in vivo, for 14 days. With a single retrospective calibration the mean absolute difference (MAD) for BHB concentrations <1.5 mM was 0.129 mM and 91.7% of the sensor results were within ±0.3 mM of the reference. For BHB ≥1.5mM the mean absolute relative difference (MARD) was 14.4%. Teymouran et al. reported data of a new real‐time CKM microneedle platform based on the electrochemical monitoring of BHB alongside with glucose. This sensor detects BHB based on the NAD‐dependent dehydrogenase enzyme and a selective low‐potential fouling‐free anodic detection of NADH using an ionic liquid‐based carbon paste transducer electrode. In vitro data showed that the sensor had a high sensitivity (with low detection limit, 50 μM), high selectivity in the presence of potential interferences, along with good stability. The BHB microneedle sensor has been coupled with an oxidase‐based glucose microneedle sensor on the same array platform, leading to an attractive sensor array towards the simultaneous real‐time continuous monitoring of both glucose and ketones. The ability to detect lactacte has also been demonstrated based on lactate oxidase catalyzed lactate oxidation to pyruvate. A third sensor that has been developed by Indigo Diabetes nv is an implantable continuous multimetabolite sensor monitoring glucose, BHB, and lactate using near‐infrared (NIR) spectroscopy technology with an expected lifetime of 2 years. In a first‐in‐man study, exploratory data on accuracy were promising (95.6 % of all data points for glucose ranging between 40‐400 mg/dl were located in zone A, a MAD of 10.5 mg/dl for values between 40 and 70 mg/dl and a MARD of 10% for values between 70‐180 mg/dl and of 4% for values >180 mg/dl were observed). Administration of paracetamol, acetylsalicylic acid, ibuprofen, sorbitol, caffeine, fructose, aspartame and vitamin C did not significantly influence the accuracy of glucose measurements. Also for BHB good accuracy was observed. Continuous measurement of ketones was compared to blood strip measurements over a physiological range of 0‐4 mM; the sensor showed a MAD of 0.19 mM. The lactate concentrations measured over a range of 0‐20 mM showed an MAD of 0.53 mM in relation to Biosen EKF reference measurements in blood. A second area of concern relates to the design of current sensors, patient's experiences and costs. The short sensor lifespan, the likelihood of accidental sensor dislocation, the occurrence of skin reactions, and privacy reasons (keep their diabetes hidden), limit the implementation of these sensors. The Indigo Diabetes nv sensor is a miniaturized near‐infrared spectrometer on a silicon photonics chip that measures optical transmittance in the interstitial fluid at up to 24 wavelengths between 1680 and 2400 nm. The sensor is covered by a biocompatible silicone envelope. It is implanted subcutaneously in the abdominal region and has an expected lifespan of 2 years or more. In summary, there is a compelling need for a patient tailored device that is implantable, has a long lifespan and continuously monitors multiple biomarkers thereby helping to prevent episodes of hypoglycaemia or ketoacidosis under all circumstances (exercise, illness, SGLT2i therapy, very low carb diet), and possibly increasing quality of life.
PARALLEL SESSION ‐ HYPOGLYCEMIA
USING TECHNOLOGY AND BEHAVIOR CHANGE TO ADDRESS THE HYPO AVERSE PATIENT
Behavioral Diabetes Institute, N/a, San Diego, United States of America
Individuals with type 1 diabetes and type 2 diabetes often harbor excessive worries and concerns regarding hypoglycemia, which can impair their quality of life as well as their ability to achieve favorable glycemic outcomes. Technological interventions, such as the introduction of RT‐CGM or hybrid closed‐loop pumps, as well as behavioral interventions, such as BGAT (Blood Glucose Awareness Training), have been shown to reduce hypoglycemic fear and/or enhance hypoglycemic confidence, though the effect sizes are typically modest. This presentation will describe how new clinical interventions that integrate the two approaches, both technological and behavioral, may be even more efficacious, especially in those cases where hypoglycemic fears and worries are overwhelming. Through the description of actual cases, practical tips for addressing excessive hypoglycemic worries will be introduced and suggestions for future research investigations will be presented.
PARALLEL SESSION ‐ HYPOGLYCEMIA
LOW‐DOSE GLUCAGON – FOR “OPEN‐LOOP” HYPOGLYCEMIA PREVENTION
Steno Diabetes Center Copenhagen, Herlev, Denmark, Clinical Research, Herlev, Denmark
When striving for strict metabolic control to reduce late‐onset diabetes complications, episodes of mild hypoglycemia occur frequently in type 1 diabetes (T1D) due to relative insulin overdosing. Strategies aimed at preventing mild hypoglycemia have traditionally been limited to lowering the insulin dose and increasing the consumption of oral carbohydrates. Since obesity is a growing problem in T1D, it has been hypothesized that avoiding the extra caloric intake associated with supplementary carbohydrates to prevent hypoglycemia can help maintain a positive weight balance. In the last few decades, where the development of closed‐loop treatment has taken place, several academic research groups have gathered experience with dual‐hormone (glucagon and insulin) closed‐loop treatment. Systematic reviews have shown superiority of dual‐hormone to single‐hormone closed‐loop systems in lowering the incidence of hypoglycemia. Yet, no dual‐hormone closed‐loop system has been brought to market and used in clinical practice. Until recently, glucagon was only available in powder form, but several companies have now developed soluble glucagon. Soluble glucagon is available not only in vials but also in injection pens. This opens up the possibility for people with T1D to self‐administer low‐dose glucagon as a means to prevent and/or treat mild hypoglycemia, independent of their insulin regime per se. The objective of this talk is to present studies in which the efficacy, safety, and feasibility of injecting low‐dose native or soluble glucagon on different causes of hypoglycemia in T1D have been assessed.
PARALLEL SESSION ‐ COVID‐19 AND DIABETES
OVERALL DIABETES MORBIDITY AND MORTALITY WITH COVID‐19
University of Colorado, Barbara Davis Center For Diabetes, Aurora, United States of America
PARALLEL SESSION ‐ COVID‐19 AND DIABETES
THE DANGER OF HYPERGLYCEMIA DURING COVID‐19
IRCCS MultiMedica, Diabetes Research, Milan, Italy
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an RNA beta‐coronavirus responsible for the coronavirus disease 2019 (COVID‐19). COVID‐19 encompasses a large range of disease severity, from mild symptoms to severe forms with Intensive Care Unit admission and eventually death. The severe forms of COVID‐19 are usually observed in high‐risk patients, as those with type two diabetes mellitus. Acute hyperglycemia at hospital admission represents a risk factor for poor COVID‐19 prognosis in patients with and without diabetes. Acute and chronic glycemic control are both emerging as major determinants of vaccination efficacy, disease severity, and mortality rate in COVID‐19 patients. Mechanistically, it has been proposed that hyperglycemia might be a disease‐modifier for COVID‐19 through multiple mechanisms: 1‐ induction of glycation and oligomerization of ACE2, the main receptor of SARS‐CoV‐2; 2‐ increased expression of the serine protease TMPRSS2, responsible for S protein priming; 3‐ impairment of the function of innate and adaptive immunity despite the induction of higher pro‐inflammatory responses, both local and systemic. Consistently, managing acute hyperglycemia through insulin infusion has been suggested to improve clinical outcomes while implementing chronic glycemic control positively affects the immune response following vaccination. Here, we review the available evidence linking acute and chronic hyperglycemia to COVID‐19 outcomes, describing also the putative mediators of such interactions and proposing glycemic control as a potential route to optimize disease prevention and management.
PARALLEL SESSION ‐ COVID‐19 AND DIABETES
WORLDWIDE EFFECTS OF COVID‐19 PANDEMIC ON CHILDREN WITH DIABETES: RESULTS FROM THE SWEET REGISTRY
Children's and Adolescent‘s Hospital „AUF DER BULT“,, Hannover, Hannover, Germany
PARALLEL SESSION ‐ CLOSED‐LOOP USERS' EXPERIENCE
CLOSED‐LOOP IN VERY YOUNG CHILDREN
1University of Cambridge, Wellcome‐mrc Institute Of Metabolic Science‐metabolic Research Laboratories And Medical Research Council Metabolic Diseases Unit, Cambridge, United Kingdom, 2University of Cambridge, Department Of Paediatrics, Cambridge, United Kingdom
It is well recognised that hybrid closed‐loop insulin delivery improves glycaemic control and quality of life in older children and adolescents with type 1 diabetes, but data in very young children is limited. As a result, the majority of commercially available closed‐loop systems are not licensed for use in this age‐group. While challenging to manage at any age, maintaining recommended glycaemic control is particularly difficult in very young children, due to their high variability of insulin requirements and unpredictable eating and activity patterns. In this talk we discuss the specific challenges of diabetes management in very young children and how hybrid closed‐loop therapy might address these. We review most recent published evidence in this age‐group, including results of the longest randomised closed‐loop study in very young children to date, which showed significant improvements in glycaemic control with closed‐loop therapy. Finally, we identify areas for future research with regards to closed‐loop technology tailored for very young children and how these might alleviate disease burden.
PARALLEL SESSION ‐ CLOSED‐LOOP USERS' EXPERIENCE
PARENTS' EXPERIENCES OF, AND VIEWS ABOUT, USING A HYBRID CLOSED‐LOOP SYSTEM TO CARE FOR A VERY YOUNG CHILD WITH TYPE 1 DIABETES: QUALITATIVE STUDY
1University of Edinburgh, Usher Institute, Edinburgh, United Kingdom, 2University of Cambridge, Wellcome‐mrc Institute Of Metabolic Science‐metabolic Research Laboratories And Medical Research Council Metabolic Diseases Unit, Cambridge, United Kingdom, 3University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 4Department of Pediatrics and Adolescent Medicine, Medical University Of Graz, Graz, Austria, 5Hospital for Children and Adolescents, University Of Leipzig, Leipzig, Germany, 6Department of Pediatric and Adolescent Medicine, Medical University Of Vienna, Vienna, Austria, 7Centre Hospitalier, Department Of Pediatric Diabetes And Endocrinology, Luxembourg City, Luxembourg
Objectives: We explored parents' experiences of using a hybrid closed‐loop system (CamAPS FX) when caring for a very young child (aged 1‐7 years) with type 1 diabetes to better understand how this technology can affect their own, their child's and wider family life. Methods: We interviewed n = 33 parents of 30 children who used the closed‐loop system during a randomised controlled trial (KidsAP02 study). Data were analysed using a descriptive thematic approach. Findings: As well as highlighting clinical benefits to using the closed‐loop system, parents reported wide‐ranging quality‐of‐life benefits. Parents described sleeping better and worrying less about their child due to the system's ability to help keep glucose in range and their own ability to remote monitor insulin and glucose data. Parents also described being better placed to get on with their own lives (e.g., returning to employment) as caregiving demands were lessened, other people felt more confident caring for their child, and parents felt more confident entrusting their child's care to others. They also noted how their child had more opportunities to socialise with peers and experienced improved concentration and mood due to better glucose control, improved sleep and not being distracted by diabetes management tasks. Siblings also benefited from parental time and effort no longer being so focused on diabetes management. Discussion: Our findings suggest that, alongside clincal benefits, using a closed‐loop system can have life changing consequences for parents, young children with type 1 diabetes and their siblings.
PARALLEL SESSION ‐ CLOSED‐LOOP USERS' EXPERIENCE
TEAMWORK, TARGETS, TECHNOLOGY, AND TIGHT CONTROL (4T PROGRAM): PERSONALIZED MEDICINE AT POPULATION SCALE, TECHNICAL, FINANCIAL, AND ADVOCACY CHALLENGES
Stanford University, Pediatric Endocrinology & Diabetes, Stanford, United States of America
Translation of optimal diabetes outcomes from the Diabetes Control and Complications Trial and diabetes technology research to routine clinical care has been suboptimal. The Stanford Pediatric Diabetes Team designed, implemented, and iterated on a pragmatic research study: ‘Teamwork, Targets, Technology, and Tight Control (4T Program)’ with the goal of improving care after diagnosis of type 1 diabetes in pediatric patients. We hypothesized that early introduction of CGM and systematic education combined with reducing the friction of CGM analysis to allow for more timely education interventions and dose adjustments would result in improved glucose metrics and quality of life. Pilot study data will be reviewed as well as approaches to technical and financial challenges to scaling the 4T program to a larger patient population in our clinic and to share the 4T program with other diabetes centers. Future directions include systematically implementing automated insulin delivery, scaling the 4T project to a wider population within our clinic and in collaboration with external colleagues, incorporating an exercise education sub‐study, and advocating for better insurance coverage for diabetes care for all. We would like to thank the other members of the 4T Study Group for their help with this project. Study team members include: Brianna Leverenz, BS, Julie Hooper MPH, RD, Ana Cortes, BS, Franziska Bishop, MS, CDCES, Natalie Pageler, MD, Jeannine Leverenz, RN, CDCES, Piper Sagan, RN, CDCES, Anjoli Martinez‐Singh, RD, CDCES, Barry Conrad RD, CDCES, Annette Chmielewski, RD, CDCES, Julie Senaldi RN, CDCES, Nora Arrizon‐Ruiz, Erica Pang, BS, Carolyn Herrera, BS, Victoria Ding, MS, Rebecca Gardner, MS, Kim Clash, NP, Erin Hodgson, RD, CDCES, Johannes Ferstad BS, Ryan Pie, MS, Michael Gao, BS, Annie Chang, BS, Simrat Ghuman, PhD, Priya Prahalad MD, Ananta Addala MD, Dessi Zaharieva PhD, Korey Hood PhD, Manisha Desai PhD, Ramesh Johari PhD, David Scheinker PhD and Esli Osmanlliu, MD
PARALLEL SESSION ‐ BRAIN AND DIABETES
DEVELOPING BRAIN IN CHILDREN: A LONGITUDINAL DIRECNET STUDY
Yale University, Pediatrics, New Haven, United States of America
It has been increasingly appreciated that chronic exposure to hyperglycemia is detrimental to the brain, particularly during the critical periods of growth and development in young children. The Diabetes Research in Children Network conducted a longitudinal study focused on neuroanatomical and cognitive consequences of type 1 diabetes (T1D). Over six years of study, we conducted unsedated MRI, cognitive testing batteries, and continuous glucose monitoring assessments in 144 children with diabetes and 72 age‐matched controls, beginning at the age of 4‐9; compared anatomical and cognitive outcomes between groups; and within the T1D group, correlations with measures of glycemia. Total brain, gray and white matter volumes, and full‐scale and verbal intelligence quotients were lower in the T1D group at all assessment points, and rates of growth of cortical and subcortical gray and white matter were consistently slower in T1D children over this time period spanning childhood and early puberty. Within the T1D group, brain volumes and cognitive scores were negatively correlated with higher CGM‐measured glucose levels and a calculated lifetime A1c index. Resting‐state fMRI demonstrated increased functional connectivity in executive function control areas in the T1D group, suggesting a mechanism to compensate for the adverse effects of dysglycemia to maintain cognitive and behavioral performance. The need for improved control of hyperglycemia during the developmental window of childhood and puberty is clear. A recently completed six‐month pilot study utilizing automated delivery systems in adolescents with T1D may help to determine the potential impact of improved short‐term glycemic control on these critical anatomic and cognitive outcomes.
PARALLEL SESSION ‐ SPORTS AND DIABETES
EXERCISE AND TYPE 1 DIABETES: PRELIMINARY RESULTS FROM THE TYPE 1 DIABETES EXERCISE INITIATIVE (T1DEXI)
York University, School Of Kinesiology And Health Science, Toronto, Canada
Regular exercise has numerous health and fitness benefits for people living with type 1 diabetes, however the acute management of glycemia during and after a bout of exercise remains a major clinical challenge. The Type 1 Diabetes Exercise Initiative (T1Dexi) is a real‐world study designed to create a shareable dataset that will help researchers better understand modifiable and non‐modifiable factors that may influence the glycemic responses to different types of exercise in those living with type 1 diabetes. This session will highlight results of a one‐month observational study of exercise‐related glycemia from 497 adults in the US living with type 1 diabetes (n = 183 on standard pump therapy; n = 226 on hybrid closed loop; n = 88 on multiple daily injections). Participants self‐reported physical activity events, including randomized assignment to study‐designed aerobic, resistance or interval type exercise, and food intake using a custom smart phone application. Data collection also included insulin delivery and activity monitors (Polar heart rate chest strap, Verily Health Watch) to contextualize each activity event and relate to exercise‐associated changes in glycemia as assessed by continuous glucose monitoring (Dexcom G6).
PARALLEL SESSION ‐ SPORTS AND DIABETES
SEPARATING INSULIN‐MEDIATED AND NON‐INSULIN‐MEDIATED GLUCOSE DISPOSAL DURING AND AFTER DIFFERENT FORMS OF EXERCISE IN DIABETES. PHYSIOLOGICAL EFFECTS THAT MAY IMPACT AUTOMATED INSULIN DELIVERY
1Oregon Health & Science University, Endocrinology, Diabetes And Nutrition, Portland, United States of America, 2Oregon Health & Science University, Internal Medicine, Portland, United States of America, 3Oregon Health & Science University, Endocrinology, Portland, United States of America, 4Oregon Health & Science University, Biomedical Engineering, Portland, United States of America, 5Oregon Health and Science University, Biomedical Engineering, Portland, United States of America, 6Oregon Health and Sciences University, Endocrinology, Portland, United States of America
PARALLEL SESSION ‐ SPORTS AND DIABETES
INTEGRATING METABOLIC EXPENDITURE DATA FROM WEARABLE SENSORS INTO AN AUTOMATED INSULIN DELIVERY SYSTEM: CLINICAL STUDY RESULTS
1Oregon Health & Science University, Biomedical Engineering, Portland, United States of America, 2Oregon Health and Science University, Biomedical Engineering, Portland, United States of America, 3Oregon Health and Sciences University, Endocrinology, Portland, United States of America, 4Oregon Health & Science University, Endocrinology, Portland, United States of America, 5Oregon Health & Science University, Endocrinology, Diabetes And Nutrition, Portland, United States of America
PARALLEL SESSION ‐ SPORTS AND DIABETES
GLUCOSE CONTROL DURING EXERCISE USING AUTOMATED INSULIN DELIVERY IN TYPE 1 DIABETES
1University of Ljubljana, Faculty Of Medicine, Ljubljana, Slovenia, 2University Children's Hospital, 2. department Of Pediatric Endocrinology, Diabetes And Metabolic Diseases, Ljubljana, Slovenia
While the benefits of regular physical activity are well established for individuals with type 1 diabetes, glucose control remains a challenge with conventional therapeutic tools, especially during and after physical activity. Factors affecting glycemic control include activity type (aerobic, anaerobic or mixed), intensity and duration of the activity, level of hydration, the secretion of counter‐regulatory hormones as well as the amount of insulin and nutrients in the body, when the physical activity is performed. Glucose‐responsive automated insulin (and glucagon) delivery is now a routine clinical reality for many individuals living with type 1 diabetes. There are several automated insulin delivery systems are already available, at the same time there are several other devices extensively evaluated at home, mainly unsupervised, and for longer periods. The performance of automated insulin delivery devices has been challanged with different types of physical activity, using different exercise settings and duration, adding additional signals to detect physical activity, such as activity and heart rate monitoring, and including individuals with type 1 diabetes of different ages. In this presentation, we will present current data on automated insulin delivery in type 1 diabetes challenged by physical activity.
PARALLEL SESSION ‐ JDRF SESSION ‐ UTILITY OF PROS IN THERAPY DEVELOPMENT FOR TYPE 1 DIABETES: PUTTING THE END‐USER UPFRONT
PRO WORK ON THE INTANDEM STUDIES AND PROPOSE A FORWARD‐LOOKING STRATEGY ON PROS FOR DKD
Lexicon Pharmaceuticals, Inc., Chief Medical Officer, The Woodlands, United States of America
PATIENT‐REPORTED OUTCOMES IN THE inTANDEM STUDIES AND PROPOSAL FOR A FORWARD‐LOOKING STRATEGY ON PATIENT‐REPORTED OUTCOMES FOR DIABETIC KIDNEY DISEASE IN TYPE 1 DIABETES Presenter: Craig Granowitz Affiliation: Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA
PARALLEL SESSION ‐ JDRF SESSION ‐ UTILITY OF PROS IN THERAPY DEVELOPMENT FOR TYPE 1 DIABETES: PUTTING THE END‐USER UPFRONT
PATIENT‐REPORTED OUTCOMES ASSOCIATED WITH CELL THERAPY IN T1D
ViaCyte, Head Of Clinical Development, San Diego, United States of America
Some patients living with type 1 diabetes (T1D) are participating in clinical trials of cell therapy. As these trials advance, Physician Investigators and clinical trial Sponsors are learning more about outcomes desired and experienced by patients. Three themes that emerge in this setting are fear of hypoglycemia, a reduction of the burden of daily management of T1D, and a desire for better glycemic control in order to reduce the risk for micro‐ and macro‐vascular complications. Hypoglycemia has a major impact on patients and their behavior,1 and a history and fear of severe hypoglycemia may be a prominent concern driving interest in cell therapy; these issues are even more pronounced for parents and their offspring. For others, cell therapy may be attractive because it does not require daily monitoring. HbA1C control is recognized as important by patients, yet its improvement has to be tempered by reducing hypoglycemia risk and improving glucose time in range, in the context of simplifying the burden of T1D management. Recent experience suggests that patients with T1D and hypoglycemia unawareness in particular have a strong interest in cell therapy. The interest exists despite the availability of continuous glucose monitoring and advancements in diabetes technological tools. Patients suggest that cell therapy can be successful in several dimensions other than A1C control, and it can be attractive without offering complete insulin independence. Patient personal experiences may not always be related to changes in traditional clinical indicators2 including A1C. Questionnaires used in clinical trials help capture real‐time feedback from patients with T1D and can help illuminate both benefits and burdens associated with these interventions. Given the diversity of perspectives and the lack of PRO questionnaires specific to diabetes cell therapy, additional research should include qualitative interviews of patients receiving cell therapy and validation of these instruments. Interviews in the clinical trial setting may be a good supplement for capturing clinically meaningful patient‐reported outcomes. References: 1. K. Khunti, S. Alsifri, R. Aronson, M. Cigrovski Berković, C. Enters‐Weijnen, T. Forsén, G. Galstyan, P. Geelhoed‐Duijvestijn, M. Goldfracht, H. Gydesen, R. Kapur, N. Lalic, B. Ludvik, E. Moberg, U. Pedersen‐Bjergaard and A. Ramachandran. 2017. Impact of hypoglycaemia on patient‐reported outcomes from a global, 24‐country study of 27,585 people with type 1 and insulin‐treated type 2 diabetes. Diabetes research and clinical practice, 130, 121‐129. 2. L. Fisher, W. Polonsky, V. Bowyer and D. Hessler. 2020. When patient‐reported experience does not match change in clinical outcomes: A perplexing view from the inside of a diabetes distress intervention. Journal of diabetes and its complications, 34(4), 107533. 3. S. N. DuBose, C. Bauza, A. Verdejo, R. W. Beck, R. M. Bergenstal, J. Sherr and H. S. Group. 2021. Real‐World, Patient‐Reported and Clinic Data from Individuals with Type 1 Diabetes Using the MiniMed 670G Hybrid Closed‐Loop System. Diabetes technology & therapeutics, 23(12), 791‐798.
PARALLEL SESSION ‐ SOCIOECONOMIC BARRIERS & DISPARITIES TO DIABETES TECHNOLOGY
EXPERIENCE IN THE UNITED STATES
Stanford University, Pediatric Endocrinology & Diabetes, Stanford, United States of America
Diabetes technology has improved quality of life, increased time‐in‐range, and decreased hypoglycemia over the past decade. Healthcare in the US is inequitable, including care for people with diabetes. Recent data on disparities in diabetes technology use and outcomes will be reviewed. Local and national efforts to improve access to diabetes technology and to improve outcomes with the goal or reducing socioeconomic disparities will be described. We would like to thank the other members of the 4T Study Group for their help with this project. Study team members include: Brianna Leverenz, BS, Julie Hooper MPH, RD, Ana Cortes, BS, Franziska Bishop, MS, CDCES, Natalie Pageler, MD, Jeannine Leverenz, RN, CDCES, Piper Sagan, RN, CDCES, Anjoli Martinez‐Singh, RD, CDCES, Barry Conrad RD, CDCES, Annette Chmielewski, RD, CDCES, Julie Senaldi RN, CDCES, Nora Arrizon‐Ruiz, Erica Pang, BS, Carolyn Herrera, BS, Victoria Ding, MS, Rebecca Gardner, MS, Kim Clash, NP, Erin Hodgson, RD, CDCES, Johannes Ferstad BS, Ryan Pie, MS, Michael Gao, BS, Annie Chang, BS, Simrat Ghuman, PhD, Priya Prahalad MD, Ananta Addala MD, Dessi Zaharieva PhD, Korey Hood PhD, Manisha Desai PhD, Ramesh Johari PhD, David Scheinker PhD and Esli Osmanlliu, MD
PARALLEL SESSION ‐ SOCIOECONOMIC BARRIERS & DISPARITIES TO DIABETES TECHNOLOGY
EXPERIENCE IN GERMANY
1German Center for Diabetes Research, Dzd, Neuherberg, Germany, 2University of Ulm, Institute Of Epidemiology And Medical Biometry, Zibmt, Ulm, Germany
Efficacy and safety of diabetes technology improve continuously. As a consequence, established technologies, like insulin pumps and continuous glucose monitoring systems (CGM), now benefit from improved reimbursement that facilitates their wider use in high‐income countries. Nevertheless, ethnic and socioeconomic disparities continue to be reported. Based on the DPV registry, the use of CGM in patients aged under 26 years increased from 5% in 2009 to 76% in 2021 and the use of insulin pump increased from 32% to 58% in the same period in Germany. Despite increasing use, disparities based on patient's characteristics persist. In 2021, the use of insulin pumps was still significantly higher in girls than in boys (61% in girls vs. 55% in boys, P < 0.001), whereas the gender difference for the use of CGM remained negligible (77% in girls vs. 76% in boys, P = 0.02). The gender difference in pump use has been observed above age 10 years and increased with age. Poorer metabolic control, variable insulin requirement during the menstrual cycle, and possibility of pregnancy, are factors that contribute to the higher use of insulin pump in female adolescents and young adults compared to males of the same age. Regional disparities in the use of diabetes technology also persist in Germany. Whereas the use of insulin pumps was still associated with area deprivation until 2019, the association with CGM use disappeared in the last years. Nevertheless, in 2021, both technologies were still more frequently used in the former Western Germany, compared to the Eastern part of the country (Pump: 55 vs. 52%, CGM: 76 vs. 71%, both p < 0.001). Independent of area deprivation, the effect of migration background on CGM use decreased over the last years in Germany. However, patients without migration background still use both insulin pump and CGM more frequently. In 2019, 58% of the patients up to age 26 years without migration background used an insulin pump compared to 52% of the second‐generation migrants (at least one parent born outside Germany) and 38% of the first‐generation migrants (patient himself born outside Germany). Similarly, 77% of the patients without migration background used a CGM, compared to 68 and 60% for the second and first‐generation migrants, respectively. Besides complex discriminatory reasons which cannot be excluded, language and cultural barriers may limit the access to diabetes technology. To conclude, our findings raise the concern that inequitable access to diabetes technology in Germany continues to systematically disadvantage some patients, on the basis of their gender, migration history or socioeconomic situation.
PARALLEL SESSION ‐ SOCIOECONOMIC BARRIERS & DISPARITIES TO DIABETES TECHNOLOGY
EXPERIENCE IN INDIA
Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Diabetology, Chennai, India
SOCIOECONOMIC BARRIERS & DISPARITIES IN DIABETES TECHNOLOGY : EXPERIENCE IN INDIA DR.V. MOHAN, M.D., FRCP (London, Edinburgh, Glasgow & Ireland), Ph.D., D.Sc. D.Sc (Hon. Causa), FNASc, FASc, FNA, FACE, FACP, FTWAS, MACP, FRSE
PARALLEL SESSION ‐ SENSORS IN HOSPITALS
ACCURACY OF GLUCOSE SENSORS IN PATIENTS WITH ACUTE OR CHRONIC COMORBIDITIES
Institut für Diabetes‐Technologie, Forschungs‐ und Entwicklungsgesellschaft mbH an der Universität Ulm, Scientific Operations, Ulm, Germany
Continuous glucose monitors (CGMs) have become part of routine diabetes care in the last years. The use of CGM for the management of diabetes in special patient groups with comorbidities, in hospitals and nursing homes is of great interest and gets additionally stimulated by coronavirus disease that necessitates remote monitoring. However, these patient groups or settings are usually not represented in large studies on reliability and accuracy of CGM devices. Different physiological processes and possibly interfering medication might impair CGM performance. In the last years a couple of small studies that evaluated the accuracy of CGM in different patient groups and settings, like patients undergoing dialysis or ICU patients, were published. The presentation will provide a brief overview about studies and study results and will discuss the consequences of these results for CGM use in such patient groups.
PARALLEL SESSION ‐ SENSORS IN HOSPITALS
CLOSED‐LOOP INSULIN THERAPY IN HOSPITALS
University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom
Fully automated closed‐loop insulin delivery in the inpatient setting has been shown to be safe and effective. The use of inpatient closed‐loop therapy is associated with significantly improved glycaemic control compared to standard insulin therapy without increasing the risk of hypoglycaemia, including in those requiring nutrition support (enteral and parenteral nutrition) or haemodialysis during their admission. Closed‐loop systems may provide an important opportunity to address the challenges associated with inpatient diabetes management. In this talk we review the available evidence from randomised clinical trials, and report on our experience of implementation of inpatient closed‐loop technology in a real‐world setting. We will discuss key considerations for healthcare providers to adopt inpatient closed‐loop technology.
PARALLEL SESSION ‐ METHODS AND REGULATORY ISSUES IN DIABETES
IS POC HBA1C ADEQUATE?
NIH, Dlm, Bethesda, United States of America
Hemoglobin A1c (HbA1c) is used very widely both to monitor patients with diabetes mellitus and to diagnose diabetes. An International Expert Committee recommended that HbA1c ≥6.5% rather than fasting glucose be used to diagnose diabetes (Diabetes Care 2009; 32:1327). Since 2010 when HbA1c was advocated by the American Diabetes Association (ADA) for both screening and diagnosis of diabetes (and endorsed in 2011 by the World Health Organization), there has been a dramatic increase in the use of HbA1c for diagnosis. Initially HbA1c was measured only in central laboratories, but subsequently smaller point‐of‐care testing (POCT) devices became commercially available to analyze HbA1c in doctors' offices and clinics. At present, the ADA cautions that POCT devices for HbA1c should not be used for diagnosis. Although several point‐of‐care HbA1c assays are NGSP‐certified, the test is waived in the USA and proficiency testing is not necessary. Therefore, no objective information is available concerning their performance in the hands of those who measure HbA1c in patient samples. Nevertheless, some advocate for use of POCT HbA1c devices for diagnosis and the topic remains highly contentious. Numerous publications have evaluated performance of HbA1c POCT devices, with many shown to have inadequate analytic performance (eg, Clin Chem 2010; 56:44; Clin Chem 2014; 60:1062). The use of HbA1c POCT in diabetes diagnosis has also been addressed in both the clinical and laboratory published literature (eg, Clin Chem 2013; 59:1790; Prim Care Diabetes. 2017;11:248; Ann Fam Med. 2017;15:162; JAMA 2019; 322:1404). This talk will provide a current perspective on these issues.
PARALLEL SESSION ‐ METHODS AND REGULATORY ISSUES IN DIABETES
THE IMPACT ON POLICY OF THE CHANGING SCIENCE IN T1D
P. Kar
NHS England, Diabetes, Portsmouth, United Kingdom
The introduction of the clinical use of HbA1c in the early 1980s was a revolutionary step for the modern management and eventually the diagnosis of diabetes. The use of this objective and relatively inexpensive biomarker allowed both researchers and clinicians to track diabetes control. In fact, the Diabetes Control and Complications Trial (DCCT) would not have been possible if not for the use of HbA1c. The test now is standard of care for all types of diabetes for assessment of glycemic control. While limitations of HbA1c (anemias, hemoglobinopathies, etc.) have been understood for 40 years, it has been more recently that the real limitations of HbA1c have been reported due to the use of continuous glucose monitoring (CGM). This was first observed in a population with no anemia, renal disease, or liver disease in 2008‐an individual with a HbA1c of 9% could have the same mean glucose as someone with a HbA1c of 7%. For a population, the test is robust, but for any given individual, there may be major discordance between mean glucose and HbA1c. While more factors have been found to impact HbA1c since the 1980s, we have also learned that race/ethnicity may impact this biomarker. For example, on average we now know that in African Americans, HbA1c runs 0.4% higher than in Caucasian Americans. The introduction of glucose management indicator (GMI) has resulted in many clinicians wondering if we need to measure HbA1c moving forward. While using GMI during the pandemic when it was not possible for patients to get blood work was helpful, HbA1c will remain as part of our standard of care. First, the majority of people with diabetes do not use CGM, so GMI is not possible. Still, in an ideal world it would be good to know if there is discordance between mean glucose and HbA1c tested with a one‐time professional HbA1c for at least 14 days. Secondly, many clinicians and patients feel HbA1c is an important piece of information they want for routine clinic visits. It should also be noted that regulatory agencies are still dependent on HbA1c as an objective measure to confirm the efficacy of a pharmaceutical therapy. Still, it is also true HbA1c does not provide the granularity of someone's diabetes control, particularly as it pertains to hypoglycemia. After four decades of the use of HbA1c, it is not realistic that it will go away and more importantly, it will continue to have a role in the immediate future. Given the cost of CGM, it likely will continue to be used in the long‐term future too.
PARALLEL SESSION ‐ RCT EVIDENCE ON TIME‐IN‐RANGE IN TYPE 1 DIABETES
RCT EVIDENCE ON TIME‐IN‐RANGE IN TYPE 1 DIABETES
1University of Ljubljana, Faculty Of Medicine, Ljubljana, Slovenia, 2Children's and Youth Hospital Auf Der Bult, Diabetes Center For Children And Adolescents, Hannover, Germany, 3University Of California San Diego, Veterans Affairs Medical Center, Department Of Medicine, San Diego, United States of America, 4University of Leicester, Diabetes Research Centre, Leicester, United Kingdom, 5Montpellier University Hospital, Department Of Endocrinology, Diabetes And Nutrition, Montpellier, France, 6Sanofi, Global Medical Affairs, Paris, France, 7IVIDATA Life Sciences, Biostatistics, Levallois‐Perret, France, 8Sanofi, R&d, Paris, France, 9International Diabetes Center, Healthpartners Institute, Minneapolis, United States of America
PARALLEL SESSION ‐ CONNECTED PENS: NEEDS, EXPECTATIONS, VARIETIES AND EXPERIENCE OF USE
CONNECTED PENS: NEEDS AND EXPECTATIONS
University Hospitals of Derby and Burton, Diabetes And Endocrinology, Derby, United Kingdom
Connected insulin pens are the latest technology to be introduced to the diabetes clinic. These pens use Bluetooth or Near Field Communication to transfer insulin dosing data from the pen to an app or online platform, allowing for the review of both glucose an insulin data in the clinic. This lecture will explore the concept of connected pens, unmet needs and expectations of both health care professionals and people living with diabetes. Just a decade ago, paper diaries were central to an effective diabetes consultation. They contained information on insulin doses, glucose levels and carbohydrate intake to enable informed shared decision making. Fast forward 10 years and the diabetes consultation has evolved with paper diaries largely replaced with uploaded or ‘in the cloud’ glucose data. For those on insulin pumps the ability to have the glucose, insulin and carbohydrate data available to review is an advantage. However, this data is not readily available for those on multiple daily injections. A data gap exists between multiple daily injection and insulin pump therapies. Connected pens bridge this gap by providing insulin data alongside glucose data, essential for optimisation. For those living with diabetes, connected pens may support therapy and behaviour change, for example, providing insight into the impact of mealtime insulin timing on postprandial glucose levels or the ability to identify missed insulin doses. This new technology is promising. Future feedback from both people living with diabetes and the health care professionals supporting them will determine their future role in diabetes services.
PARALLEL SESSION ‐ CONNECTED PENS: NEEDS, EXPECTATIONS, VARIETIES AND EXPERIENCE OF USE
THE INDUSTRY APPROACH: SMART PENS: THE NEED, OUTCOMES, AND FUTURE APPLICATIONS
Medtronic, Medical Affairs, Northridge, United States of America
Major milestones in non‐automated insulin administration include plastic syringes, pre‐filled insulin pens, and smart insulin pens. The InPenTM smart insulin pen enables users to capture both the time and amount of insulin delivered and can provide missed bolus reminders to the person with diabetes. The need for such advance technology was found in observational data of over 1.1 million meals where on‐time bolusing occurred in just over half of all boluses and that boluses were missed almost one‐third of the time. The time‐in‐range (70‐180 mg/dL) was strongly correlated with the frequency of on‐time bolusing (r = 0.59, p < 0.001). When the InPenTM is used with the accompanying smartphone app to calculate the meal dose or correction dose of insulin, the user can safely determine the dose because insulin‐on‐board is incorporated in the dose calculation. InPenTM use is associated with almost 2% less time‐below‐range (TBR) in those who had TBR greater than 8% before initiating its use. In adolescents (13‐17) and young adults (18‐22) using MDI for management of their diabetes, those using InPenTM (with CGM) had significantly lower GMI's compared to those using traditional insulin pens (p < 0.001). Combining the data provided by a smart insulin pen and CGM with sensors that capture the duration/intensity of exercise, sleep and meal gestures may allow MDI users to obtain real‐time and/or retrospective decision support for their diabetes management.
PARALLEL SESSION ‐ CONNECTED PENS: NEEDS, EXPECTATIONS, VARIETIES AND EXPERIENCE OF USE
THE INDUSTRY APPROACH: VALUE OF BASAL INSULIN CONNECTIVITY IN THE DIABETES MANAGEMENT ECOSYSTEM
Sanofi, Digital Healthcare, Frankfurt, Germany
Development of effective technologies supporting patient self‐care behaviors, real‐time monitoring or optimization of treatment regimen is essential for people living with chronic health conditions, such as diabetes, where suboptimal adherence to medication and lifestyle modification can compromise patient outcomes. When people living with diabetes receive basal insulin, as part of their treatment regimen, it is assumed that basal insulin treatment is adapted and personalized. However, only ∼25% of those on basal insulin achieve glycemic control, indicating that a significant gap remains. Since basal insulin is a foundational pilar for management of people with diabetes, we believe it is imperative to address the gaps in treatment regimen optimization and improve adherence to basal insulin using effective technologies. The suggested strategies include the use of digital devices amongst which the connected insulin pen plays a key role. However, at Sanofi we believe that the game‐changing determinant for adoption of next‐generation pens is user experience. The question we asked ourselves is – what matters most to people with diabetes: Convenience of use? Live data? Device autonomy? Interoperability with digital companions? Fit into existing life and care routines? Or health outcomes? In this context and as part of its commitment to help people with diabetes, Sanofi will present its connected solutions designed with the intention to support basal insulin management in fitting user expectations and guided by strict user safety standards. We believe such solutions could provide greater convenience for people with diabetes and support improved patient‐healthcare provider interaction.
PARALLEL SESSION ‐ DUAL AGONIST
MECHANISMS OF ACTION OF TIRZEPATIDE IN HUMANS: BETA AND ALPHA CELLS EFFECTS AND INSULIN SENSITIVITY
Institute of Neuroscience, National Research Council, Padova, Italy
Tirzepatide, a novel dual GIP/GLP‐1 receptor agonist, has shown in clinical trials consistent efficacy as treatment for type 2 diabetes, with marked improvement of glycemic control, decrease of HbA1c and weight loss. These changes have been shown to be superior to those obtained with long‐acting GLP‐1 receptor agonists. A recent study has been performed to clarify the mechanisms underlying such a marked improvement in glucose control. The study assessments included a euglycemic hyperinsulinemic clamp to measure insulin sensitivity, a hyperglycemic clamp to assess insulin secretion and beta‐cell function, and a meal test to evaluate the treatment effects in physiological conditions and in particular the glucagon response. The 28‐week randomized controlled study included both placebo and GLP‐1 receptor agonist semaglutide 1mg as comparators. The study has confirmed greater improvement in HbA1c and weight loss with tirzepatide compared to semaglutide. Consistently with the superior improvement in HbA1c, both fasting and mean glucose during the meal test were reduced to a greater extent with tirzepatide. The study of the underlying mechanisms of action has revealed a considerably larger improvement in insulin sensitivity with tirzepatide compared to semaglutide, which was paralleled by similar results obtained from the meal‐based insulin sensitivity surrogates. Enhancement of insulin secretion from the hyperglycemic clamp, as both first‐ and second‐phase secretion, was larger with tirzepatide vs. semaglutide. During the meal test, both fasting and mean glucagon concentration decreased more with tirzepatide than with semaglutide. The combined effects on insulin sensitivity and insulin secretion, assessed with disposition index (the product of insulin sensitivity and total insulin secretion normalized to glucose, from the clamps), were largely superior with tirzepatide, which showed an almost double disposition index increase compared to semaglutide. In conclusion, large improvements in insulin sensitivity and insulin secretion and glucagon suppression underlie the strong effects of tirzepatide on glycemic control.
PARALLEL SESSION ‐ DUAL AGONIST
TIRZEPATIDE ACTIONS ON ECTOPIC FAT ACCUMULATION: RESULTS OF MRI ADDENDUM OF SURPASS‐3
Institute of Clinical Physiology, CNR, Cardiometabolic Risk Unit, Pisa, Italy
PARALLEL SESSION ‐ DIABETES TECHNOLOGY ONBOARDING – ONE SIZE FITS NOBODY – EASY WAYS TO GET BEST FROM YOUR DEVICE
CGM TOP TIPS ‐ BALANCING THE BENEFIT/BURDEN SEESAW
Southern Health NHS Foundation Trust, R&d, Southampton, United Kingdom
Continuous glucose monitoring (CGM) is increasingly used amongst people with type 1 diabetes, type 2 diabetes and pre‐diabetes as a tool to visualise glycemic patterns and excursions. The are widely reported clinical benefits across different systems and study designs. There are also a number of downsides that contribute to discontinuation of CGM use including increased visibility of disease state, alarm fatigue and interference in daily living. Effective onboarding of such systems, including exploration of personalised expectations and goals can mitigate these downsides. This presentation will explore benefits and burdens of CGM systems, as well as provide practical tips and advice on how to get the best out of them for improved physical and mental wellbeing.
PARALLEL SESSION ‐ DIABETES TECHNOLOGY ONBOARDING – ONE SIZE FITS NOBODY – EASY WAYS TO GET BEST FROM YOUR DEVICE
WHY IS MY TECH NOT GIVING ME THE RESULTS I WANT
Behavioral Diabetes Institute, N/a, San Diego, United States of America
When individuals grow discouraged or disappointed with their personal diabetes devices, such as an insulin pump or RT‐CGM, it increases the possibility that they will at some point choose to quit their devices altogether. To address this potentially harmful decision in a proactive manner, we must seek to understand the the individual's underlying reasoning and, when needed, develop clear strategies for intervention. This presentation will review how such factors as unreasonable device expectations (e.g., 100% CGM accuracy), history of hypoglycemic fear, and problematic device‐related hassles (e.g., alarm fatigue) can all lead to worry, discouragement and potential discontinuation. In addition, practical strategies for addressing these issues will be discussed.
PARALLEL SESSION ‐ PREGNANCY AND DIABETES TECHNOLOGY
USING TEMPORAL CGM PROFILES TO UNDERSTAND CLINICAL OUTCOMES IN DIABETES PREGNANCY
University of Leeds, Leeds Institute Of Cardiovascular And Metabolic Medicine, Leeds, United Kingdom
Clinicians are increasingly familiar with using the visual 24 hour glucose profile obtained by CGM to personalise the clinical management of diabetes. However at a population level the temporal profiles are not used to ascertain where clinically relevant differences lie across the 24 hour day and any differences in glucose are often masked by summary statistics. This talk will highlight the importance of examining the full 24 hour temporal glucose profiles and illustrate the relevance of this to understanding pregnancy outcomes in women with diabetes.
PARALLEL SESSION ‐ PREGNANCY AND DIABETES TECHNOLOGY
IS THERE A ROLE FOR MORE DIABETES TECHNOLOGY USE IN TYPE 2 DIABETES PREGNANCY
University of East Anglia, Norwich Medical School, Norwich, United Kingdom
During 2019‐20, there were 5,085 pregnancies in women with T2D and 4,175 in those with T1D, making T2D now the commonest form of pregestational diabetes in pregnancy in England and Wales. This represents a doubling in the prevalence of T2D pregnancies in the past two decades. Compared to pregnant women with T1D, those with T2D are older, have higher BMI, with more metabolic comorbidities (hypertension, dyslipidemia) and are more likely to belong to minority ethnic groups, and live in higher deprivation areas. There were seven times more pregnancies (>40% vs <6%) among women with T2D living in the most vs least deprived communities. Fewer than one in four were taking high dose folic acid before pregnancy. Glycaemic management was also inadequate with 25% of women untreated, 50% taking metformin alone, and only 15% taking insulin (10 % metformin and insulin, 5% insulin alone) before pregnancy. Approximately one in seven pregnant women (median age 34 years) were taking ACE‐inhibitors, statins (13%) or other potentially harmful therapies (7%). Pregnant women with T2D had higher rates of perinatal death across all HbA1c categories compared to pregnant women with T1D. After adjusting for relevant confounding risk factors, an above target HbA1c after 24 weeks was associated with a four‐times increased risk of perinatal death in T2D. Rates of preterm births, LGA and neonatal intensive care unit admissions are all significantly reduced in women with T2D who achieve HbA1c < 6.1% (43mmol/mol) after 24 weeks gestation (Figure 1), emphasizing the crucial importance of antenatal glucose levels during T2D pregnancy.
PLENARY ‐ CLOSED‐LOOP UPDATES
THE USE OF REAL WORLD DATA TO OPTIMIZE THE PERFORMANCE OF AUTOMATED INSULIN DELIVERY DEVICES
Medtronic, Diabetes, Tolochenaz, Switzerland
Real‐world evidence (RWE) of a new therapy provides insights into whether or not results from relatively small and highly structured clinical trials can be generalized to a wider user and provider populations. While randomized controlled trials provide a standardized mean to isolate an attribute, so the effect of a single therapy, can be deduced, in real‐world situation , myriad of interaction and differing care structures occur that effect outcomes. Analyzing RWE from large data bases can, therefore, provides a more realistic scenario to assess the outcomes of therapeutic interventions. In this presentation, the use of RWE driven insights to drive therapy recommendation for the individual user of automated insulin delivery systems, and the care provider, will be demonstrated . Harnessing the objectively and unbiased collected data requires attention to technical, analytical and privacy issues to ensure data quality and analytic integrity. The limited individual data and challenges of anonymization of RWE will be discussed as well. The clinical outcome effect of applying the insights from the prediction analysis of RWE, will be demonstrated in the case of the MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system.
PLENARY ‐ CLOSED‐LOOP UPDATES
LONG‐TERM, REAL‐LIFE USE OF CLOSED‐LOOP CONTROL
University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America
After years of development and testing of system components and algorithms, closed‐loop control (CLC) of diabetes, known as the “artificial pancreas,” is a clinical reality. Two CLC systems, Medtronic's 670G/770G and Tandem's Control‐IQ, have FDA clearance for clinical use in the U.S. and CE mark for clinical use in Europe. Insulet's Omnipod 5 received FDA clearance in January 2022, but has no CE mark and is not available in Europe. Another two systems, Medtronic 780G, and CamAPS FX, received CE mark for use in European countries. These systems are at different stages of their clinical use: while 670G/770G and Control‐IQ already have hundreds of thousands of users around the world, 780G, Omnipod 5, and CamAPS FX are making their first strides in real‐life application. Several other systems have passed extensive testing and are along their ways to regulatory approval, including Diabeloop, Tidepool Loop, the bi‐hormonal (insulin plus glucagon) Inreda, and iLet, in two configurations – insulin only and insulin plus glucagon. Real‐life data began to emerge. The MiniMed 670G helped with improved glycemic control and quality of life, but also resulted in frequent discontinuation of system use due to suboptimal user experience: approximately one‐third of those starting on the 670G system discontinued use within months. It was concluded that “While auto mode utilization correlates with improved glycemic control, a focus on usability and human factors is necessary to ensure use of auto mode. Alarms and sensor calibration are a major patient concern, which future technology should alleviate.” Thus, it is not a surprise that more advanced systems enjoy better user acceptance. In a clinical trial, the 780G (known as Advanced Hybrid Closed‐Loop System, AHCL) achieved 86% use in auto mode, compared to 75% for the 670G. Published real‐life CLC data for over 9,000 Control‐IQ users confirmed almost exactly the glycemic results from the two pivotal trials of this system. In this 2021 report, Control‐IQ had 94% use of auto mode throughout a year of observation. To these literature data, this presentation adds new unpublished results of Basal‐IQ and Control‐IQ use by over 20,000 people with type 1 and type 2 diabetes.
PARALLEL SESSION ‐ CGM AND TYPE 2 DIABETES
MEDICAL AND PSYCHOLOGICAL APPROACHES TOWARDS ENHANCING THE VALUE OF PERSONAL CGM IN THE TYPE 2 POPULATION
1University Of California San Diego, Veterans Affairs Medical Center, Professor Medicine, San Diego, United States of America, 2Behavioral Diabetes Institute, N/a, San Diego, United States of America
Real‐time continuous glucose monitoring (RT‐CGM) has become the standard of care for people with type 1 diabetes (T1D) and it is the rare individual who would not benefit greatly from it. With the advent of hybrid closed loop systems, RT‐CGM has taken on an even greater level of importance. However, the use of RT‐CGM in people with type 2 diabetes (T2D) remains very limited.
Currently, only patients with T2D treated with 3 or more injections a day or insulin pump therapy are able to obtain a CGM that is covered by insurance or Medicare in the United States. However, we believe that every patient with T2D, no matter what their current antidiabetic medication regimen may be, could potentially benefit from RT‐CGM. The key will be to provide both HCPs and patients with the necessary guidance, education and support to interpret and respond effectively to RT‐CGM data. In this presentation, we will put forward a series of practical strategies designed to promote a more successful introduction to RT‐CGM for both HCPs and individuals with type 2 diabetes, and also to enhance ease of use and patient enthusiasm regarding RT‐CGM as well as long‐term glycemic success.
PARALLEL SESSION ‐ CGM AND TYPE 2 DIABETES
THE MEANING OF GLUCOSE CONTROL IN DIABETES TODAY: IT`S TIME FOR A PARADIGM SWITCH
IRCCS MultiMedica, Diabetes Research, Milan, Italy
Glycated haemoglobin (HbA1c) is the most used parameter to assess glycaemic control. However, recent evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and maintaining optimal HbA1c levels as soon as possible, but to obtain this result by reducing postprandial hyperglycaemia, glycaemic variability and to extend as much as possible the time in range in near‐normoglycaemia. These goals should be achieved avoiding hypoglycaemia and, if this happens, hypoglycaemia should be reverted to normoglycaemia. Modern technology, i.e. intermittently‐scanned glucose monitoring and continuous glucose monitoring together with the new available drug therapies (e.g. ultra‐fast insulin, SGLT‐2i, and GLP‐1RAs) may help to change the paradigm of glycaemia management based on HbA1c in favour of a holistic approach considering all the different aspects of this commonly oversimplified pathological feature of diabetes.
VIRTUAL PARALLEL SESSION (PRE‐RECORDED + LIVE Q&A) ‐ DIABETES INDIA
PRECISION DIABETES IN INDIA‐ WHERE ARE WE?
Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Diabetology, Chennai, India
VIRTUAL PARALLEL SESSION (PRE‐RECORDED + LIVE Q&A) ‐ DIABETES INDIA
WHATSAPP SUPPORT GROUP FOR 950 CHILDREN AND ADOLESCENTS/PARENTS WITH TYPE 1 DIABETES ‐ PHYSICIAN'S PERSPECTIVE ON MERITS AND DEMERITS
Jothydev's Diabetes Research Centre, Diabetes, Trivandrum, India
During the Covid pandemic, telemedicine(TM) has been more and more accepted by doctors and patients all over the world. Evidence‐based research has found telemedicine‐based management of type 1 diabetes efficient in delivering equivalent or better care and outcomes when compared to only face to face visits. A year before the covid, Kerala, the most literate state in India, with 96.2% literacy rate, had a community consisting of parents and children with type 1 diabetes. Almost all these parents had access to WhatsApp and were part of the type 1 diabetes community in Whatsapp. This of course doesn't include all of those with type 1 diabetes in the state but included most of those who were economically compromised and didn't have access to the premier hospitals and doctors. There were total of 4 WhatsApp groups, each consisting of 250 parents and children from all over the state of Kerala, receiving treatment from government hospitals or other private hospitals. The groups also included volunteering doctors, nurses, educators and dietitians where we were also part. Our duty was to give them directions and advices rather than to treat them. We in addition, provided the economically disadvantaged families with free supplies including insulin, glucometers, strips and injection needles based on their needs. All the communications in the group were based on updated telemedicine guidelines in India. As a team, we have been providing 24/7 advices and services free of cost to the entire community together with multiple online educational programs via the zoom. Some of these programs were with parents and children together and some other programs incorporated only parents so that counselling can be given to them to specifically address psychosocial issues of these kids. In each WhatsApp group, one of us in the team, always made sure we replied to the questions posted by the parents or grown up children, without any delay. Most frequently asked questions during Covid pandemic were related to stress and anxiety of children including abnormal/aggressive behaviour, uncontrolled glucose, reluctance with insulin injections and glucose monitoring. We also had to arrange exclusive counseling sessions with psychologist to address the multiple emotional issues of the kids/caregivers. We also created educational videos addressing different aspects of type 1 diabetes and Covid based on the frequently raised questions and concerns.
All their concerns are addressed even during the middle of the night.
Could avoid multiple episodes of DKA
Could successfully avert/treat multiple episodes of life‐threatening hypoglycemia
Dietitians in the groups could advise on diet, specific to individual requirements
Diabetes nurses could retrain parents and children on injection techniques whenever found essential, multiple times
Questions on stopping insulin or Complementary and Alternate Medicines(CAM), side effects of insulin where not only answered but also explained via videos.
Whoever is in short of glucometer strips or needles could get it from community itself or from us without any delay.
The patients in the WhatsApp groups are getting treated in different hospitals and not by the volunteering doctors and healthcare providers in the Whatsapp groups and hence the medical history and records are not with them.
Many a time, the patients with uncontrolled glucose might be on an insulin formulation or regimen not suitable for them but the team would not be able to commend on it.
Hundreds of parents will be messaging or calling via WhatsApp privately to doctors. However,due to legal implications, they are not replied to unless it is posted in community group.
Though there is no hesitancy for the type 1 diabetes community members to open up about disease in the group, there would be many concerns and questions which cannot be posted in a group.
Since it is an open community, whatever communications are exchanged; including lab reports are not secure or confidential.
The health care professionals(HCPs) will not get a remuneration and there is no funding for this activity; so those getting involved should volunteer out of their commitment to the society.
The HCPs may be under tremendous pressure since the patients will have easy and free access to the health care professional. The WhatsApp community of type 1 diabetes children and their parents were provided support throughout the day and night by the physicians and allied healthcare professionals in each group. This telemedicine model prevented hospital admissions which was widely appreciated by the patient community and it also reduced the overall cost and burden of treatment. However,this model is not free of demerits which may include the legal implications, the errors and mistakes, which can happen in the process of communication and implementation. This advantageous model may not be applicable in many other health systems.
VIRTUAL PARALLEL SESSION (PRE‐RECORDED + LIVE Q&A) ‐ DIABETES INDIA
TIR THROUGH PROFESSIONAL CGM ‐ THE INDIA FRIENDLY METRIC
Lina Diabetes Care Mumbai Diabetes Research Centre, Diabetes, Mumbai, India
The Time in Range (TIR) metrics are now accepted internationally and in India as a means of assessing the entire glycemic movement and glycemic variability. The TIR is measured using predominantly CGM devices and also SMBG (although SMBG does have limitations). Professional CGM systems have been available in India for over a decade with the Libre Pro Flash Glucose monitoring being introduced in India for the first time in 2015. Despite the availability of the libre freestyle and other real time CGM devices like Guardian Rt in India, their use is limited in comparison with the retrospective, professional cgms due to cost and poor awareness. Though the Indian CGM guidelines recommend routine use of cgm for patients with type 1 DM and those with type 2 DM with potential for hypoglycemia the uptake is still slow. TIR as supplementary to HBA1C is slowly gaining relevance amongst Indian physicians and as the use of this technology is predominantly intermittent where used the assessment of TIR through professional blinded CGM (does not get influenced by change in lifestyle and drug dose like in case of real time CGM use) seems most appropriate in the Indian population context. An important component of the TIR metrics besides the Time in Target and Time above Target percentage is the Time below Target Range as unrecognized hypoglycemia is one of the biggest drawback and limitation of the current approach towards diabetes management. We have identified significant time spent by patients below range inspite of being in higher hba1c bracket and that is an important indicator for routine assessment of TIR in Indian patients through intermittent professional CGM.
PARALLEL SESSION ‐ NUTRITION AND FOOD TECHNOLOGIES
DIGITAL NUTRITION TECHNOLOGIES FOR DIABETES PREVENTION
University of Virginia, Division Of Endocrinology And Metabolism, Charlottesville, United States of America
Using Digital Technology for Diabetes Prevention Delivery and Engagement Despite medical and technological advances in diabetes care, the prevalence of diabetes continues to rise. It is becoming critically important to use technology not only to improve diabetes management but also for delivery and engagement in Lifestyle Change Programs for the prevention of type 2 diabetes. Based on the Diabetes Prevention Program and the DPPOS, intense lifestyle intervention aimed at weight loss decreased the incidence of type 2 diabetes by 58% at study's end and had a long‐lasting risk reduction of 25% by 22 years. The National Diabetes Prevention Program (National DPP) in the United States is a widely available Lifestyle Change Program for people with prediabetes with the goal of 5% weight loss, improvement in food quality and quantity to promote weight loss and an increase in physical activity. Technology can improve access to the program, delivery, engagement, and effectiveness of the National DPP. This seminar will discuss how to use technology to deliver the National DPP, best practices around synchronous delivery and engagement, how asynchronous delivery can augment the program, and how digital technologies can support effectiveness.
PARALLEL SESSION ‐ NUTRITION AND FOOD TECHNOLOGIES
PERSONALIZED NUTRITION FOR IMPROVING GLYCEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES
1Weismann institute of science, Mathematics And Cs, Rehovot, Israel, 2Haifa university, School Of Public Health, Haifa, Israel
Dietary modifications are crucial for managing newly‐diagnosed type‐2 diabetes mellitus (T2DM) and preventing its health complications, but many patients fail to achieve clinical goals with diet alone. We previously developed a machine‐learning algorithm for predicting personalized postprandial glucose responses (PPGR) to meals using clinical and gut microbiome features, and showed that dietary interventions based on this algorithm successfully lowered PPGRs in adults with prediabetes. Here, we sought to evaluate the clinical effects of a personalized postprandial‐targeting (PPT) diet on glycemic control and metabolic health in individuals with newly‐diagnosed T2DM. We preformed a short‐term randomized controlled crossover trial and compared the effects of an algorithm‐based personalized postprandial‐targeting (‘PPT’) diet, to those of a commonly used Mediterranean‐style (MED) diet on glucose levels in 23 newly diagnosed T2DM subjects. The PPT diet lead to significant decrease in glycemic parameters as compared to the MED diet, for example, average PPGR (mean difference between diets, ‐19.8 ± 16.3 mg/dl × h, p < 0.001), mean glucose (mean difference between diets, ‐7.8 ± 5.5mg/dl, p < 0.001), daily time of glucose levels >140mg/dl (mean difference between diets, ‐2.42 ± 1.7 hour/day, p < 0.001) and blood fructosamine (mean change difference between diets, ‐16.4 ± 37μmol/dl, p < 0.0001). We further evaluated the long‐term clinical effects of the PPT diet in 16 of the participants by an additional 6‐month PPT intervention program, and found significant improvements in multiple metabolic health parameters, including HbA1c (mean±SD, ‐0.39 ± 0.48%, p < 0.001), fasting plasma glucose (FPG) (‐16.4 ± 24.2mg/dl, p = 0.02) , fasting insulin (‐2.3 ± 4.0MCU/ml, p = 0.04), triglycerides (‐49 ± 46mg/dl, p < 0.001) and body composition measurements including body fat% (‐2.5 ± 3%, p = 0.005) and waist circumference (‐4.7 ± 3.7cm, p = 0.001). Importantly, 61% of the participants exhibited diabetes remission at the end of the intervention, as measured by HbA1c. Finally, we show that some of the improvements in clinical outcomes were accompanied by significant alterations to the gut microbiome composition per person. Our findings suggest that a personalized postprandial‐targeting diet may be an effective alternative treatment compared to standard dietary approaches for improving glycemic control in newly diagnosed T2DM.
PARALLEL SESSION ‐ EDUCATION AND ADHERENCE TO TREATMENT
DAILY PREDICTORS OF DIABETES ADHERENCE IN ADOLESCENTS AND YOUNG ADULTS WITH T1D
University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America
Glycemic control is typically measured by aggregate glucose data spanning 14 days. Little is known about the daily fluctuations in diabetes self‐management, glycemic control, and ability to achieve goals in adolescents and young adults (AYA) with type 1 diabetes. There are likely a myriad of underlying physiological, emotional, and cognitive factors that fluctuate on a day‐by‐day basis that predict these daily diabetes outcomes. This is important because daily patterns and habits are proximal to the momentary experience of AYA, and may provide unique foci for precision interventions to improve diabetes self‐management among AYA with diabetes. Newer health behavior theories such as Two Minds Theory suggest that such momentary biopsychosocial factors require state‐level assessment close to the time of the actual behavior rather than trait‐level global assessment. We prospectively studied 100 AYA with T1D on a daily basis to determine novel biopsychosocial factors that predict glycemia, adherence, and goal attainment, in an effort to identify novel intervention targets and strategies to improve glycemic control in AYA with type 1 diabetes.
PARALLEL SESSION ‐ ISPAD SESSION: USE OF TECHNOLOGY IN VARIOUS POPULATIONS
PATIENT REPORTED OUTCOME WHEN USING AID/TECHNOLOGY
Southern Health NHS Foundation Trust, R&d, Southampton, United Kingdom
Automated insulin delivery (AID) systems are increasingly being used by children of all ages with type 1 diabetes. Glycemic benefits have been widely reported, with a 70% time in target range reported to be clinically beneficial. The impact of such systems on the quality of life and psychosocial functioning of children and their parents, however, is less well understood. This presentation will explore some of the benefits and burdens of AID technology use amongst young children with type 1 diabetes. These will include competing priorities between children and their parents; relationships with other caregivers and balancing diabetes management with simply growing up. Finally, appropriate ways to assess patient reported outcomes will be explored.
PARALLEL SESSION ‐ ISPAD SESSION: USE OF TECHNOLOGY IN VARIOUS POPULATIONS
SLEEP AND DIABETES
Vanderbilt University Medical Center, Pediatrics, Nashville, United States of America
Sleep is a potentially modifiable risk or protective factor for diabetes‐related outcomes that has recently gained interest. In addition, new diabetes technology and devices have the potential to both disrupt sleep (with alarms) and improve sleep (through reduced glycemic variability overnight). This session will highlight recent findings from studies of sleep in type 1 diabetes (T1D), with a focus on the role of sleep in self‐management, diabetes‐specific sleep disturbances, and the potentially modifiable aspects of sleep, as well as emerging evidence from studies of sleep‐promoting interventions to improve outcomes in youth with T1D and their caregivers.
PARALLEL SESSION ‐ ISPAD SESSION: USE OF TECHNOLOGY IN VARIOUS POPULATIONS
DIABETES IN LOW (MEDIUM) INCOME COUNTRIES (L(M)IMC): WHAT TECHNOLOGY TO PRIORITIZE?
NGO Santé Diabète, Ceo, Bamako, Mali
PARALLEL SESSION ‐ THE ITALIAN TECHNOLOGY EXPERIENCE (ENDORSED BY THE ITALIAN TECHNOLOGY SOCIETY)
USE OF DIABETES TECHNOLOGY AT DIABETES ONSET, PROS AND CONS
1Division of Pediatrics, Maggiore Della Carità, Hospital, Novara, Italy, 2University of Piemonte Orientale, Health Sciences, Novara, Italy
Advanced technologies have become an integral part of type 1 diabetes (T1D) management. The aim of this presentation is to review current technologies with emphasis on the advantages and disadvantages of their use from the onset of T1D. Immediate start of pump therapy at the time of diagnosis has been shown to be successful in terms of glycemic control achieved and might help to preserve residual β‐cell function, although larger clinical trials would be required to confirm this. In very young children, the advantages are more evident and related to the need for a more physiological delivery of precise doses of insulin through continuous subcutaneous insulin infusion (CSII) rather than multiple daily injections (MDI). Furthermore, parents of children treated with CSII reported superior quality of life for their children compared with parents of children treated to MDI but CSII use is lower in patients from ethnic minorities and those with the greatest socio‐economic deprivation. Initiation of technological devices so early in the course of T1D requires highly coordinated teamwork to provide the education needed for youth and families to manage a large volume of data and notions to learn. The use of CSII may be associated with an increased risk of diabetes ketoacidosis (DKA) due to unrecognized malfunction and/or failure of the device. Other potential complications are infusion site infections and lipodystrophies. In our experience, intensive MDI/CSII regimens from the onset of diabetes are both safe and efficient. Data from the SCIPI (subcutaneous insulin: pumps or injections?) study on TID children and young people newly diagnosed, indicate that the use of CSII was neither clinically beneficial nor cost‐effective in the first year of type 1 diabetes, concluding that resources could be more effectively invested in other measures to improve glycemic control. Recent studies show instead the importance of closed‐loop in the pediatric T1D population, even at the onset. In particular, the ongoing CLOuD study (a randomised parallel study protocol) was aimed at assessing the effect of closed‐loop insulin delivery from the onset of type 1 diabetes in youth on residual beta‐cell function compared to standard insulin therapy. The future widespread use of an advanced hybrid closed‐loop from the onset of diabetes will improve and probably change the metabolic outcomes.
PARALLEL SESSION ‐ ADVANCED TECHNOLOGIES AND REGULATORY ADJUSTMENTS IN TREATING DIABETES
A BIONIC FULLY AUTOMATED INTRAPERITONEAL INSULIN DELIVERY SYSTEM: THE EU PROJECT FORGETDIABETES
University of Padova, Department Of Woman And Child's Health, Padova, Italy
The last decade has seen important developments in closed‐loop subcutaneous (sc) sensing and insulin delivery closed‐loop systems. However major limitations of subcutaneous insulin delivery still exist, including the hyper‐insulinemia due to the non‐physiologic sc route and need for meal announcement. FORGETDIABETES introduces a radically new approach to Type 1 Diabetes (T1D) treatment, by developing a fully‐implantable, fully‐automated bionic invisible pancreas (BIP) based on physiological intraperitoneal (ip) hormone delivery, thus enabling an optimal glycemic control. BIP will free individuals with T1D from therapeutic actions and from the related psychological burden. BIP will become a life‐condition (like contact lens), allowing T1D patients to live just as everybody else. An interdisciplinary team with top experts in micronano mechatronics, control engineering, biomaterials, endocrinology, surgery and behavioral sciences has been assembled to develop a long‐lasting system relying on a physiological glucose sensing and hormone delivery, orchestrated by personalized adaptive algorithms with advanced self‐diagnostic capabilities. Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of treatment actions. Wireless power transfer and data transmission to cloud‐based data management system round‐up to a revolutionary treatment device for this incurable chronic disease. In this project, the key technologies enabling BIP will be developed. Furthermore, extensive in vivo preclinical experiments along with massive in silico testing will establish the prototype system, paving the way to the ambitious first‐in‐human inpatient trial of BIP. This paradigm will revolutionize diabetes treatment and stimulate an innovation ecosystem including research bodies, SMEs, patient organizations, diabetes societies and clinicians.
PARALLEL SESSION ‐ ADVANCED TECHNOLOGIES AND REGULATORY ADJUSTMENTS IN TREATING DIABETES
PATCH PUMPS: WHAT ARE THE ADVANTAGES FOR PEOPLE WITH DIABETES
1Forschungsinstitut der Diabetes‐Akademie Bad Mergentheim (FIDAM), Fidam, Bad Mergentheim, Germany, 2Institut für Diabetes‐Technologie, Forschungs‐ und Entwicklungsgesellschaft mbH an der Universität Ulm, Scientific Operations, Ulm, Germany, 3Science Consulting in Diabetes GmbH, Profil Neuss, Neuss, Germany, 4Sciarc GmbH, Sciarc, Baierbrunn, Germany, 5Roche Diabetes Care GmbH, Dcsb, Mannheim, Germany, 6Diabetologische Schwerpunktpraxis für Kinder und Jugendliche, Münster, Münster, Germany
PARALLEL SESSION ‐ ADVANCED TECHNOLOGIES AND REGULATORY ADJUSTMENTS IN TREATING DIABETES
FLASH GLUCOSE MONITORING WITH THE FREESTYLE LIBRE 2: RESULTS FROM THE FLASH‐UK RANDOMISED CONTROLLED TRIAL (ON BEHALF OF THE STUDY GROUP)
1Manchester University NHS Foundation Trust,, Diabetes, Endocrinology And Metabolism Centre, Manchester, United Kingdom, 2University Hospitals of Derby and Burton and University of Nottingham, Diabetes And Endocrinology, Derby and Nottingham, United Kingdom, 3University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 4Norfolk and Norwich University Hospitals NHS FT, Diabetes, Norwich, United Kingdom, 5The Ipswich Hospital, The Ipswich Diabetes Centre And Research Unit, Ipswich, United Kingdom, 6The Adam Practice, The Adam Practice, Poole, United Kingdom, 7Queen Alexandra Hospital, Academic Department Of Diabetes And Endocrinology, Portsmouth, United Kingdom, 8University of Birmingham, Institute of immunology and immunotherapy, Birmingham, United Kingdom, 9University Hospitals Birmingham NHS Foundation Trust, Department of diabetes, Birmigham, United Kingdom, 10Barnard Health, Bhr Ltd, Portsmouth, United Kingdom, 11University of Manchester, Division Of Population Health, Health Sciences Research And Primary Care, Manchester, United Kingdom, 12University of Manchester, Centre For Biostatistics, Division Of Population Health, Health Service Research & Primary Care, Manchester, United Kingdom, 13University of Manchester, Manchester Clinical Trials Unit, Division Of Population Health, Health Service Research & Primary Care, Manchester, United Kingdom
PARALLEL SESSION ‐ ADDRESSING UNIQUE HEALTH CARE NEEDS OF WOMEN WITH DIABETES BY TECHNOLOGY: CHALLENGES AND OPPORTUNITIES
GLYCEMIC CONTROL AND HEALTH COMPLICATIONS IN WOMEN VS. MEN WITH TYPE 1 AND TYPE 2 DIABETES
University of California San Francisco, Pediatrics, Division Of Pediatric Endocrinology, San Francisco, United States of America
While diabetes mellitus affects both men and women, there is limited data regarding gender specific differences in diabetes outcomes. Existing studies, however, reveal several differences between men and women with diabetes. As the impact of personalized medicine on improving clinical outcomes expand, gender specific health needs and treatments for people with diabetes mellitus have come to the forefront. Data regarding gender specific differences in diabetes outcomes and gender‐related risk factors would be key to devise customized diabetes management plans to improve diabetes outcomes and quality of life for people with diabetes. This presentation highlights some of the health challenges that are common to women with diabetes and outlines gender‐based differences, gender‐specific risk enhancers and clinical outcomes in diabetes.
PARALLEL SESSION ‐ ADDRESSING UNIQUE HEALTH CARE NEEDS OF WOMEN WITH DIABETES BY TECHNOLOGY: CHALLENGES AND OPPORTUNITIES
PSYCHO‐BEHAVIORAL CHALLENGES FACED BY WOMEN WITH DIABETES
University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America
It is well‐documented that women with type 1 and type 2 diabetes report significantly higher levels of emotional distress than men with diabetes. Research has documented this for diabetes‐related distress, depression, anxiety, and fear of hypoglycemia and shown that these differences occur over a broad age span, with adolescent girls reporting more distress than boys, especially problems with body image and disordered eating patterns. Increased emotional distress is also higher in mothers of children with type 1 diabetes as compared to fathers. Importantly, these gender differences appear to occur pan globally with studies emerging across continents and cultures. This presentation will review some of the psychological issues and challenges that are unique to women with diabetes. In addition, this presentation will examine some of the implications of these gender differences for the adoption and use of diabetes technology in women. To explore the impact of gender, psychological and behavioral data from recent pivotal trials of hybrid closed loop control (CLC) use will be presented, focusing primarily on Diabetes Distress Surveys completed by study participants at baseline and after 24 weeks of CLC use. These data show that more female participants, both adults and adolescents, reported clinically significant levels of diabetes distress at baseline (adult women vs. men = 38% vs 24%, adolescent girls vs. boys = 47% vs. 13%). After use of CLC, higher scores tended to remain high for the majority of participants, indicating that diabetes technology may not be effective in lowering diabetes distress.
PARALLEL SESSION ‐ ADDRESSING UNIQUE HEALTH CARE NEEDS OF WOMEN WITH DIABETES BY TECHNOLOGY: CHALLENGES AND OPPORTUNITIES
PHYSIOLOGY OF MENSTRUAL CYCLE AND ITS RELATIONSHIP TO INSULIN NEEDS AND GLYCEMIC CONTROL IN WOMEN WITH TYPE 1 DIABETES
University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America
Individuals with type 1 diabetes (T1D) need to continuously calibrate insulin therapy, to account for time‐varying insulin requirements driven by multiple metabolic and psycho‐behavioral factors ‐ eg, meals, physical activity, psychological stress. Among these factors, the menstrual cycle has been documented to impact insulin needs and complicate insulin dosing in women with T1D. According to several studies, women with T1D may experience a decrease in insulin sensitivity during the second half of their menstrual cycle (ie, the luteal phase), which is oftentimes accompanied by an increased exposure to hyperglycemia. Also, increased occurrence of hypoglycemia has been documented during the initial days of the menstrual cycle, as women transition from luteal to follicular phase. These patterns are not consistent across women and elevated inter‐subject variability has been observed; further, intra‐subject variability has also been documented in some studies. During this talk, we will review the physiology of the menstrual cycle and the effect that phases of the menstrual cycle have on insulin requirements and glycemic control in women with T1D. Further, the talk will discuss how technology in the form of open‐loop decision support systems or closed‐loop automated insulin delivery systems can support women in the management of T1D across the menstrual cycle.
PARALLEL SESSION ‐ ADDRESSING UNIQUE HEALTH CARE NEEDS OF WOMEN WITH DIABETES BY TECHNOLOGY: CHALLENGES AND OPPORTUNITIES
AUTOMATED INSULIN TREATMENT IN WOMEN WITH TYPE 1 DIABETES: EVIDENCE FROM REAL‐WORLD DATA
University of Virginia, Division Of Endocrinology, Center For Diabetes Technology, Charlottesville, United States of America
Automated Insulin Delivery systems (AID) have consistently demonstrated improved glycemic outcomes and therefore have been in increasing use for people with Type 1 Diabetes. Pivotal trials have been completed with several systems that are now available for outpatient use. Although women have been adequately represented in these pivotal trials, it is unclear if women have a different glycemic response to AID treatment. A preliminary secondary analysis of AID trials conducted at UVA identified no significant change in hemoglobin A1c or time in range following AID use comparing female and male participants. In terms of changes across the menstrual cycle, there is little information available regarding the impact of AID systems on glycemic control. Preliminary studies have not observed trends in glycemic control or insulin delivery across menstrual cycle phases during AID use, but these studies are small and uncontrolled. Available real‐world data will be discussed to consider whether differences are observed between female and male users of AID systems.
ATTD 2022 Oral Abstract Presentations
Topic:
AS01‐Closed‐loop System and Algorithm
INSULIN REQUIREMENTS FOR BASAL AND AUTO‐CORRECTION INSULIN DELIVERY IN MINIMED 780G: A REAL‐WORLD DATA OF CHILDREN IN 2 DIFFERENT AGE GROUPS
1Koç University, School Of Medicine, istanbul, Turkey, 2Koc University Hospital, Pediatric Endocrinology And Diabetes, Istanbul, Turkey
Topic:
AS01‐Closed‐loop System and Algorithm
IMPROVED GLYCAEMIC CONTROL WITH THE MEDTRONIC MINIMED™ 780G ADVANCED HYBRID CLOSED‐LOOP SYSTEM IN PEDIATRIC PATIENTS WITH TIPE 1 DIABETES.
1BADAJOZ UNIVERSITY PEDIATRIC HOSPITAL, Pediatric Endocrinology, BADAJOZ, Spain, 2Badajoz University Hospital, Endocrinology And Nutrition, BADAJOZ, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
A DUAL‐HORMONE ARTIFICIAL PANCREAS IN A PRE‐TRIAL VIRTUAL CLINICAL TRIAL
1Technical University of Denmark, Department Of Applied Mathematics And Computer Science, Kgs. Lyngby, Denmark, 2Steno Diabetes Center Copenhagen, Clinical Research, Herlev, Denmark
Topic:
AS01‐Closed‐loop System and Algorithm
IMPLEMENTATION OF FULLY AUTOMATED CLOSED‐LOOP INSULIN DELIVERY FOR INPATIENTS WITH DIABETES
1Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes And Endocrine Clinic, Cambridge, United Kingdom, 2University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom
Topic:
AS01‐Closed‐loop System and Algorithm
FEASIBILITY AND SAFETY STUDY TESTING HYBRID, SEMI AND FULL CLOSED LOOP VERSIONS OF THE AUTOMATED INSULIN SYSTEM DERIVED FROM OPEN SOURCE ANDROIDAPS: PANCREAS4ALL
Motol University Hospital and 2nd Faculty of Medicine, Charles University in Prague, Czech Republic, Department Of Pediatrics,, Prague, Czech Republic
Topic:
AS03‐Artificial Pancreas
PREDICTING 12‐MONTH SUCCESS WITH A SECOND‐GENERATION HYBRID CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM
Barbara Davis Center, Pediatric Endocrinology, Aurora, United States of America
Topic:
AS03‐Artificial Pancreas
WHICH CHARACTERISTICS ARE ASSOCIATED WITH ATTAINING AN OPTIMAL GLYCEMIC MANAGEMENT AMONG ADULTS LIVING WITH TYPE 1 DIABETES AND USING AUTOMATED INSULIN DELIVERY SYSTEMS?
1McGill University, Department Of Medicine, Division Of Experimental Medicine, Montreal, Canada, 2Institut de recherches cliniques de Montréal (IRCM), Montreal, Canada, 3McGill University, School Of Human Nutrition, Sainte‐Anne‐de‐Bellevue,, Canada, 4Université de Montréal, Department Of Nutrition, Faculty Of Medicine, Montreal, Canada
Topic:
AS03‐Artificial Pancreas
SUSTAINING IMPROVEMENT IN GLYCEMIC CONTROL FOR YOUTH USING CONTROL‐IQ (CIQ) FOR ONE YEAR
University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America
Topic:
AS03‐Artificial Pancreas
MEAL ANTICIPATION MAY IMPROVE FULL CLOSED LOOP CONTROL IN ADULTS WITH TYPE 1 DIABETES
1University of Virginia, School Of Medicine, Center For Diabetes Technology, Charlottesville, United States of America, 2University of Virginia, Department Of Pediatrics, Charlottesville, United States of America, 3University of Virginia, Division Of Endocrinology, Charlottesville, United States of America
Topic:
AS03‐Artificial Pancreas
VALIDATION OF A NOVEL MODEL OF GLUCAGON EFFECT INCLUDING GLUCAGON RECEPTOR DYNAMICS
1Universitat Politècnica de València, Instituto Universitario De Automática E Informática Industrial, Valencia, Spain, 2Technical University of Denmark, Department Of Applied Mathematics And Computer Science, Kgs. Lyngby, Denmark, 3Steno Diabetes Center Copenhagen, Clinical Research, Herlev, Denmark, 4Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Ciberdem, Madrid, Spain
Topic:
AS03‐Artificial Pancreas
A REINFORCEMENT LEARNING BOLUS CALCULATOR WITH NO MEAL INFORMATION FOR PATIENTS WITH TYPE 1 DIABETES
University of Girona, Institute Of Informatics And Applications, Girona, Spain
Topic:
AS04‐Clinical Decision Support Systems/Advisors
ALGORITHM‐DRIVEN BASAL‐BOLUS THERAPY IN HOSPITALIZED PATIENTS WITH TYPE 2 DIABETES: IMPLICATIONS FOR DISCHARGE THERAPY
1Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 2decide Clinical Software GmbH, ‐, Graz, Austria
Topic:
AS04‐Clinical Decision Support Systems/Advisors
PREDICTING THE RISK OF NOCTURNAL HYPOGLYCEMIA AT BEDTIME FOR INSULIN‐TREATED PEOPLE WITH TYPE 2 DIABETES
1Aalborg University Hospital, Steno Diabetes Center Nordjylland, Aalborg, Denmark, 2Aalborg University, Department Of Health Science And Technology, Aalborg, Denmark, 3Aalborg University Hospital, Department Of Endocrinology, Aalborg, Denmark, 4Aalborg University Hospital, Department Of Clinical Medicine, Aalborg, Denmark
Topic:
AS04‐Clinical Decision Support Systems/Advisors
VALIDATION OF FEAR OF HYPOGLYCEMIA SCREENER: RESULTS FROM THE T1D EXCHANGE REGISTRY
J. Liu1,
1T1D Exchange, T1d Exchange, Boston, United States of America, 2Eli Lilly and Company, Diabetes, Indianapolis, United States of America, 3Vrije Universiteit Amsterdam, Department Of Medical Psychology Amsterdam University Medical Centres, Amsterdam, United States of America, 4University of California San Francisco School of Medicine, Family And Community Medicine, San Francisco, United States of America
Topic:
AS17‐Big data and artificial intelligence based decision support systems
CLASSIFICATION OF DAILY CGM PROFILES AND ITS CLINICAL INTERPRETATION
1University of Virginia, School Of Data Science, Charlottesville, United States of America, 2University of Virginia, School Of Medicine, Center For Diabetes Technology, Charlottesville, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
HBA1C DETERMINATIONS ACCORDING TO TELEMEDICINE ACCESS PRE AND POST LOCKDOWN IN LATIN AMERICAN CHILDREN WITH TYPE 1 DIABETES
1UBA, Statistics, CAPITAL FEDERAL, Argentina, 2UBA School of Pharmacy and Biochemistry, Mathematics, CAPITAL FEDERAL, Argentina, 3Hospital San Camilo, Universidad de Valparaiso, Pediatric Diabetology, valparaiso, Chile, 4Hospital San Roque, Endocrinology, Parana, Argentina, 5National Institute of Child Health, Endocrinology And Metabolism Service, Lima, Peru, 6National University Federico Villarreal, Faculty Of Medicine, Lima, Peru, 7Private Clinic former Ushuaia Regional Hospital, Diabetes, Ushuaia, Argentina, 8Hospital Regional Ushuaia. Ushuaia, Diabetes, Ushuaia, Argentina, 9Neuquén Regional Hospital, Diabetes, Neuquen, Argentina, 10Universidad Nacional del Nordeste, Diabetes, Corrientes, Argentina, 11CEMIC, Medicine Department, Buenos Aires, Argentina
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
EFFECTIVENESS OF MY DOSE COACH (MDC) USE DURING BASAL INSULIN (BI) TITRATION IN TYPE 2 DIABETES (T2D): REAL‐WORLD DATA FROM ALGERIA, COLOMBIA, INDIA AND MEXICO
1M.V. Hospital for Diabetes, Internal Medicine, Chennai, India, 2Chellaram Diabetes Institute, Endocrinology, Pune, India, 3Sanofi, Real World Evidence Generation, Digital Rwe, Bridgewater, United States of America, 4Sanofi, General Medicines, Bridgewater, United States of America, 5Clinica Integral de Diabetes‐CLID, Internal Medicine And Endocrinology, Medellín, Colombia, 6Universidad Autonoma de Nuevo Leon, Endocrinology Division, Medical School And University Hospital, Nuevo Leon, Mexico, 7Mustapha Pacha Hospital Algiers, Diabetes Department, Algiers, Algeria
Topic:
AS14‐Human factor in the use of diabetes technology
DEFAULT HIGH AND LOW ALERT SETTINGS AND ACTIVATION FREQUENCIES AMONG NOVICE CGM USERS
1Dexcom, Inc., Data Science, San Diego, United States of America, 2Dexcom, Inc., Clinical Research, San Diego, United States of America
Topic:
AS05‐Glucose Sensors
SENSOR‐DETECTED HYPOGLYCAEMIA IN SHORT‐DURATION CGM DATA FROM MULTIPLE CLINICAL TRIALS IN DIABETES. PRELIMINARY RESULTS FROM THE HYPO‐RESOLVE DATABASE.
1Medical University of Graz, Division For Endocrinology & Diabetology, Graz, Austria, 2SIB Swiss Institute of Bioinformatics, ‐, Lausanne, Switzerland, 3Eli Lilly and Company Limited, Diabetes And Endocrinology France, Neuilly‐sur‐Seine, France, 4King's College London,, Department Of Diabetes, School Of Life Course Sciences, Faculty Of Life Sciences And Medicine, London, United Kingdom, 5University of Sheffield, Department Of Oncology And Metabolism, Sheffield, United Kingdom, 6Novo Nordisk A/S, ‐, Bagsvaerd, Denmark, 7Radboud University Medical Centre, Department Of Internal Medicine, Nijmegen, Netherlands, 8Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 9University of Leicester, Leicester General Hospital, 1. leicester Diabetes Centre – Bloom, Leicester, United Kingdom
Topic:
AS05‐Glucose Sensors
COST‐EFFECTIVENESS OF A REAL‐TIME CONTINUOUS GLUCOSE MONITORING SYSTEM VERSUS SELF‐MONITORING OF BLOOD GLUCOSE IN TYPE 2 DIABETES PATIENTS ON INSULIN IN THE UNITED KINGDOM
1Vyoo‐Agency, Global Health Economics And Outcomes Research, Ramona, United States of America, 2Vyoo Agency, Global Health Economics And Outcomes Research, Paris, France, 3Manchester University NHS Foundation Trust,, Diabetes, Endocrinology And Metabolism Centre, Manchester, United Kingdom, 4Dexcom, Health Economics Outcomes Research, Global Access, San Diego, United States of America
Topic:
AS05‐Glucose Sensors
COMPARATIVE EFFICACY OF ISCGM, RTCGM, AND SMBG AMONG PATIENTS WITH TYPE 1 DIABETES: REAL‐WORLD EVIDENCE FROM A MULTI‐CENTER STUDY
S. Hsieh1, O. Ebekozien2, N. Rioles2, E. Ospelt2, S. Majidi3, H. Akturk4, D. Buckingham5, B. Miyazaki6, N. Hawa Yayah Jones7, R. Mcdonough8, C. Demeterco‐Berggren9, L. Jacobson10,
1Cook Children's Hospital, Endocrinology, TX, United States of America, 2T1D Exchange, Qi And Population Health, Boston, United States of America, 3Barbara Davis Center, Endocrinology, CO, United States of America, 4University of Colorado, Barbara Davis Center For Diabetes, AURORA, United States of America, 5Nationwide Children's Hospital, Endocrinology, OH, United States of America, 6Children's Hospital of Los Anglese, Endocrinology, LA, United States of America, 7Cincinnati Children's Hospital, Endocrinology, OH, United States of America, 8Children's Mercy‐ Kansas City, Endocrinology, MO, United States of America, 9Rady Children's Hospital, Endocrinology, CA, United States of America, 10University of Florida, Endocrinology, FL, United States of America
Topic:
AS05‐Glucose Sensors
INEQUITIES IN DIABETES DEVICE USE: T1D EXCHANGE BASELINE TREND ANALYSIS
1T1D Exchange, Qi And Population Health, Boston, United States of America, 2Nationwide Children Hospital, Quality Improvement, Columbus, United States of America, 3University of Alabama at Birmingham, Endocrinology, Birmingham, United States of America, 4University of Tennessee, Endocrinology, Nashville, United States of America, 5Upstate Medical University, Endocrinology, Syracuse, United States of America, 6Cincinnati Children's Hospital Medical Center, Endocrinology, Cincinnati, United States of America
Topic:
AS05‐Glucose Sensors
A TOOL NOT A TREATMENT: THE EFFECT OF LONG‐TERM CONTINUOUS/FLASH GLUCOSE MONITORING ON REAL‐WORLD HYPOGLYCEMIA RATES (INPHORM STUDY)
1Western University, Department Of Family Medicine, London, Canada, 2Western University, Department Of Epidemiology, London, Canada, 3Robarts Research Institute, Department Of Epidemiology And Biostatistics, London, Canada
Topic:
AS05‐Glucose Sensors
NOVEL APPROACH OF DAY‐1 PERFORMANCE IMPROVEMENT OF AN AMPEROMETRIC GLUCOSE SENSOR BY ACCELERATING SENSOR READINESS DURING WARM‐UP PERIOD
R. Dutt‐Ballerstadt1,
1WaveForm Technologies, R&d, Wilsonville, United States of America, 2WaveForm Technologies, Engineering Manager, Cgm, Wilsonville, United States of America
Topic:
AS05‐Glucose Sensors
REAL WORLD TIME BELOW RANGE RELATED TO GLUCOSE VARIABILITY MEASURED BY EITHER TOTAL OR WITHIN‐DAY COEFFICIENT OF VARIATION
1CHUV, University of Lausanne, Department Of Endocrinology, Diabetes And Metabolism, Lausanne, Swaziland, 2Lariboisiere Hospital, Department Of Diabetology And Endocrinology, Paris, France, 3Brabois Hospital, CHRU of Nancy & University of Lorraine, Department Of Endocrinology Diabetology And Nutrition, Nancy, France, 4Abbott, Abbott Diabetes Care, Wiesbaden, Germany, 5Abbott, Abbott Diabetes Care, Alameda, United States of America
Topic:
AS15‐Trials in progress
DEVELOPMENT OF A NOVEL VIRTUAL CGM INITIATION SERVICE TO ENHANCE CGM UPTAKE IN PRIMARY CARE PRACTICES
1University of Colorado School of Medicine, Family Medicine, Aurora, United States of America, 2University of Colorado Anschutz Medical Campus, Skaggs School Of Pharmacy And Pharmaceutical Sciences, Aurora, United States of America, 3University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America
Topic:
AS15‐Trials in progress
IMPLEMENTING CGM IN PRIMARY CARE PRACTICES VIA THE AMERICAN ACADEMY OF FAMILY PHYSICIANS TIPS CGM MODULE WITH AND WITHOUT PRACTICE FACILITATION: A RANDOMIZED TRIAL
1University of Colorado School of Medicine, Family Medicine, Aurora, United States of America, 2University of California San Francisco School of Medicine, Family And Community Medicine, San Francisco, United States of America
Topic:
AS07‐Insulin Pumps
NIGHT‐SHIFT WORK IS ASSOCIATED WITH POORER GLYCEMIC CONTROL IN PATIENTS WITH TYPE 1 DIABETES ON INSULIN PUMP THERAPY
Centro hospitalar universitário de Coimbra, Endocrinology, Coimbra, Portugal
Topic:
AS07‐Insulin Pumps
CONTINUOUS GLUCOSE MONITORING IN CSII THERAPY IN DIFFERENT AGE GROUPS (0.5‐
1DRK Children´s Hospital Kirchen, Paediatrics, Kirchen, Germany, 2University of Ulm, Institute Of Epidemiology And Medical Biometry, Zibmt, Ulm, Germany, 3German Center for Diabetes Research, Dzd, Neuherberg, Germany, 4University of Erlangen, Children's Hospital, Paediatric Endocrinology Division, Erlangen, Germany, 5Kliniken Südostbayern, Department Of Paediatrics, Traunstein, Germany, 6Medical Clinic Leverkusen, Centre For Paediatrics, Leverkusen, Germany, 7Medical University Innsbruck, Department Of Paediatrics, Innsbruck, Austria, 8Müritzklinikum Waren, Children's Hospital, Waren, Germany, 9Paediatric Practice, ‐, Herford, Germany, 10University of Bonn, Children's Hospital, Paediatric Diabetology, Endocrinology, Metabolism And Obesity, Bonn, Germany
Topic:
AS08‐New Medications for Treatment of Diabetes
EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON LIVER FAT CONTENT AND ABDOMINAL ADIPOSE TISSUE IN PATIENTS WITH TYPE 2 DIABETES (SURPASS‐3 MRI)
1Institute of Clinical Physiology, CNR, Cardiometabolic Risk Unit, Pisa, Italy, 2The University of Florida, Division Of Endocrinology, Diabetes And Metabolism, Gainesville, United States of America, 3Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America
52 was significantly greater for the pooled tirzepatide 10/15‐mg arms vs IDeg arm and for all individual tirzepatide doses vs IDeg. The proportions of participants achieving LFC targets were significantly greater in each tirzepatide arm vs IDeg arm. All tirzepatide doses reduced VAT and ASAT volumes at Week 52 while IDeg increased both. The results were similar regardless of the concomitant use of SGLT‐2i.
Topic:
AS08‐New Medications for Treatment of Diabetes
EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON GLYCEMIC CONTROL CAPTURED WITH CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES (SURPASS‐3 CGM)
1University of Ljubljana, Faculty Of Medicine, Ljubljana, Slovenia, 2University Medical Center Ljubljana, Pediatric And Adolescent Endocrinology, Ljubljana, Slovenia, 3International Diabetes Center HealthPartners Institute, International Diabetes Center Healthpartners Institute, Minneapolis, United States of America, 4Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
AUTOMATED INSULIN DELIVERY (AID)‐ENHANCED WITH SGLT2I AS COMBINED THERAPY IN TYPE 1 DIABETES
1University of Virginia, School Of Medicine, Center For Diabetes Technology, Charlottesville, United States of America, 2University of Virginia, Division Of Endoncrinology And Metabolism, Center For Diabetes Technology, Charlottesville, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
ACHIEVEMENT OF HBA1C LESS THAN 5.7% WITHOUT WEIGHT GAIN AND HYPOGLYCEMIA IN PEOPLE WITH T2D TREATED WITH TIRZEPATIDE ACROSS THE PHASE 3 SURPASS PROGRAM
1University of Leicester, Diabetes Research Centre, Leicester, United Kingdom, 2University of Texas Southwestern Medical Center, Department Of Internal Medicine/endocrinology And Department Of Population And Data Sciences, Dallas, United States of America, 3St Michael's Hospital, Department Of Medicine, Toronto, Canada, 4University of Toronto, Department Of Medicine, Toronto, Canada, 5Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
T1DM REMISSION AND Β‐CELL REGENERATION, INDUCED BY ORAL ADMINISTRATION OF TRIPLE‐DRUG COMBINATION OF DPP‐4 INHIBITOR, PPI, AND GABA IN NOD MICE. A PROOF‐OF‐CONCEPT
1Institute of Endocrinology and Metabolism, Ramat Ha Hayal, Tel Aviv, Israel, 2Sechenov University, Center Of Preclinical Studies, Moscow, Russian Federation
Our previous pilot studies in adults have shown that with triple therapy (TT) insulin demands were reduced by 59%, in parallel with a significant reduction of HBA1C and without weight loss. 31.6% of participants entered a long‐term remission and became insulin‐free.
Topic:
AS08‐New Medications for Treatment of Diabetes
AT278 (U500) – PK/PD AND SAFETY OF RAPID‐ACTING CONCENTRATED INSULIN ASPART
1Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 2Joanneum Research, Health ‐ Institute Of Health And Biomedical Sciences, Graz, Austria, 3Arecor Limited, Product Development, Great Chesterford, United Kingdom
Topic:
AS08‐New Medications for Treatment of Diabetes
PREVENTION OF T1DM, INDUCED BY ORAL ADMINISTRATION OF TRIPLE‐DRUG COMBINATION OF DPP‐4 INHIBITOR, PPI, AND GABA IN NOD MICE. A PROOF‐OF‐CONCEPT
1Institute of Endocrinology and Metabolism, Ramat Ha Hayal, Tel Aviv, Israel, 2Sechenov University, Center Of Preclinical Studies, Moscow, Russian Federation
Topic:
AS03‐Artificial Pancreas
IP‐IP PADOVA SIMULATOR: INTRAPERITONEAL INSULIN DELIVERY AND GLUCOSE SENSING
1University of Pavia, Department Of Electrical, Computer And Biomedical Engineering, Pavia, Italy, 2University of Padova, Department Of Information Engineering, Padova, Italy, 3University of Pavia, Department Of Civil And Architecture Engineering, Pavia, Italy, 4University of Padova, Department Of Woman And Child's Health, Padova, Italy
To this aim, an IP extended version of the FDA accepted SC simulator (IP‐T1DS) has been developed.
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
THE ASSOCIATION BETWEEN TIME IN RANGE %, MEASURED BY CONTINUOUS GLUCOSE MONITORING (GCM) AND PHYSICAL & FUNCTIONAL INDICES AMONGST OLDER PEOPLE WITH TYPE 2 DIABETES
Y. Basson‐Shleymovich1,2,
1Sheba medical center, Center For Successful Aging With Diabetes, RAMAT‐GAN, Israel, 2Clalit Health Services, "blumental" Physical Therapy Clinic, Bnei‐Brak, Israel, 3Sheba medical center, Head Of The Endocrinology & Diabetes Service For Women And In Pregnancy Division Of Endocrinology, Diabetes And Metabolism, RAMAT‐GAN, Israel, 4Tel‐Aviv University, Herczeg Institute On Aging, Tel Aviv, Israel, 5Ariel University, Physiotherapy, Ariel, Israel
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
COMPARING THE BENEFITS OF A PAINLESS LANCING DEVICE IN PEOPLE WITH DIABETES IN IMPROVING SELF‐MONITORING FREQUENCY AND HBA1C
Jothydev's Diabetes Research Centre, Diabetes, Trivandrum, India
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
PERIOPERATIVE CLOSED‐LOOP INSULIN DELIVERY VERSUS STANDARD INSULIN THERAPY ‐ A RANDOMISED CONTROLLED PARALLEL CLINICAL TRIAL IN ADULTS WITH TYPE 2 DIABETES
1University of Bern, Department Of Diabetes, Endocrinology, Nutritional Medicine And Metabolism Inselspital, Bern, Switzerland, 2Inselspital, Bern University Hospital, University of Bern, Department Of Anesthesiology And Pain Medicine, Bern, Switzerland, 3Laboratory of Biometry, School of Agriculture, University Of Thessaly, Nea Ionia‐volos, Magnesia, Greece, Nea Ionia‐Volos, Greece, 4Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, University Institute Of Clinical Chemistry,, Bern, Switzerland, 5Inselspital, Bern University Hospital and University of Bern, Department Of Cardiovascular Surgery, Bern, Switzerland, 6Inselspital, Bern University Hospital and University of Bern, Department Of General Thoracic Surgery, Bern, Switzerland, 7Inselspital, Bern University Hospital and University of Bern, Department Of Neurosurgery, Bern, Switzerland, 8Inselspital, Bern University Hospital and University of Bern, Department Of Orthopaedic Surgery And Traumatology, Bern, Switzerland, 9Inselspital, Bern University Hospital, University of Bern, Department Of Visceral Surgery And Medicine, Inselspital, Bern University Hospital, Bern, Switzerland, 10University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
STENOPOOL: A SYSTEM FOR MANAGING ALL DIABETES DEVICE DATA
1Steno Diabetes Center Copenhagen, Herlev, Denmark, Clinical Research, Herlev, Denmark, 2Region Hovedstaden, Telemedicinsk Videncenter, Hillerød, Denmark, 3Line Systems ApS, Research And Development, Vedbæk, Denmark
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
REDUCTION IN DIABETES‐RELATED HOSPITALIZATION RATES AFTER REAL‐TIME CONTINUOUS GLUCOSE MONITOR (RTCGM) INITIATION
Dexcom, Health Economics And Outcomes Research, Global Access, San Diego, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
PRINCIPAL DIMENSIONS OF GLYCEMIC VARIABILITY AND QUALITY OF GLYCEMIC CONTROL IN DIABETES
University of Virginia, School Of Medicine, Center For Diabetes Technology, Charlottesville, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
ACTIVE & PASSIVE SHARING OF DIABETES DEVICE DATA TO CLINICS IS ASSOCIATED WITH REDUCED A1C AND DECREASED DKA RATES
1Children's Mercy Kansas City, Pediatrics, Kansas City, United States of America, 2Children's Mercy Kansas City, Pediatric Endocrinology, Kansas City, United States of America
Topic:
AS15‐Trials in progress
ALPHA‐MELANOCYTE STIMULATORY HORMONE: A NOVEL PLAYER IN POST‐PRANDIAL GLUCOSE DISPOSAL IN SKELETAL MUSCLE IN HUMANS
1Conway Institute, University College Dublin, Ucd Diabetes Complications Research Centre, Dublin, Ireland, 2Imperial College London, Department Of Metabolism, Digestion, And Reproduction, London, United Kingdom, 3University College Dublin, Ucd School Of Public Health, Physiotherapy And Sports Science, Dublin, Ireland, 4Monash University, Monash Biomedicine Discovery Institute, Melbourne, Australia
Topic:
AS15‐Trials in progress
RATES OF SENSOR DETECTED HYPOGLYCAEMIA AND PATIENT REPORTED HYPOGLYCAEMIA; PRELIMINARY DATA FROM THE HYPO‐METRICS TRIAL
1King's College London,, Department Of Diabetes, School Of Life Course Sciences, Faculty Of Life Sciences And Medicine, London, United Kingdom, 2University of Southern Denmark, Department Of Psychology, Odense, Denmark, 3Maastricht University Medical Centre, . Department Of Internal Medicine, Division Of Endocrinology And Metabolic Disease, Maastricht, Netherlands, 4Maastricht University, Carim School For Cardiovascular Diseas, Maastricht, Netherlands, 5Nordsjællands Hospital, Hillerød, Department Of Endocrinology And Nephrology, Hillerød, Denmark, 6University of Dundee, Systems Medicine, School Of Medicine, Dundee, United Kingdom, 7Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France, 8University of Sheffield, Department Of Oncology And Metabolism, Sheffield, United Kingdom, 9University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 10Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 11Abbott Diabetes Care, Medical Affairs, Wiesbaden, Germany, 12University of Leicester, Leicester General Hospital, 1. leicester Diabetes Centre – Bloom, Leicester, United Kingdom, 13University of Leicester, Diabetes Research Centre, Leicester, United Kingdom
Topic:
AS16‐COVID‐19 and Diabetes
TYPE 2 DIABETES IMPAIRS ANTIVIRAL IMMUNITY BY PREVENTING THE INDUCTION OF FASTING METABOLISM
M. Šestan1, A. Benić1, S. Mikasinović1, D. Konrad2, S. Wueest2, T. Turk Wensveen3, B. Polić1,
1University of Rijeka faculty of medicine, Histology & Embryology, Rijeka, Croatia, 2Universitats‐kinderspital Zurich, Endocrinology & Diabetology, Zurich, Switzerland, 3Thalassotherapia Opatija, Center For Diabetes, Endocrinology And Cardiometabolism, Opatija, Croatia
Topic:
AS01‐Closed‐loop System and Algorithm
IN SILICO DESIGN AND ASSESSMENT OF A TIME‐VARYING PID CONTROLLER FOR AN INTRAPERITONEAL ARTIFICIAL PANCREAS
1University of Padova, Department Of Woman And Child's Health, Padova, Italy, 2University of Pavia, Department Of Electrical, Computer And Biomedical Engineering, Pavia, Italy, 3University of Padova, Information Engineering, Padova, Italy
Topic:
AS01‐Closed‐loop System and Algorithm
COMPARATIVE EFFICACY OF HYBRID CLOSED‐LOOP INSULIN DELIVERY SYSTEMS (HCLS) AND SENSOR AUGMENTED PUMPS (SAP) AMONG PEOPLE WITH TYPE 1 DIABETES: A U.S. BASED MULTI‐CENTER STUDY
D. Desalvo1,
1Texas Children's Hospital, Endocrinology, Houston, United States of America, 2T1D Exchange, Qi And Population Health, Boston, United States of America, 3Natiowide Children's Hospital, Endocrinology, Ohio, United States of America, 4Barbara Davis Center, Pediatrics, CO, United States of America, 5SUNY UPSTATE MEDICAL UNIVERSITY, Endocrinology, SY, United States of America, 6Children's Mercy‐ Kansas City, Endocrinology, MO, United States of America, 7Cook Children's Hospital, Endocrinology, TX, United States of America, 8Rady Children's Hospital, Endocrinology, CA, United States of America, 9University of Florida, Endocrinology, FL, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
DIABELOOP IN LONG STANDING TYPE 1 DIABETES WITH DEMENTIA
Gemeinschaftskrankenhaus Bonn, Endocrinology, Bonn, Germany
Topic:
AS01‐Closed‐loop System and Algorithm
IMPROVED GLYCEMIA AND QUALITY OF LIFE AMONG LOOP USERS ‐ A RETROSPECTIVE ANALYSIS OF REAL‐WORLD DATA FROM A SINGLE CENTRE.
University of Alberta, Medicine, Edmonton, Canada
Topic:
AS01‐Closed‐loop System and Algorithm
COMPARING GLUCOSE CONTROL DURING MODERATE‐INTENSITY, HIGH‐INTENSITY AND RESISTANCE EXERCISE WITH CLOSED‐LOOP INSULIN DELIVERY WHILE PROFILING POTENTIAL ADDITIONAL SIGNALS IN ADULTS WITH TYPE 1 DIABETES
1St Vincent's Hospital, Department Of Endocrinology And Diabetes, Melbourne, Australia, 2University of Melbourne, Department Of Medicine, Melbourne, Australia, 3Stanford University, Department Of Pediatrics, Palo Alto, United States of America, 4St Vincent's Hospital, Department Of Cardiology, Melbourne, Australia, 5Baker Heart and Diabetes Institute, Clinical Research Domain, Melbourne, Australia, 6University of Sydney, Nhmrc Clinical Trials Centre, Sydney, Australia, 7Royal Melbourne Hospital, Department Of Diabetes And Endocrinology, Melbourne, Australia, 8John Hunter Children's Hospital, Department Of Endocrinology And Diabetes, Newcastle, Australia, 9York University, School Of Kinesiology And Health Science,muscle Health Research Centre, Toronto, Canada
Topic:
AS01‐Closed‐loop System and Algorithm
SAFETY AND GLYCEMIC CONTROL DURING THE MEDTRONIC ADVANCED HYBRID CLOSED‐LOOP (AHCL) PIVOTAL TRIAL IN YOUTH AGED 7‐17 YEARS WITH TYPE 1 DIABETES (T1D)
R. Slover1, C. Pihoker2,
1Barbara Davis Center for Childhood Diabetes, Endocrinology, Aurora, United States of America, 2Seattle Children's Hospital, Pediatric Endocrinology, Seattle, United States of America, 3University of South Florida, Pediatric Endocrinology, Tampa, United States of America, 4SoCal Diabetes, Endocrinology, Torrance, United States of America, 5Rocky Mountain Diabetes and Osteoporosis Center, PA, Pediatric Endocrinology, Idaho Falls, United States of America, 6Yale University School of Medicine, Pediatric Endocrinology, New Haven, United States of America, 7International Diabetes Center, Endocrinology, Minneapolis, United States of America, 8Atlanta Diabetes Associates Hospital, Atlanta Diabetes Associates, Atlanta, United States of America, 9Diabetes and Glandular Clinic, Endocrinology, San Antonio, United States of America, 10Medical Investigations Inc., Endocrinology, Little Rock, United States of America, 11Stanford University, Pediatric Endocrinology, Palo Alto, United States of America, 12Medtronic, Clinical Research, Northridge, United States of America, 13Medtronic, Medical Affairs, Northridge, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
YOUTH WITH TYPE 1 DIABETES BENEFIT FROM EARLY CONTINUOUS GLUCOSE MONITORING INITATION IRRESPECTIVE OF DIABETIC KETOACIDOSIS AT DIAGNOSIS: 4T PILOT STUDY RESULTS
Stanford University School of Medicine, Pediatrics, Palo Alto, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
INTRALYMPHATIC GAD‐ALUM (DIAMYD®) IMPROVES GLYCEMIC CONTROL IN TYPE 1 DIABETES PATIENTS CARRYING HLA DR3‐DQ2
1Linköping university, Crown Princess Victoria Children´s Hospital And Div Of Pediatrics, Dept Of Biomedical And Clinical Sciences, Linköping, Sweden, 2Karolinska institutet, Department Of Neurobiologi, Vårdvetenskap Och Samhälle, Huddinge, Sweden, 3Diamyd Medical, Nn, Stockholm, Sweden
Topic:
AS08‐New Medications for Treatment of Diabetes
INDIRECT TREATMENT COMPARISON OF READY‐TO‐USE GLUCAGON RESCUE TREATMENTS FOR SEVERE HYPOGLYCEMIA: NASAL GLUCAGON VERSUS LIQUID STABLE GLUCAGON
Y. Yan, C. Child,
Eli Lilly and Company, Diabetes, Indianapolis, United States of America
Topic:
AS10‐Devices Focused on Diabetic Preventions
TRANSDERMAL CAPILLARY BLOOD COLLECTION FOR C‐PEPTIDE IS A PRACTICAL, ACCEPTABLE AND RELIABLE ALTERNATIVE TO VENOUS SAMPLING IN CHILDREN AND ADULTS WITH TYPE 1 DIABETES
1Oxford University Hospitals NHS Foundation Trust, Pediatric Endocrinology And Diabetes, Oxford, United Kingdom, 2Wellcome Centre for Human Genetics, University of Oxford, Nuffield Department Of Medicine, Nihr Oxford Biomedical Research Centre, Roosevelt Drive, United Kingdom, 3Bristol Medical School, University of Bristol., Diabetes And Metabolism, Translational Health Sciences, Bristol, United Kingdom, 4Oxford University Hospitals NHS Foundation Trust, Oxford Nihr Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom, 5Royal Devon and Exeter NHS Foundation Trust, Academic Department Of Blood Sciences, Exeter, United Kingdom, 6Oxford University Hospitals NHS Foundation Trust, Pediatrics, Oxford, United Kingdom, 7Oxford NIHR Biomedical Research Centre, University of Oxford, Centre For Statistics In Medicine, Oxford, United Kingdom
Topic:
AS14‐Human factor in the use of diabetes technology
FAMILY SHARING OF DIABETES RESPONSIBILITIES FOR CONTINUOUS GLUCOSE MONITORING (CGM) USE: AN UPDATE OF THE DIABETES FAMILY RESPONSIBILITY QUESTIONNAIRE (DFRQ)
1Joslin Diabetes Center, Pediatric Endocrinology, Boston, United States of America, 2Boston Children's Hospital, Endocrinology, Boston, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
FOUNDATIONAL USER EXPERIENCE NEEDS FOR NEWLY‐DIAGNOSED PEOPLE WITH T2 DIABETES
Novo Nordisk A/S, Devices & Delivery Solutions, Hillerød, Denmark
Topic:
AS15‐Trials in progress
EFFICACY, DURABILITY, AND SAFETY OF FARICIMAB IN DIABETIC MACULAR EDEMA (DME): 1‐YEAR RESULTS FROM THE PHASE 3 YOSEMITE AND RHINE TRIALS
1Retina Associates, LLC, Ophthalmology, Lenexa, United States of America, 2Genentech, Inc., Ophthalmology, South San Francisco, United States of America, 3Roche Products Ltd., Ophthalmology, Welwyn Garden City, United Kingdom, 4Roche Products (Ireland) Ltd., Ophthalmology, Dublin, Ireland
Topic:
AS15‐Trials in progress
A COGNITIVE BEHAVIORAL THERAPY INTERVENTION (FREE)TO REDUCE FEAR OF HYPOGLYCEMIA IN YOUNG ADULTS WITH TYPE 1 DIABETES (T1D): A RANDOMIZED CONTROLLED TRIAL
1University of Illinois Chicago, Biobehavioral Nursing Science, Chicago, United States of America, 2University of Illinois Chicago, Department Of Psychiatry, Chicago, United States of America, 3Cook County Health, Endocrinology, Chicago, United States of America, 4Loyola University Chicago, Nursing, Maywood, United States of America, 5University of Illinois Chicago, Endocrinology, Chicago, United States of America
Topic:
AS15‐Trials in progress
GAS‐PHASE BIOSENSOR FOR EXHALED ACETONE AS AN EARLY DIAGNOSTIC MARKER FOR DIABETES
M. Ye, P.‐J. Chien, K. Iitani, K. Toma, T. Arakawa,
Tokyo Medical and Dental University, Institute Of Biomaterials And Bioengineering, Tokyo, Japan
Topic:
AS14‐Human factor in the use of diabetes technology
DIABETES PROVIDER BIAS TO RECOMMENDING DIABETES TECHNOLOGY FOR PATIENTS ON PUBLIC INSURANCE IN THE UNITED STATES
1T1D Exchange, Qi And Population Health, Boston, United States of America, 2Nationwide Children Hospital, Quality Improvement, Columbus, United States of America, 3Cincinnati Children's Hospital Medical Center, Endocrinology, Cincinnati, United States of America, 4Upstate Medical University, Endocrinology, Syracuse, United States of America, 5Children Hospital of Atlanta, Endocrinology, Atlanta, United States of America, 6University of Alabama at Birmingham, Endocrinology, Birmingham, United States of America, 7Albert Einstein College of Medicine, Endocrinology, Bronx, United States of America, 8University of Tennessee, Endocrinology, Nashville, United States of America, 9Stanford University, Endocrinology, Stanford, United States of America, 10Medtronic Diabetes, Other, Fridley, United States of America
Topic:
AS02‐New Insulin Analogues
GLYCEMIC CONTROL WITH ONCE WEEKLY BASAL INSULIN FC IN PERSONS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE MONITORING IN A PHASE 2 STUDY
1Eli Lilly and Company, Diabetes, Indianapolis, United States of America, 2National Research Institute, Clinical Research, California, United States of America
with a basal insulin showed HbA1c non‐inferiority of BIF vs degludec with significantly fewer hypoglycemic events (≤70 mg/dL). Here we present continuous glucose monitoring (CGM) data derived by Dexcom G6, allowing a more detailed assessment of glycemic control of BIF vs degludec.
Topic:
AS01‐Closed‐loop System and Algorithm
IMPROVED GLYCEMIC CONTROL WITH HYBRID CLOSED‐LOOP (HCL) VERSUS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) THERAPY: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (RCT)
1Barbara Davis Center for Childhood Diabetes, Endocrinology, Aurora, United States of America, 2Endocrine Research Solutions, Endocrinology, Roswell, United States of America, 3Atlanta Diabetes Associates Hospital, Atlanta Diabetes Associates, Atlanta, United States of America, 4Grunberger Diabetes Institute, Endocrinology, Bloomfield, United States of America, 5Rainier Clinical Research Center, Endocrinology, Renton, United States of America, 6Diablo Clinical Research, Endocrinology, Walnut Creek, United States of America, 7Rocky Mountain Diabetes and Osteoporosis Center, PA, Endocrinology, Idaho Falls, United States of America, 8Park Nicollet, Health Partners, International Diabetes Center, Minneapolis, United States of America, 9SoCal Diabetes, Endocrinology, Torrance, United States of America, 10University of Michigan Health System‐ University Hospital, Endocrinology, Ann Arbor, United States of America, 11Mayo Clinic, Endocrinology, Rochester, United States of America, 12SUNY, Upstate Medical University, Syracuse, United States of America, 13Diabetes and Glandular Clinic, Endocrinology, San Antonio, United States of America, 14Sanford Research USD, Endocrinology, Vermillion, United States of America, 15Children's Hospital of Eastern Ontario, Endocrinology, Ottawa, Canada, 16Stanford University, Pediatric Endocrinology, Palo Alto, United States of America, 17Washington University School of Medicine‐ St. Louis, Endocrinology, St. Louis, United States of America, 18Indiana University‐ Riley Hospital for Children, Endocrinology, Indianapolis, United States of America, 19Scripps Whittier Diabetes Center, Endocrinology, San Diego, United States of America, 20Medtronic, Clinical Research, Northridge, United States of America, 21Medtronic, Medical Affairs, Northridge, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
PERFORMANCE OF OMNIPOD® 5 AUTOMATED INSULIN DELIVERY SYSTEM AT SPECIFIC GLUCOSE TARGETS FROM 110‐150MG/DL OVER THREE MONTHS IN VERY YOUNG CHILDREN WITH TYPE 1 DIABETES
1University Hospitals Cleveland Medical Center, Rainbow Babies And Children's Hospital, Cleveland, United States of America, 2Yale University School of Medicine, Pediatric Endocrinology, New Haven, United States of America, 3Atlanta Diabetes Associates, Clinical Research, Atlanta, United States of America, 4University of Colorado, Barbara Davis Center For Diabetes, Aurora, United States of America, 5Harvard Medical School, Joslin Diabetes Center, Boston, United States of America, 6University of Virginia School of Medicine, Pediatric Endocrinology, Charlottesville, United States of America, 7Stanford University, Pediatric Endocrinology, Palo Alto, United States of America, 8Park Nicollet, HealthPartners, International Diabetes Center, St Louis Park, United States of America, 9Baylor College of Medicine, Pediatric Diabetes And Endocrinology, Houston, United States of America, 10SUNY, Upstate Medical University, Syracuse, United States of America, 11Insulet Corporation, Clinical Department, Acton, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
HYBRID CLOSED‐LOOP GLUCOSE CONTROL COMPARED WITH SENSOR AUGMENTED PUMP THERAPY IN OLDER ADULTS WITH TYPE 1 DIABETES: A MULTICENTRE, MULTINATIONAL, RANDOMISED, CROSSOVER STUDY
1University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 2Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes And Endocrine Clinic, Cambridge, United Kingdom, 3Manchester University NHS Foundation Trust,, Diabetes, Endocrinology And Metabolism Centre, Manchester, United Kingdom, 4University Hospitals Birmingham NHS Foundation Trust, Diabetes, Birmingham, United Kingdom, 5Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 6Stanford University, Stanford Diabetes Research Center, California, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
A COMPARISON OF TWO HYBRID CLOSED‐LOOP SYSTEMS IN ITALIAN CHILDREN AND ADULTS WITH TYPE 1 DIABETES
Istituto Giannina Gaslini, Diabetologia, Genova, Italy
Topic:
AS01‐Closed‐loop System and Algorithm
ACCURACY OF BGL PREDICTION FROM A PERSONALIZABLE PHYSIOLOGICAL MODEL OF BLOOD GLUCOSE DYNAMICS USING REAL‐WORLD DATA
E. Rodrigues1, P. Saddi‐Rosa2, M. Costa1, C. Neto3, M. Teles2,
1GlucoGear, Research & Development, Ribeirão Preto, Brazil, 2Grupo Fleury, Endocrinology, São Paulo, Brazil, 3University of São Paulo, School Of Arts, Sciences And Humanities, São Paulo, Brazil, 4University of São Paulo, Internal Medicine, Ribeirão Preto, Brazil
Topic:
AS01‐Closed‐loop System and Algorithm
DOES PARENTAL SLEEP QUALITY IMPROVE AFTER HIBRID CLOSE‐LOOP SYSTEM MEDTRONIC 780G INSTAURATION?
Hospital Universitario Puerta del Mar, Pediatric Departement. Pediatric Endocrinology Unit., Cadiz, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
COMPARISON OF NOCTURNAL GLUCOSE MANAGEMENT AFTER EXERCISE AMONG DUAL‐HORMONE, SINGLE‐HORMONE AUTOMATED INSULIN DELIVERY SYSTEM AND USUAL CARE IN TYPE 1 DIABETES: A POOLED ANALYSIS
1McGill University, Department Of Medicine, Division Of Experimental Medicine, Montreal, Canada, 2Institut de recherches cliniques de Montréal (IRCM), Montreal, Canada, 3University of Alberta, Augustana Faculty, Camrose, Canada, 4Li Ka Shing Centre for Health Research Innovation, Physical Activity And Diabetes Laboratory, Alberta Diabetes Institute, Edmonton, Canada, 5University of Alberta, Faculty Of Kinesiology, Sport And Recreation, Edmonton, Canada, 6University of Alberta, Women And Children's Health Research Institute, Edmonton, Canada, 7Université de Montréal, Department Of Nutrition, Faculty Of Medicine, Montreal, Canada
Topic:
AS01‐Closed‐loop System and Algorithm
GLYCAEMIC AND SAFETY OUTCOMES ASSOCIATED WITH DO‐IT‐YOURSELF ARTIFICIAL PANCREAS SYSTEMS (DIYAPS): INITIAL INSIGHTS FROM THE ASSOCIATION OF BRITISH CLINICAL DIABETOLOGIST'S (ABCD) DIYAPS AUDIT PROGRAMME
1University Hospitals of Derby and Burton NHS Trust, Department Of Diabetes & Endocrinology, Derby, United Kingdom, 2University of Nottingham, School Of Medicine And Health Sciences, Derby, United Kingdom, 3Sandwell and West Birmingham Hospitals NHS Trust, Department Of Diabetes & Endocrinology, Birmingham, United Kingdom, 4King's College London, Department Of Diabetes, London, United Kingdom, 5King's Health Partners, Institute Of Diabetes, Endocrinology And Obesity, London, United Kingdom, 6Guy's and St Thomas' Hospital NHS Trust, Department Of Diabetes & Endocrinology, London, United Kingdom, 7Nottingham University Hospitals NHS Trust, Diabetes Unit, Nottingham, United Kingdom, 8Royal Surrey NHS Foundation Trust, Centre For Endocrinology, Diabetes And Research (cedar), Guildford, United Kingdom, 9University Hospitals of Derby and Burton and University of Nottingham, Diabetes And Endocrinology, Derby and Nottingham, United Kingdom
Topic:
AS15‐Trials in progress
SPOTLIGHT‐AQ PRECISION DIABETES MANAGEMENT: EFFICACY AND COST‐EFFECTIVENESS FOR USE IN ROUTINE CARE WITH PEOPLE WITH TYPE 1, TYPE 2 DIABETES OR PRE‐DIABETES
R. Kelly1, P. Phiri2, K. Austin2, A. Neave2, I. Stratton3, A. Ali4, H. Price2,
1Spotlight‐AQ, R&d, Fareham, United Kingdom, 2Southern Health NHS Foundation Trust, R&d, Southampton, United Kingdom, 3Gloucester Hospitals NHS Trust, Statistics, Gloucester, United Kingdom, 4Blackburn and Darwen CCG, Oakenhurst Medical Practice, Blackburn, United Kingdom
Topic:
AS01‐Closed‐loop System and Algorithm
DIABETIC KETOACIDOSIS AFTER INITIATION OF SGLT‐INHIBITION UNDER HYBRID CLOSED‐LOOP THERAPY IN TYPE 1 DIABETES
UZ Leuven ‐ KU Leuven, Endocrinology, Leuven, Belgium
Topic:
AS01‐Closed‐loop System and Algorithm
SIGNIFICANCE AND FUTURE TRENDS OF AID‐SYSTEMS FROM THE PERSPECTIVE OF PHYSICIANS
1Science Consulting in Diabetes GmbH, Profil Neuss, Neuss, Germany, 2Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany
Topic:
AS05‐Glucose Sensors
THE RELATIONSHIP BETWEEN CHRONIC COMPLICATIONS AND TIME IN RANGE IN PEOPLE WITH TYPE 1 DIABETES: A RETROSPECTIVE CROSS‐SECTIONAL REAL‐WORLD STUDY
1KU Leuven, Clinical And Experimental Endocrinology, Leuven, Belgium, 2University Hospitals Leuven, Endocrinology, Leuven, Belgium
DR, DN, DPN or any macrovascular complication per 1% increase in TIR was 0.969 (95%CI: 0.957‐0.982, p < 0.001), 0.959 (95%CI: 0.945‐0.974, p < 0.001), 0.981 (95%CI: 0.967‐0.995, p = 0.008), 0.980 (95%CI: 0.964‐0.997, p = 0.019) and 0.975 (95%CI: 0.958‐0.992, p = 0.005) respectively.
Topic:
AS05‐Glucose Sensors
IMPAIRED AWARENESS OF HYPOGLYCAEMIA; PREVALENCE AND ASSOCIATED FACTORS BEFORE AND AFTER FREESTYLE LIBRE USE IN THE ASSOCIATION OF BRITISH CLINICAL DIABETOLOGISTS (ABCD) AUDIT
1Hull University Teaching Hospitals NHS Trust, Academic Diabetes, Endocrinology And Metabolism, Hull, United Kingdom, 2York and Scarborough Teaching Hospitals NHS Foundation Trust, Diabetes And Endocrinology, York, United Kingdom, 3Hull University Teaching Hospitals NHS Trust, Diabetes And Endocrinology, Hull, United Kingdom, 4Hull York Medical School, University of Hull, Academic Diabetes, Endocrinology And Metabolism, Hull, United Kingdom, 5University Hospitals of Derby and Burton, Diabetes And Endocrinology, Derby, United Kingdom, 6Warrington and Halton Teaching Hospitals NHS Foundation Trust, Diabetes And Endocrinology, Warrington, United Kingdom, 7Sandwell and West Birmingham NHS Trust, Diabetes And Endocrinology, Birmingham, United Kingdom
Topic:
AS05‐Glucose Sensors
BEYOND TIME‐IN‐RANGE: IDENTIFYING TIME‐OF‐DAY WITH HYPOGLYCEMIA RISK
Abbott Diabetes Care, Research & Development, Alameda, United States of America
Topic:
AS05‐Glucose Sensors
REDUCING DISPARITIES IN HEMOGLOBIN A1C DURING THE FIRST YEAR OF DIABETES DIAGNOSIS: ACCOMPLISHMENTS AND AREAS FOR IMPROVEMENT IN THE 4T STUDY
1Stanford University, Pediatric Endocrinology & Diabetes, Stanford, United States of America, 2Stanford University, Stanford Diabetes Research Center, California, United States of America
Youth from racial/ethnic minority groups and youth with public insurance use CGM less and have higher HbA1c. To expand CGM access, all youth with T1D were offered CGM within one month of diagnosis through the 4T Study.
Topic:
AS05‐Glucose Sensors
AMBULATORY GLUCOSE PROFILE ACCORDING TO DIFFERENT PHASES OF MENSTRUAL CYCLE IN WOMEN LIVING WITH TYPE 1 DIABETES
1Avicenne hospital, Endocrinology, Bobigny, France, 2Lariboisiere hospital, Endocrinologie And Diabetes, Paris, France, 3Avicenne hospital, Clinical Research Unit, Bobigny, France
Topic:
AS05‐Glucose Sensors
THE RELATIONSHIP BETWEEN TIME‐IN RANGE (TIR), MEAN CGM GLUCOSE AND HBA1C IN YOUTH WITH TYPE 1 DIABETES
Barbara Davis Center, Pediatric Endocrinology, Aurora, United States of America
Topic:
AS05‐Glucose Sensors
TIME IN RANGE WITH FREESTYLE LIBRE (FSL); IMPACT ON GLYCAEMIC CONTROL AND RESOURCE UTILIZATION IN THE ASSOCIATION OF BRITISH CLINICAL DIABETOLOGIST NATIONAL AUDIT
1Hull University Teaching Hospitals NHS Trust, Diabetes And Endocrinology, Hull, United Kingdom, 2Hull University Teaching Hospitals NHS Trust, Academic Diabetes, Endocrinology And Metabolism, Hull, United Kingdom, 3Hull York Medical School, University of Hull, Academic Diabetes, Endocrinology And Metabolism, Hull, United Kingdom, 4University Hospitals of Leicester, Diabetes And Endocrinology, Leicester, United Kingdom, 5Danetre Hospital, London Road, Daventry NN11 4DY, UK, Diabetes And Endocrinology, London, United Kingdom, 6Queen Elizabeth Hospital Sheriff Hill, Gateshead, Tyne and Wear, NE9 6SX, Diabetes And Endocrinology, Tyne and Wear, United Kingdom, 7Sandwell and West Birmingham Hospitals NHS Trust, Department Of Diabetes & Endocrinology, Birmingham, United Kingdom, 8University Hospitals of Derby and Burton and University of Nottingham, Diabetes And Endocrinology, Derby and Nottingham, United Kingdom
Topic:
AS05‐Glucose Sensors
CONTINUOUS GLUCOSE MONITORING IN TYPE 2 DIABETES: DEMOGRAPHICS AND CHARACTERIZATION OF USE ACROSS A LARGE INTEGRATED HEALTHCARE SYSTEM
1Park Nicollet, Health Partners, International Diabetes Center, Minneapolis, United States of America, 2HealthPartners Institute, Research Informatics, Minneapolis, United States of America
Topic:
AS05‐Glucose Sensors
CONTINUOUS GLUCOSE MONITORING PATTERNS AMONG PEOPLE WITH TYPE 2 DIABETES ON HEMODIALYSIS TREATED WITH INSULIN.
Emory University School of Medicine, Department Of Medicine, Atlanta, United States of America
Topic:
AS05‐Glucose Sensors
EFFECTIVENESS OF A STEPPED‐CARE APPROACH VERSUS IMMEDIATE CONTINUOUS GLUCOSE MONITORING‐BASED TECHNOLOGIES IN HYPOGLYCEMIA‐PRONE PATIENTS WITH TYPE 1 DIABETES (ECSPECT‐HYPO)
1Amsterdam UMC, Internal Medicine, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Department Of Medical Psychology, Amsterdam, Netherlands, 3Vrije Universiteit Amsterdam, Department Of Medical Psychology Amsterdam University Medical Centres, Amsterdam, United States of America
Topic:
AS05‐Glucose Sensors
THE USE OF FLASH GLUCOSE MONITORING REDUCES THE RISK OF HYPOGLYCEMIA IN PEOPLE WITH DIABETES ON MAINTENANCE HEMODIALYSIS
1University of Pisa, Department Of Clinical And Experimental Medicine, Section Of Metabolic Diseases And Diabetes, University Of Pisa, Pisa, Italy, 2University Hospital of Pisa, Nephrology Dialysis And Kidney Transplantation Unit, Pisa, Italy
Topic:
AS09‐New Insulin Delivery Systems: Inhaled, Transderma, Implanted Devices
THE EFFECT OF GLUCAGON ON LOCAL SUBCUTANEOUS BLOOD FLOW IN HEALTHY VOLUNTEERS; A PROOF‐OF‐CONCEPT STUDY.
1Norwegian University of Science and Technology (NTNU), Department Of Clinical And Molecular Medicine, Trondheim, Norway, 2St. Olav's Hospital, Department Of Endocrinology, Trondheim, Norway
Topic:
AS09‐New Insulin Delivery Systems: Inhaled, Transderma, Implanted Devices
INFLUENCE OF BOLUS INJECTION DOSING FREQUENCY AND SMART PEN ENGAGEMENT ON GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 1 DIABETES
J. Hellman1, N. Væver Hartvig2, A. Kaas3, J. Bech Møller2, M. Reinholdt Sørensen2,
1Uppsala University Hospital, Department Of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Novo Nordisk A/S, Data Science, Søborg, Denmark, 3Novo Nordisk A/S, Digital Health, Søborg, Denmark, 4Örebro University, Dept Of Medical Sciences, Örebro, Sweden
Topic:
AS07‐Insulin Pumps
IMPACT OF X‐RAY EXPOSURE FROM COMPUTED TOMOGRAPHY (CT) ON A WEARABLE INSULIN DELIVERY DEVICE
F. Dong1,
1Cleveland Clinic, Radiology, Beachwood, United States of America, 2Insulet Corporation, Clinical And Medical Affairs, Acton, United States of America
Topic:
AS07‐Insulin Pumps
EXTENDING THE LIFE OF INSULIN PUMP INFUSION SETS BY REMOVAL OF PHENOLIC EXCIPIENTS FROM INSULIN INJECTION
L. Zhou, K. Chou, A. Abrams, A. Eden, D. Huber,
University of California, Santa Barbara, Mechanical Engineering, Santa Barbara, United States of America
Topic:
AS07‐Insulin Pumps
GLYCEMIC OUTCOMES BY AGE AND PREVIOUS INSULIN DELIVERY METHOD IN CONTROL‐IQ TECHNOLOGY USERS: 9 MONTHS OF CLIO STUDY DATA
R. Graham1, H. Singh2, L. Mueller3, K. White4, S. Habif2,
1University of California San Diego, Health System, San Diego, United States of America, 2Tandem Diabetes Care, Behavioral Sciences, San Diego, United States of America, 3Tandem Diabetes Care, Data Science, San Diego, United States of America, 4Tandem Diabetes Care, Clinical Affairs, San Diego, United States of America
CGM use were included in the analysis. Impact of baseline factors on sensor glycemic outcomes were analyzed. Differences between baseline HbA1c and GMI were compared using a Wilcoxon test.
Topic:
AS07‐Insulin Pumps
CHARACTERIZATION OF CHANGES AT INSULIN PUMP INFUSION SITES IN T1D: THE DERMIS STUDY
1University of Washington, Department Of Medicine, Seattle, United States of America, 2University of Washington, Medicine/dermatology, Seattle, United States of America, 3University of Washington, Department Of Laboratory Medicine And Pathology, Seattle, United States of America, 4University of Washington, Bioengineering, Seattle, United States of America, 5University of Washington, Medicine, Seattle, United States of America
Topic:
AS07‐Insulin Pumps
INEQUALITIES AND HETEROGENEITY IN ACCESSING DIABETES‐RELATED TECHNOLOGY: DETERMINANTS OF UPTAKE AND ACCESS TO INSULIN PUMP THERAPY BY ADULTS WITH TYPE 1 DIABETES IN IRELAND.
1University College Cork, School Of Public Health, Cork, Ireland, 2Diabetes Ireland, Advocacy And Research, Dublin, Ireland, 3University of Groningen, Faculty Of Medical Sciences, Groningen, Netherlands, 4Royal College of Surgeons in Ireland, Population Health Sciences, Dublin, Ireland, 5Royal College of Surgeons in Ireland, Diabetes Day Centre, Connolly Hospital, Blanchardstown, Dublin, Ireland
Topic:
AS07‐Insulin Pumps
LONG‐TERM IMPROVEMENTS IN PATIENT‐REPORTED OUTCOMES IRRESPECTIVE OF BASELINE GLYCEMIC CONTROL AND PREVIOUS INSULIN DELIVERY METHOD WITH THE T:SLIM X2 PUMP WITH CONTROL‐IQ TECHNOLOGY
H. Singh1, G. Alencar1, M. Manning1, K. White2, L. Mueller3, J. Pinsker2,
1Tandem Diabetes Care, Behavioral Sciences, San Diego, United States of America, 2Tandem Diabetes Care, Clinical Affairs, San Diego, United States of America, 3Tandem Diabetes Care, Data Science, San Diego, United States of America
Topic:
AS07‐Insulin Pumps
ULTRASOUND MEASURED VASCULARIZATION AND ECHOGENICITY IN THE SUBCUTIS – A PROSPECTIVE STUDY SHOWING SKIN REACTIONS TO DIABETES DEVICES IN PEDIATRIC PATIENTS WITH TYPE 1 DIABETES
1Steno Diabetes Center Copenhagen, Clinical Research ‐ Diabetes Technology, Herlev, Denmark, 2Copenhagen University Hospital, Herlev and Gentofte Hospital, Pediatric Department, Herlev, Denmark, 3Copenhagen University Hospital, Herlev and Gentofte Hospital, Department Of Radiology, Herlev, Denmark
Topic:
AS07‐Insulin Pumps
THE EFFECT OF A SKIN CARE INTERVENTION ON FREQUENCIES OF SKIN PROBLEMS IN PEDIATRIC PATIENTS SIX MONTHS AFTER INITIATION OF DIABETES DEVICES
1Copenhagen University Hospital, Herlev and Gentofte Hospital, Pediatric Department, Herlev, Denmark, 2Steno Diabetes Center Copenhagen, Clinical Research ‐ Diabetes Technology, Herlev, Denmark, 3Copenhagen University Hospital, Bispebjerg, Department Of Dermatology And Venereology, Copenhagen NV, Denmark, 4Copenhagen University Hospital, Gentofte, Department Of Dermatology And Venereology, Hellerup, Denmark
Topic:
AS07‐Insulin Pumps
MULTIPLE BASAL INFUSION RATES IN OPEN‐LOOP INSULIN DELIVERY SYSTEMS: IS THERE METABOLIC BENEFIT?
J. Marques‐Sá, S. Campos‐Lopes, M.J. Santos, M. Alves,
Hospital de Braga, Endocrinology Department, Braga, Portugal
Topic:
AS14‐Human factor in the use of diabetes technology
THE IMPACT OF REAL‐TIME CONTINUOUS GLUCOSE MONITORING ON TREATMENT SATISFACTION IN ADULTS WITH TYPE 2 DIABETES: FURTHER FINDINGS FROM THE MOBILE RANDOMIZED CLINICAL TRIAL
1Behavioral Diabetes Institute, N/a, San Diego, United States of America, 2Scripps Whittier Diabetes Institute, N/a, San Diego, United States of America, 3Jaeb Center for Health Research, N/a, Tampa, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
COSTS AND UNDERUSE OF INSULIN AND DIABETES SUPPLIES: FINDINGS FROM THE 2020 T1INTERNATIONAL CROSS‐SECTIONAL WEB‐BASED SURVEY.
1Charité ‐ Universitätsmedizin Berlin, Department Of Paediatric Endocrinology And Diabetes, Berlin, Germany, 2T1International, T1international, Cheltenham, United Kingdom, 3Technical University of Denmark, Center For Biosustainability, Copenhagen, Denmark, 4University College Cork, School Of Public Health, Cork, Ireland, 5University College Dublin, School Of Sociology, Belfield, Ireland
Topic:
AS14‐Human factor in the use of diabetes technology
ATTITUDES TOWARDS A FULLY IMPLANTABLE BIONIC INVISIBLE PANCREAS: RESULTS OF A QUALITATIVE STUDY IN PEOPLE WITH TYPE 1 DIABETES
Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany
Topic:
AS14‐Human factor in the use of diabetes technology
HYBRID THERAPY IN YOUTH WITH TYPE 1 DIABETES ‐ CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) COMBINED WITH LONG‐ACTING INSULIN: A REAL‐LIFE EXPERIENCE
1*Equal contribution. National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, The Jesse Z. And Sara Lea Shafer Institute For Endocrinology And Diabetes,, petach tikva, Israel, 2*Equal contribution‐Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Shamir (Assaf Harofeh) Medical Center,, Pediatric Endocrinology And Diabetes Institute, Tzrifin, Israel, 3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Edith Wolfson Medical Center, Pediatric Endocrine And Diabetes Unit,, holon, Israel, 4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israe, Edith Wolfson Medical Center, Pediatric Endocrinology And Diabetes Unit, holon, Israel, 5National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel Faculty of Health Sciences, Ben‐Gurion University of the Negev, Beer‐Sheva, Israel Barzilai Medical Center, Pediatrics Department, Ashkelon, Israel, 6Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Dana‐Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Pediatric Endocrinology And Diabetes Unit, Tel aviv, Israel, 7Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Pediatric Endocrine And Diabetes, Ramat‐Gan, Israel, 8Faculty of Health Sciences, Ben‐Gurion University of the Negev, Beer‐Sheva, Israel , Soroka Medical School, Beer Sheba, Israel, Pediatric Endocrine And Diabetes Unit, Beer Sheba, Israel, 9Faculty of Health Sciences, Ben‐Gurion University of the Negev, Beer‐Sheva, Israel Assuta Medical Center, Pediatric Endocrine And Diabetes Unit, Ashdod, Israel, 10Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Schneider Children's Medical Center of Israel, The Jesse Z. And Sara Lea Shafer Institute For Endocrinology And Diabetes, National Center For Childhood Diabetes,, petach tikva, Israel, 11Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Shamir (Assaf Harofeh) Medical Center, Pediatric Endocrinology And Diabetes, Tzrifin, Israel
Topic:
AS14‐Human factor in the use of diabetes technology
NOVEL VISUAL TOOL TO ASSESS THE PREVALENCE OF HYPOGLYCAEMIA SYMPTOMS IN TYPE 1 DIABETES
1King's College London,, Department Of Diabetes, School Of Life Course Sciences, Faculty Of Life Sciences And Medicine, London, United Kingdom, 2University of Southern Denmark, Department Of Psychology, Odense, Denmark, 3Radboud University Medical Centre, Department Of Internal Medicine, Nijmegen, Netherlands, 4Maastricht University Medical Centre, . Department Of Internal Medicine, Division Of Endocrinology And Metabolic Disease, Maastricht, Netherlands, 5Maastricht University, Carim School For Cardiovascular Diseases, Maastricht, Netherlands, 6Nordsjællands Hospital, Hillerød, Department Of Endocrinology And Nephrology, Hillerød, Denmark, 7University of Copenhagen, Institute Of Clinical Medicine, Copenhagen, Denmark, 8University of Dundee, Systems Medicine, School Of Medicine, Dundee, United Kingdom, 9University of Montpellier, Institute Of Functional Genomics, Montpellier, France, 10Montpellier University Hospital, Department Of Endocrinology, Diabetes, Nutrition, Montpellier, France, 11University of Sheffield, Department Of Oncology And Metabolism, Sheffield, United Kingdom, 12University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 13Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 14Deakin University, School Of Psychology, Geelong, Australia, 15Diabetes Victoria, The Australian Centre For Behavioural Research In Diabetes, Melbourne, Australia, 16Abbott Diabetes Care, Medical Affairs, Wiesbaden, Germany, 17Steno Diabetes Center Odense (SDCO), Steno Diabetes Center Odense (sdco), Odense, Denmark, 18University of Leicester, Diabetes Research Centre, Leicester, United Kingdom
Topic:
AS14‐Human factor in the use of diabetes technology
YOU'RE NOT WRONG, BUT YOU'RE NOT ENTIRELY RIGHT: HOW PATIENTS' BELIEFS INFLUENCE HOW THEY ARE PERCEIVED
1Stevens Institute of Technology, Computer Science, Hoboken, United States of America, 2Lehigh University, Department Of Psychology, Bethlehem, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
GLYCEMIC OUTCOMES IN ADULTS FROM RACIAL/EDUCATION/SOCIOECONOMIC MINORITIZED POPULATIONS WITH TYPE 1 DIABETES IN A PIVOTAL AUTOMATED INSULIN DELIVERY (AID) TRIAL
University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
DIABETES RESPONSE SPECIALISTS ASSOCIATED WITH IMPROVED BLOOD GLUCOSE CONTROL FOR A LARGE DIABETES POPULATION USING A CONNECTED BLOOD GLUCOSE METER
S. Painter1, W. Lu1, R. James2,
1Teladoc Health, Clinical Research And Analytics, Purchase, United States of America, 2Teladoc Health, Clinical Research And Analytics, Mountain View, United States of America, 3University of California, Department Of Medicine, San Francisco, United States of America, 4Teladoc Health, International Case Manager, Barcelona, Spain, 5Duke University, School Of Medicine, Durham, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
REAL‐WORLD PERFORMANCE EVALUATION OF A SMARTPHONE BASED BOLUS CALCULATOR APPLICATION
J. Wrede, R. Biven, S. Phatak, P. Rams,
mySugr GmbH, Medical Research, Vienna (Austria), Germany
Topic:
AS16‐COVID‐19 and Diabetes
CAN PHYSICAL ACTIVITY AS AN INDEPENDENT PARAMETER INFLUENCE TIR?
1Jothydev's Diabetes Research Centre, Diabetes, Trivandrum, India, 2Diacare Diabetes & Hormone Clinic, Diabetes, Ahmedabad, India, 3Lina Diabetes Care Centre, Diabetes, Mumbai, India
Topic:
AS17‐Big data and artificial intelligence based decision support systems
PREVALENCE OF DIABETIC RETINOPATHY SCREENED BY ARTIFICIAL INTELLIGENCE BASED DEEP LEARNING ALGORITHM WITH HIGH SENSITIVITY: A MULTICENTRIC CROSS SECTIONAL STUDY FROM INDIA
1Apollo Sugar Clinic, Diabetology, Kolkata, India, 2Artelus, R&d, Kolkata, India, 3State General Hospital, Ophthalmology, Kolkata, India
Topic:
AS17‐Big data and artificial intelligence based decision support systems
DIABETES NOVEL SUBGROUP ASSESSMENT (DIANA)‐ ADVANCED MACHINE LEARNING‐BASED TOOL TO CLASSIFY INDIVIDUALS WITH NEWLY DETECTED TYPE 2 DIABETES INTO SPECIFIC SUBGROUPS AND ASSESS DRUG RESPONSE
1Madras Diabetes Research Foundation, Diabetology, Chennai, India, 2Madras Diabetes Research Foundation, Data Management, Chennai, India, 3School of Medicine, University of Dundee, Division Of Population Health & Genomics, Dundee, United Kingdom, 4Madras Diabetes Research Foundation, Research Operations, Chennai, India
Topic:
AS17‐Big data and artificial intelligence based decision support systems
PREDICTING HYPOGLYCEMIA AND IDENTIFYING RISK FACTORS DURING AND FOLLOWING PHYSICAL ACTIVITY IN TYPE 1 DIABETES USING EXPLAINABLE MODELS
Oregon Health and Science University, Biomedical Engineering, Portland, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
MEAL DETECTION AND SIZE ESTIMATION USING MACHINE LEARNING: TOWARDS FULLY AUTOMATED INSULIN DELIVERY SYSTEMS
Oregon Health and Science University, Biomedical Engineering, Portland, United States of America
Topic:
AS17‐Big data and artificial intelligence based decision support systems
REMOTE PATIENT MONITORING IN YOUTH WITH TYPE 1 DIABETES (T1D) PREDICTED TO EXPERIENCE A RISE IN A1C%: COMPARISON TO A CLINIC‐DERIVED, PROPENSITY SCORE‐MATCHED CONTROLS
D. Williams1, D. Ferro2, E. Dewit2, B. Lockee2, M. Barnes2, S. Carrothers2, C. Vandervelden2, S. Patton3, R. Mcdonough2, L. D'Avolio4,
1Children's Mercy Kansas City, Pediatrics, Kansas City, United States of America, 2Children's Mercy Kansas City, Pediatric Endocrinology, Kansas City, United States of America, 3Nemours Children's Health System, Nemours Center For Healthcare Delivery Science, Jacksonville, United States of America, 4Cyft, Inc., Machine Learning, Cambridge, United States of America
Topic:
AS17‐Big data and artificial intelligence based decision support systems
ENABLING INFORMED DECISION MAKING IN THE ABSENCE OF DETAILED NUTRITION LABELS: A MODEL TO ESTIMATE FOODS' ADDED SUGAR CONTENT IN A DIABETES‐TAILORED WEIGHT MANAGEMENT PROGRAM
1WW International, Inc, ., New York, United States of America, 2University of Florida College of Medicine, Department Of Health Outcomes And Biomedical Informatics, Gainesville, United States of America, 3University of Florida, Center For Integrative Cardiovascular And Metabolic Disease, Gainesville, United States of America, 4Perelman School of Medicine, University of Pennsylvania, Center For Weight And Eating Disorders, Philadelphia, United States of America
Topic:
AS04‐Clinical Decision Support Systems/Advisors
REAL LIFE ESTIMATION OF POSTPRANDIAL GASTRIC RETENTION, GLUCOSE ABSORPTION AND INSULIN SENSITIVITY IN TYPE 1 DIABETES USING MINIMALLY INVASIVE TECHNOLOGIES AND COMPUTATIONAL MODELING
1University of Padova, Department Of Information Engineering, Padova, Italy, 2Stanford University, Pediatric Endocrinology, Palo Alto, United States of America
Topic:
AS04‐Clinical Decision Support Systems/Advisors
EFFICACY OF THE INSULIN PEN SMART CAP INSULCLOCK® IN PEOPLE WITH NON‐CONTROLLED TYPE 1 DIABETES MELLITUS (T1DM): A MULTICENTER, RANDOMIZED CLINICAL TRIAL
1Hospital General de Segovia, Endocrinology And Nutrition Unit, SEGOVIA, Spain, 2Cruces University Hospital, Endocrinology And Nutrition, Bilbao, Spain, 3Hospital Arquitecto Marcide, Ferrol (A Coruña), Endocrinoly And Nutrition, Ferrol,, Spain, 4Hospital Universitario Central de Asturias, Endocrinology And Nutrition, Oviedo, Spain, 5Insulcloud S.L., Research And Development Unit, Madrid, Spain
Topic:
AS04‐Clinical Decision Support Systems/Advisors
GLYCEMIC CARE OPTIMIZATION IN THE HOSPITAL USING CLINICAL DECISION SUPPORT HELPS REDUCE LENGTH OF STAY
1Penn State College of Medicine, Department Of Medicine, Division Of Endocrinology, Hershey, United States of America, 2Penn State College of Medicine, Departments Of Medicine, Humanities, And Public Health Sciences, And The Woodward Center For Excellence In Health Sciences Education, Hershey, United States of America, 3Emory University, Department Of Medicine, Division Of Endocrinology, Atlanta, United States of America, 4Penn State College of Medicine, Department Of Public Health Sciences, Hershey, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
ASSOCIATION BETWEEN CHANGE IN HBA1C AND PROFESSIONAL CGM USE IN ADULTS WITH TYPE 2 DIABETES ON NON‐INSULIN THERAPIES–A REAL WORLD EVIDENCE STUDY
Dexcom, Health Economics And Outcomes Research, Global Access, SanDiego, United States of America
Topic:
AS04‐Clinical Decision Support Systems/Advisors
MY DIABETIC: SERIOUS GAME TO SUPPORT CHILDREN'S EDUCATION IN DIABETES MELLITUS I
Czech Technical University in Prague, Of Cybernetics, Prague, Czech Republic
The study was supported by the Research Centre for Informatics, grant number CZ.02.1.01/0.0/16_019/0000765
Topic:
AS03‐Artificial Pancreas
M. Jaloli,
University of Houston, Mechanical Engineering, Houston, United States of America
ATTD 2022 E‐Poster Viewing
Topic:
AS01‐Closed‐loop System and Algorithm
1Badajoz University Hospital, Endocrinology And Nutrition, BADAJOZ, Spain, 2Badajoz University Hospital, Paediatrics, Badajoz, Spain, 3Badajoz University Hospital, Endocrinology And Nutrition, Badajoz, Spain
The autocorrection feature was activated in all the subjects, the glucose target was 100 mg/dl in 85% and active insulin time was 2 hours in 82% of the individuals. At the end of the follow‐up, time in automode was 96 ± 5% and autocorrection insulin was 28 ± 13% of bolus inulin. The percentage of subjects with time <70mg/dl ≥4% decreased from 80% at baseline to 57% at the end of the follow‐up and the percentage with time <54mg/dl ≥1% decreased from 97% at baseline to 63% at the end of follow‐up; the percentage of people with the optimal combination of TIR >70% and time <70mg/dl <4% increased from 10% to 28% and
the percentage with TIR >70% and time <54 mg/dl <1% increased from 8% to 30% (all p < 0.02).
Topic:
AS01‐Closed‐loop System and Algorithm
1University of Southern California, Keck School of Medicine, Medicine, Los Angeles, United States of America, 2Emory University School of Medicine, Endocrinology, Atlanta, United States of America, 3Atlanta Diabetes Associates, Clinical Research, Atlanta, United States of America, 4Park Nicollet, Health Partners, International Diabetes Center, Minneapolis, United States of America, 5Insulet Corporation, Clinical Department, Acton, United States of America
range 70‐180mg/dL (3.9‐10.0mmol/L) for prior basal‐bolus and basal‐only users, respectively (Table). HbA1c decreased by 1.3% overall (p < 0.05). AID was used for median 94.4% of time. There was no change in BMI (p > 0.05). No related serious adverse events occurred.
Topic:
AS01‐Closed‐loop System and Algorithm
1Stanford University, Pediatric Endocrinology, Palo Alto, United States of America, 2Insulet Corporation, Clinical Department, Acton, United States of America, 3Park Nicollet, Health Partners, International Diabetes Center, Minneapolis, United States of America, 4University of Virginia, Division Of Endocrinology, Charlottesville, United States of America, 5SUNY, Upstate Medical University, Syracuse, United States of America, 6Atlanta Diabetes Associates, Clinical Research, Atlanta, United States of America, 7University of Colorado, Barbara Davis Center For Diabetes, Aurora, United States of America, 8Icahn School of Medicine at Mount Sinai, Department Of Medicine, New York, United States of America, 9University Hospitals Cleveland Medical Center, Rainbow Babies And Children's Hospital, Cleveland, United States of America, 10Baylor College of Medicine, Pediatric Diabetes And Endocrinology, Houston, United States of America, 11University of Washington, Department Of Medicine, Seattle, United States of America, 12The Jones Center, East Coast Institute For Research, Macon, United States of America, 13Harvard Medical School, Joslin Diabetes Center, Boston, United States of America, 14Yale University School of Medicine, Pediatric Endocrinology, New Haven, United States of America, 15Iowa Diabetes and Endocrinology Research Center, Iowa Diabetes, West Des Moines, United States of America
67 ± 12g CHO (range 58‐116g) in adults and 74 ± 21g (40‐180g) in children. Following meals without bolus, median glucose increased from 125 to 214mg/dL (6.9 to 11.9mmol/L) after 1.7h and returned <180mg/dL (<10.0mmol/L) after 3.4h in adults, and increased from 129 to 241mg/dL (7.2 to 13.4mmol/L) after 1.8h and returned <180mg/dL (<10.0mmol/L) after 3.6h in children (Figure). Following meals with bolus, median glucose remained within target range (70‐180mg/dL; 3.9‐10.0mmol/L) through 6 hours post‐meal.
Topic:
AS01‐Closed‐loop System and Algorithm
1University of Alberta, Medicine, Edmonton, Canada, 2Diabetes Action Canada, Patient Partner And Co‐lead For Innovations In Type 1 Diabetes, Toronto, Canada, 3Université Laval, Department Of Family And Emergency Medicine And Office Of Education And Professional Development, Québec, Canada, 4University Hospitals of Derby and Burton, Diabetes And Endocrinology, Derby, United Kingdom, 5University of Nottingham, School Of Medicine And Health Sciences, Nottingham, United Kingdom
Topic:
AS01‐Closed‐loop System and Algorithm
Helsinki University Hospital, Pediatrics And Adolescence, HUS, Finland
Topic:
AS01‐Closed‐loop System and Algorithm
1Jagiellonian University Medical College, Department Of Psychiatry, Kraków, Poland, 2Hospital University in Krakow, Psychiatry Clinical Department For Adults, Children, And Youth, Kraków, Poland, 3Jagiellonian University Medical College, Department Of Metabolic Diseases, Kraków, Poland, 4Hospital University in Krakow, Metabolic Diseases And Diabetology Clinical Department, Krakow, Poland, 5KSW Nr 1 im. Chopina, Diabetes Inpatient Clinic, Rzeszów, Poland, 6Medtronic International Trading Sàrl, Toluchenaz,, Toluchenaz, Switzerland, 7Belarusian Medical Academy of Postgrafduate Education, Endocrinology Department, Minsk, Belarus
Topic:
AS01‐Closed‐loop System and Algorithm
L. Mueller1, H. Singh2, S. Habif2, M. Malloy3, J.W. Morberg1,
1Tandem Diabetes Care, Data Science, San Diego, United States of America, 2Tandem Diabetes Care, Behavioral Sciences, San Diego, United States of America, 3Tandem Diabetes Care, Clinical Affairs, San Diego, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
1Diabetes Action Canada, Patient Partner And Co‐lead For Innovations In Type 1 Diabetes, Toronto, Canada, 2Université Laval, Department Of Family And Emergency Medicine, Quebec, Canada, 3Diabetes Action Canada, Patient Engagement, Toronto, Canada, 4University of Alberta, Medicine, Edmonton, Canada, 5Diabetes Action Canada, Co‐lead For Innovations In Type 1 Diabetes, Toronto, Canada, 6Université Laval, Department Of Family And Emergency Medicine And Office Of Education And Professional Development, Québec, Canada, 7Diabetes Action Canada, Co‐lead: Patient Engagement, Knowledge Translation, Toronto, Canada
Topic:
AS01‐Closed‐loop System and Algorithm
Hospital Universitari Vall d'Hebron, Endocrinology And Nutrition, Barcelona, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
1University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America, 2Arecor, Clinical & Regulatory, Saffron Walden, United Kingdom, 3Arecor, R&d, Saffron Walden, United Kingdom
Topic:
AS01‐Closed‐loop System and Algorithm
1University Hospitals of Derby and Burton and University of Nottingham, Diabetes And Endocrinology, Derby and Nottingham, United Kingdom, 2University of Nottingham, School Of Medicine And Health Sciences, Derby, United Kingdom, 3Sandwell and West Birmingham Hospitals NHS Trust, Department Of Diabetes & Endocrinology, Birmingham, United Kingdom, 4King's College London, Department Of Diabetes, London, United Kingdom, 5King's Health Partners, Institute Of Diabetes, Endocrinology And Obesity, London, United Kingdom, 6Guy's and St Thomas' Hospital NHS Trust, Department Of Diabetes & Endocrinology, London, United Kingdom, 7Nottingham University Hospitals NHS Trust, Diabetes Unit, Nottingham, United Kingdom, 8Royal Surrey NHS Foundation Trust, Centre For Endocrinology, Diabetes And Research (cedar), Guildford, United Kingdom
Topic:
AS01‐Closed‐loop System and Algorithm
S. Seget1, A. Polanska1, E. Rusak1, A. Ochab2, E. Ledwoń3,
1Medical University Of Silesia, Department Of Children's Diabetology, Katowice, Poland, 2Institute of Medical Sciences, University of Opole, Department Of Pediatrics, Opole, Poland, 3University Clinical Hospital in Opole, Department Of Pediatrics, Opole, Poland, 4The Silesian University of Technology, Department Of Data Science And Engineering, Gliwice, Poland
Topic:
AS01‐Closed‐loop System and Algorithm
Virgen del Rocío University Hospital, Endocrinology And Nutrition, Seville, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
1Doctor Peset University Hospital, Department Of Endocrinology And Nutrition, Valencia, Spain, 2FISABIO Foundation, Doctor Peset University Hospital, Valencia, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
Y. Pei1, J. Lu2, Y. Lin3, Z. Zhang3, W. Ke4, Y. Li4, Y. Peng3, Y. Bi2, Y. Mu1, J. Shin5, F. Peng5, S. Lee6, R. Zhang6,
1Chinese PLA General Hospital, Endocrinology, Beijing, China, 2Nanjing Drum Tower Hospital, Endocrinology, Nanjing, China, 3Shanghai General Hospital, Endocrinology, Shanghai, China, 4The First Affiliated Hospital, Sun Yat‐sen University, Endocrinology, Guangzhou, China, 5Medtronic, Clinical Research, Northridge, United States of America, 6Medtronic, Medical Affairs, Northridge, United States of America
continuous glucose monitoring [CGM]) insulin delivery with the MiniMed™ 770G system with the Guardian™ Sensor (3) glucose sensor followed by a study period (4 weeks, N = 60) with Auto Mode enabled. Analyses compared CGM data and insulin delivered during the run‐in versus study period (Wilcoxon signed‐rank test or t‐test). Safety data were summarized.
Topic:
AS01‐Closed‐loop System and Algorithm
Hospital Universitari Mutua de Terrassa, Endocrinology, Terrassa, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
1ASST Fatebenefratelli‐Sacco, Division Of Endocrinology, Milan, Italy, 2University of Milan, Biomedical And Clinical Sciences “l. Sacco”, Milan, Italy
Topic:
AS01‐Closed‐loop System and Algorithm
1Medtronic, Clinical Research, Northridge, United States of America, 2Atlanta Diabetes Associates Hospital, Atlanta Diabetes Associates, Atlanta, United States of America, 3Rainier Clinical Research Center, Endocrinology, Renton, United States of America, 4Stanford University, Pediatric Endocrinology, Palo Alto, United States of America, 5International Diabetes Center, Endocrinology, Minneapolis, United States of America, 6SoCal Diabetes, Endocrinology, Torrance, United States of America, 7Diabetes and Glandular Clinic, Endocrinology, San Antonio, United States of America, 8Rocky Mountain Diabetes and Osteoporosis Center, PA, Pediatric Endocrinology, Idaho Falls, United States of America, 9Scripps Whittier Diabetes Center, Pediatric Endocrinology, San Diego, United States of America, 10Seattle Children's Hospital, Pediatric Endocrinology, Seattle, United States of America, 11University of Michigan Health System‐ University Hospital, Endocrinology, Ann Arbor, United States of America, 12Endocrine Research Solutions, Endocrinology, Roswell, United States of America, 13Yale University School of Medicine, Pediatric Endocrinology, New Haven, United States of America, 14University of South Florida, Pediatric Endocrinology, Tampa, United States of America, 15Barbara Davis Center for Childhood Diabetes, Endocrinology, Aurora, United States of America, 16Medical Investigations Inc., Endocrinology, Little Rock, United States of America, 17Medtronic, Medical Affairs, Northridge, United States of America
72.8% (Pediatric: 70.7%, Adult: 76.3%) and overall TBR (<70mg/dL) was 1.9% (Pediatric: 2.2%, Adult: 1.6%). There was no DKA or severe hypoglycemia.
Topic:
AS01‐Closed‐loop System and Algorithm
dQ&A Market Research Inc., Diabetes Research, San Francisco, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
1Medtronic, Clinical Research, Northridge, United States of America, 2Medtronic, Medical Affairs, Northridge, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
1Hospital Universitario San Ignacio, Endocrinology Unit, Bogota, Colombia, 2Hospital Universitario San Ignacio, Internal Medicine Department, Bogota, Colombia
Topic:
AS01‐Closed‐loop System and Algorithm
1Diabeloop SA, Research, Grenoble, France, 2CERITD, Diabetes, Evry, France, 3Ceritd, Diabetes, Évry‐Courcouronnes, France, 4Université Grenoble Alpes, Diabetes, Saint‐Martin‐d'Hères, France
Topic:
AS01‐Closed‐loop System and Algorithm
1Diabeloop SA, Research, Grenoble, France, 2Ceritd, Diabetes, Évry‐Courcouronnes, France, 3Université Grenoble Alpes, Diabetes, Saint‐Martin‐d'Hères, France
Topic:
AS01‐Closed‐loop System and Algorithm
1Avicenne hospital, Endocrinology, Bobigny, France, 2CHU Caen, Endocrinologie And Diabetes, Caen, France, 3CHU Strasbourg, Endocrinologie And Diabetes, Strasbourg, France
Topic:
AS01‐Closed‐loop System and Algorithm
1Diabeloop SA, Research, Grenoble, France, 2CERITD, Diabetes, Evry, France, 3Université Grenoble Alpes, Diabetes, Saint‐Martin‐d'Hères, France
Topic:
AS01‐Closed‐loop System and Algorithm
1University of Lille, Department Of Diabetology, Lille, France, 2DIABELOOP SA, Diabeloop Sa, Grenoble, France, 3CERITD, Diabetes, Evry, France, 4University Grenoble Alpes, Inserm U1055, Grenoble, France
Topic:
AS01‐Closed‐loop System and Algorithm
1Poznan University of Medical Sciences, Department Of Internal Medicine And Diabetology, Poznań, Poland, 2Medical University of Lodz, Department Of Biostatistics And Translational Medicine, Lodz, Poland, 3Medical University of Lodz, Department Of Pediatrics, Diabetology, Endocrinology And Nephrology, Lodz, Poland
Topic:
AS01‐Closed‐loop System and Algorithm
Endocrinology and Diabetes Unit, ASL Salerno, Salerno, Italy., Asl Salerno, Cava De' Tirreni ‐ Salerno (SA), Italy
Topic:
AS01‐Closed‐loop System and Algorithm
University of Padova, Department Of Information Engineering, Padova, Italy
Topic:
AS01‐Closed‐loop System and Algorithm
B. Piccini1,
1Meyer University Children's Hospital, Diabetology Unit, Florence, Italy, 2Meyer University Children's Hospital, University of Florence, Department Of Pediatrics, Florence, Italy, 3Istituto Giannina Gaslini, University of Genova, Department Of Pediatrics, Genoa, Italy, 4Meyer University Children's Hospital, Dietetics Unit, Florence, Italy
Topic:
AS01‐Closed‐loop System and Algorithm
1Stanford University, Pediatrics, Stanford, United States of America, 2University of North Carolina at Chapel Hill, Nutrition, Chapel Hill, United States of America
Topic:
AS01‐Closed‐loop System and Algorithm
1Hospitalsenhed Vest, Paediatrics Department, Herning, Denmark, 2STENO, Diabetes Center Aarhus, Aarhus N, Denmark
Topic:
AS01‐Closed‐loop System and Algorithm
Hospital Regional de Málaga, Endocrinology, Málaga, Spain
Topic:
AS01‐Closed‐loop System and Algorithm
K. Braune1,2,3, N. Krug1,
1Charité ‐ Universitätsmedizin Berlin, Department Of Paediatric Endocrinology And Diabetes, Berlin, Germany, 2Charité ‐ Universitätsmedizin Berlin, Institute Of Medical Informatics, Berlin, Germany, 3Berlin Institute of Health, Digital Clinician Scientist Program, Berlin, Germany, 4University College Dublin, School Of Sociology, Belfield, Ireland, 5Dedoc Labs GmbH, #dedoc° Diabetes Online Community, Berlin, Germany, 6Technical University of Denmark, Center For Biosustainability, Copenhagen, Denmark, 7University College Dublin, School Of Public Health, Physiotherapy & Sports Science, Dublin, Ireland, 8Steno Diabetes Center Copenhagen, Diabetes Management Research, Copenhagen, Denmark
Topic:
AS01‐Closed‐loop System and Algorithm
1Diabeter, Centre For Pediatric And Adult Diabetes Care And Research, Rotterdam, Netherlands, 2Medtronic, Bakken Research Center, Maastricht, Netherlands, 3Medtronic International Trading Sàrl, Toluchenaz,, Toluchenaz, Switzerland
Topic:
AS01‐Closed‐loop System and Algorithm
1Australian National University, School Of Computing, College Of Engineering & Computer Science, Canberra, Australia, 2Australian National University, School Of Engineering, College Of Engineering & Computer Science, Canberra, Australia, 3Australian National University, Medical School Directorate, Chm Anu Medical School, Canberra, Australia, 4University of Turku, Department Of Computing, Turku, Finland
Topic:
AS01‐Closed‐loop System and Algorithm
Pontificia Universidad Católica de Chile, Departamento De Nutrición, Diabetes Y Metabolismo, santiago, Chile
Topic:
AS01‐Closed‐loop System and Algorithm
County Durham and Darlington Foundation Trust, Diabetes And Endocrinology, Durham, United Kingdom
Topic:
AS01‐Closed‐loop System and Algorithm
T. Biester1, T. Von Dem Berge1, K. Remus1, S. Biester1, F. Reschke1, B. Klusmeier1, M. Würsig1, K. Adolph2, O. Kordonouri1,
1AUF DER BULT, Diabetes‐center For Children And Adolescents, Hannover, Germany, 2CRO, Biostatistics, Potsdam, Germany
Hospital AUF DER BULT in Hannover were offered to update their pump from Basal IQ to Control IQ. All patients received training by a diabetes educator nurse, experienced with AID therapy. Therapy data and questionnaire for patient related outcomes were obtained before update and after 3 months.
Topic:
AS01‐Closed‐loop System and Algorithm
T. Von Dem Berge1, S. Biester1, K. Remus1, F. Reschke1, M. Würsig1, B. Klusmeier1, K. Adolph2,
1AUF DER BULT, Diabetes‐center For Children And Adolescents, Hannover, Germany, 2CRO, Biostatistics, Potsdam, Germany
Topic:
AS01‐Closed‐loop System and Algorithm
1NTNU, Engineering Cybernetics (itk), TRONDHEIM, Norway, 2NTNU, Engineering Cybernetics, Trondheim, Norway, 3Norwegian University of Science and Technology (NTNU), Engineering Cybernetics, Trondheim, Norway, 4Norwegian University of Science and Technology, Department Of Engineering Cybernetics, Trondheim, Norway
Fig. 1. Penalty used for different BG levels in the NMPC. The controller used a modified version of the model presented by Zazueta et al [1], in which the hepatic first‐pass effect was included for insulin. A moving horizon estimator was employed to estimate states and meals. Meals and physical activity were simulated in the three anesthetized animals by manipulating the intravenous glucose infusion rates as shown in Fig. 2:
Fig. 2. Glucose infusion rate used in animal experiments.
[1] Zazueta et al, 2021. DOI: 10.1109/TBME.20213125839
Topic:
AS01‐Closed‐loop System and Algorithm
1Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany, 2Science Consulting in Diabetes GmbH, Profil Neuss, Neuss, Germany
Topic:
AS01‐Closed‐loop System and Algorithm
1Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany, 2Science Consulting in Diabetes GmbH, Profil Neuss, Neuss, Germany
Topic:
AS01‐Closed‐loop System and Algorithm
1Jagiellonian University Medical College, Department Of Metabolic Diseases, Kraków, Poland, 2Hospital University in Krakow, Metabolic Diseases And Diabetology Clinical Department, Krakow, Poland, 3KSW Nr 1 im. Chopina, Diabetes Inpatient Clinic, Rzeszów, Poland, 4Jagiellonian University Medical College, Department Of Psychiatry, Kraków, Poland, 5Hospital University in Krakow, Psychiatry Clinical Department For Adults, Children, And Youth, Kraków, Poland, 6Medtronic International Trading Sàrl, Toluchenaz,, Toluchenaz, Switzerland
Topic:
AS02‐New Insulin Analogues
Endocrinology Research Centre of Health Care Ministry of Russian Federation, Diabetic Foot Department, Moscow, Russian Federation
Topic:
AS02‐New Insulin Analogues
1International Diabetes Center, Healthpartners Institute, Minneapolis, United States of America, 2Atlanta Diabetes Associates Hospital, Atlanta Diabetes Associates, Atlanta, United States of America, 3Iowa Diabetes and Endocrinology Research Center, Iowa Diabetes, West Des Moines, United States of America, 4Eli Lilly and Company, Diabetes Bu, Indianapolis, United States of America
Topic:
AS02‐New Insulin Analogues
Institute of Endocrinology, Diabetology, Kyiv, Ukraine
Topic:
AS02‐New Insulin Analogues
1Imperial College London, Diabetes Centre, Al Ain, United Arab Emirates, 2Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center,tel‐aviv University, Tel Hashomer, Israel, 3Universidad del Cauca, Department Of Internal Medicine, Popayan‐Cauca, Colombia, 4Sanofi, General Medicines, Singapore, Singapore, 5Sanofi, Biostatistics And Programming, Paris, France, 6Sanofi, Diabetes And Cardiovascular Development, R&d, Paris, France, 7Endocrinology Research Centre of Health Care Ministry of Russian Federation, Diabetic Foot Department, Moscow, Russian Federation
Gla‐300 dose were similar across subgroups. Overall, incidences and rates of reported hypoglycemia were low and similar between groups.
Topic:
AS02‐New Insulin Analogues
1Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center,tel‐aviv University, Tel Hashomer, Israel, 2Imperial College London, Diabetes Centre, Al Ain, United Arab Emirates, 3Universidad del Cauca, Department Of Internal Medicine, Popayan‐Cauca, Colombia, 4Sanofi, General Medicines, Singapore, Singapore, 5Sanofi, Biostatistics And Programming, Paris, France, 6Sanofi, Diabetes And Cardiovascular Development, R&d, Paris, France, 7Endocrinology Research Centre of Health Care Ministry of Russian Federation, Diabetic Foot Department, Moscow, Russian Federation
Topic:
AS02‐New Insulin Analogues
1CARE Hospital, Endocrinology, Hyderabad, India, 2King Saud University, University Diabetes Center, Riyadh, Saudi Arabia, 3Aydın Adnan Menderes University, Faculty Of Medicine, Aydın, Turkey, 4Sanofi, General Medicines, Singapore, Singapore, 5Sanofi, General Medicines, Mumbai, India, 6IT&M Stats, Biostatistics, Paris, France, 7Sanofi, Diabetes And Cardiovascular Development ‐ R&d, Paris, France, 8Universidad de Buenos Aires, Hospital De Clínicas, Buenos Aires, Argentina
Topic:
AS02‐New Insulin Analogues
1The University of Western Ontario, Schulich School Of Medicine & Dentistry, London, Canada, 2University of Bordeaux, Faculty Of Medicine, Bordeaux, France, 3Sanofi, General Medicines, Bridgewater, United States of America, 4Optum, Health Economics Outcome Research, Minneapolis, United States of America, 5Sanofi, Real World Evidence Generation, Digital Rwe, Bridgewater, United States of America, 6The First Clinic, Internal Medicine, Nashville, United States of America, 7University of Freiburg, Department Of Medicine, Freiburg, Germany
Topic:
AS02‐New Insulin Analogues
1Endocrinology Research Centre of Health Care Ministry of Russian Federation, Diabetic Foot Department, Moscow, Russian Federation, 2Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center Tel‐aviv University, Tel Hashomer, Israel, 3Universidad del Cauca, Department Of Internal Medicine, Popayan‐Cauca, Colombia, 4Sanofi, General Medicines, Singapore, Singapore, 5Sanofi, Biostatistics And Programming, Paris, France, 6Sanofi, Diabetes And Cardiovascular Development, R&d, Paris, France, 7Imperial College London, Diabetes Centre, Al Ain, United Arab Emirates
A very low rate of hypoglycemia was reported, although numerically higher in ≥70 years group. Increases in the Gla‐300 dose were similar across the groups. Consistent results were observed in subgroups of ≥65 and <65 years.
Topic:
AS02‐New Insulin Analogues
Eli Lilly and Company, Diabetes, Indianapolis, United States of America
Topic:
AS02‐New Insulin Analogues
1Imperial College London, Diabetes Centre, Al Ain, United Arab Emirates, 2King Abdul‐Aziz University, Department Of Medicine, Jeddah, Saudi Arabia, 3Duabi Diabetes Center, Diabetes, Dubai, United Arab Emirates, 4Sanofi, Diabetes, Singapore, Singapore, 5Sanofi, Diabetes, Dubai, United Arab Emirates, 6Ghassan Najib Pheroun Hospital, Endocrinology, Jeddah, Saudi Arabia, 7Taiba Hospital, Endocrinology, Jabriya, Kuwait, 8Dallah Hospital, Endocrinology, Riyadh, Saudi Arabia, 9Mubarak Hospital, Endocrinology, Jabriya, Kuwait
Topic:
AS02‐New Insulin Analogues
Araba University Hospital ‐ Basque Country University, Peadiatric, Vitoria, Spain
Topic:
AS02‐New Insulin Analogues
1Karl Landsteiner Institute, Endocrinology And Nephrology, Vienna, Austria, 2Clinic Hietzing, Vienna Health Care Group, 3rd Department Of Medicine Iii And Karl Landsteiner Institute For Metabolic Diseases And Nephrology, Vienna, Austria, 3Joanneum Research, DIGITAL, Forschungsgesellschaft Mbh,, Graz, Austria, 4Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria
Topic:
AS02‐New Insulin Analogues
1The Third Affiliated Hospital of Sun Yat‐sen University, Endocrinology & Metabolism, Guangzhou, China, 2Sanofi, Medical Diabetes, Shanghai, China, 3Evidinno Outcomes Research Inc, Evidence Synthesis & Literature Reviews, Vancouver, Canada, 4Sanofi, Real World Evidence Generation, Chilly Mazarin, France, 5Sanofi, General Medicines, Frankfurt, Germany
Topic:
AS02‐New Insulin Analogues
1University of Virginia, Pediatric Endocrinology, Charlottesville, United States of America, 2University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America
Topic:
AS02‐New Insulin Analogues
Prince Sultan Military Medical City, Endocrinology, Riyadh, Saudi Arabia
Topic:
AS03‐Artificial Pancreas
1McGill University, Department Of Medicine, Division Of Experimental Medicine, Montreal, Canada, 2Institut de recherches cliniques de Montréal (IRCM), Montreal, Canada, 3McGill University, School Of Human Nutrition, Sainte‐Anne‐de‐Bellevue,, Canada, 4Université de Montréal, Department Of Nutrition, Faculty Of Medicine, Montreal, Canada
between G1 and each of the other groups were statistically significant, even after adjusting for age, sex and insurance status (Table). No difference between groups were found for reported hypoglycemic episodes (<4.0 mmol/L), Diabetes Distress Scale score or Hypoglycemia Fear Survey‐II score after adjustment.
Topic:
AS03‐Artificial Pancreas
Sidra Medicine, Diabetes And Endocrine, Doha, Qatar
Topic:
AS03‐Artificial Pancreas
1University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America, 2University of Colorado Anschutz Medical Campus, School Of Nursing, Aurora, United States of America, 3University of Colorado Anschutz Medical Campus, Colorado School Of Public Health, Department Of Biostatistics And Informatics, Aurora, United States of America
Clinicians completed the system usability scale (SUS) to assess satisfaction and usability of the Tool, ranked their confidence in provided care to Control‐IQ users on a 1‐10 scale, and reported additional feedback on helpful aspects of the Tool and whether it changed their clinical practice.
Topic:
AS03‐Artificial Pancreas
1APHM, University Hospital Sainte Marguerite, Department Of Endocrinology, Nutrition And Metabolic Diseases, Marseille, France, 2Aix Marseille Univ, Cnrs, Crmbm, Marseille, France
Topic:
AS03‐Artificial Pancreas
Norwegian University of Science and Technology (NTNU), Department Of Clinical And Molecular Medicine, Trondheim, Norway
Topic:
AS03‐Artificial Pancreas
1University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America, 2University of Colorado Boulder, Information Science, Boulder, United States of America, 3University of Colorado Anschutz Medical Campus, College Of Nursing, aurora, United States of America, 4University of Colorado Boulder, Computer Science, Boulder, United States of America
Topic:
AS03‐Artificial Pancreas
1Securecell AG, Research And Development, Urdorf, Switzerland, 2B.Braun Medical Care AG, Nephrology And Dialysis Center, Zurich, Switzerland, 3City Hospital, Endocrinology And Diabetology, Zurich, Switzerland
sampling and insulin delivery. Compared to current subcutaneous technologies, the intravenous pathway enables more accurate measurements and removes the time lag between interstitial and blood compartments. A wearable device extracts plasma out of blood, photometrically measures glucose by using the hexokinase reaction and calculates the insulin dosage. Here, we present data of a feasibility study of the new AGM in a clinical environment. Volunteers with diabetes type‐1 using a CGM were included, which enabled us to additionally compare the glucose values in venous samples with the sensor results.
The new method is an effective technique to be used in automated insulin delivery systems: combined with closed‐loop computation of the insulin quantity.
Topic:
AS03‐Artificial Pancreas
University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America
Topic:
AS03‐Artificial Pancreas
1Anatomy and Regenerative Medicine Institute (REMEDI), National University Of Ireland Galway, Galway, Ireland, 2Aurum Laboratories, Explora‐biotech, Rome, Italy, 3Centre for Research in Medical Devices (CÚRAM), National University Of Ireland Galway, Galway, Ireland, 4Advanced Materials and BioEngineering Research Centre (AMBER), Trinity College Dublin, Dublin, Ireland
Topic:
AS03‐Artificial Pancreas
1Eberhard Karls University Tuebingen, Institute Of Biomedical Engineering, Department For Medical Technologies And Regenerative Medicine, Tuebingen, Germany, 2Leiden University Medical Center, Department Of Immunology, Leiden, Netherlands, 3Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Natural And Medical Sciences Institute, Reutlingen, Germany, 4Eberhard Karls University Tuebingen, Cluster Of Excellence Ifit (exc 2180) “image‐guided And Functionally Instructed Tumor Therapies”, Tuebingen, Germany, 5National University of Ireland Galway, Discipline Of Anatomy And The Regenerative Medicine Institute, Galway, Ireland, 6David Geffen School of Medicine at UCLA, Department Of Medicine / Cardiology, Cardiovascular Research Laboratories, Los Angeles, United States of America
Topic:
AS03‐Artificial Pancreas
G. Yesiltepe Mutlu, E. Eviz, E. Can, T. Gokce, S. Muradoglu,
Koc University Hospital, Pediatric Endocrinology And Diabetes, Istanbul, Turkey
The second one included the first 3 month‐period analysis regarding frequency of achievement of glycemic goals, and factors related with TIR children using Medtronic 780G system, regardless their previous treatment.
Topic:
AS03‐Artificial Pancreas
1University of Tuebingen, Institute of Biomedical Engineering, Department For Medical Technologies And Regenerative Medicine, Tuebingen, Germany, 2Leiden University Medical Center, Department Of Immunology, Leiden, Netherlands, 3Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Natural And Medical Sciences Institute, Reutlingen, Germany, 4Eberhard Karls University Tuebingen, Cluster Of Excellence Ifit (exc 2180) “image‐guided And Functionally Instructed Tumor Therapies”, Tuebingen, Germany, 5Westfälische Wilhelms‐Universität Münster, Cells In Motion Interfaculty Centre, Münster, Germany, 6National University of Ireland, Anatomy And Regenerative Medicine Institute (remedi), School Of Medicine, Galway, Ireland, 7David Geffen School of Medicine at UCLA, Department Of Medicine/cardiology, Cardiovascular Research Laboratories, Los Angeles, United States of America
Topic:
AS03‐Artificial Pancreas
1Virgen del Rocío University Hospital, Endocrinology And Nutrition, Seville, Spain, 2Infanta Sofía University Hospital, Endocrinology And Nutrition, Madrid, Spain
Topic:
AS03‐Artificial Pancreas
1CERITD, Diabetes, Evry, France, 2Sud‐Francilien Hospital, Endocrinology, Corbeil‐Essonnes, France, 3CHU Caen, Endocrinologie And Diabetes, Caen, France, 4CHU Toulouse ‐ Rangueil Hospital, Endocrinology, Toulouse, France, 5APHM, University Hospital Sainte Marguerite, Department Of Endocrinology, Nutrition And Metabolic Diseases, Marseille, France, 6University Grenoble Alpes, Inserm U1055, Grenoble, France, 7CHU Reims, Endocrinology, Diabetes And Nutrition, Reims, France, 8CHU Toulouse ‐ Purpan Hospital, Diabetology, Toulouse, France, 9APHP ‐ Necker Hospital, Pediatric Endocrinology, Diabetes, Paris, France, 10CHU Strasbourg, Endocrinology, Diabetes And Nutrition, Strasbourg, France
Topic:
AS03‐Artificial Pancreas
L. Bozzetto,
Federico II University, Clinical Medicine And Surgery, Naples, Italy
Topic:
AS03‐Artificial Pancreas
R. Bonfanti1, A. Rigamonti2,
1Instituto Scientifico H. San Raffaele Universitã Vita‐Salute, Pediatrics, Milano, Italy, 2Ospedale San Raffaele, Pediatrics, milano, Italy
Topic:
AS03‐Artificial Pancreas
Federico II University, Clinical Medicine And Surgery, Naples, Italy
Topic:
AS03‐Artificial Pancreas
M.C. Serafini, N. Rosales, F. Garelli,
Grupo de control aplicado (GCA), Instituto LEICI, Facultad De Ingeniería, Unlp‐conicet, La Plata, Argentina
It is also worth noting that insulin infusion is reduced showing that the RL strategy improves insulin infusion profile, as well as overall glycemic excursion.
Evolution over time for Adult#05 using the ARG algorithm with the RL agent (purple thinner) and with manual scheme (orange thicker). At bottom: IOB (solid line) and IOB limit (dashed line).
Topic:
AS03‐Artificial Pancreas
1Radboudumc, Department Of Medical Psychology, Nijmegen, Netherlands, 2Diabeter, Research, Rotterdam, Netherlands, 3Radboud University Medical Centre, Department Of Internal Medicine, Nijmegen, Netherlands, 4Tilburg University, Organization Studies, Tilburg, Netherlands
Topic:
AS03‐Artificial Pancreas
Kadimastem, Diabetes Cell Therapy, Nes‐Ziona, Israel
Topic:
AS03‐Artificial Pancreas
F. Garelli1,
1Grupo de control aplicado (GCA), Instituto LEICI, Facultad De Ingeniería, Unlp‐conicet, La Plata, Argentina, 2Instituto Tecnologico de Buenos Aires (ITBA), Centro De Sistemas Y Control, Buenos Aires, Argentina, 3Hospital Italiano de Buenos Aires, Servicio De Endocrinologia, Metabolismo Y Medicina, Buenos Aires, Argentina
Topic:
AS03‐Artificial Pancreas
1University of Virginia, Pediatric Endocrinology, Charlottesville, United States of America, 2University of Virginia School of Medicine, Pediatric Endocrinology, Charlottesville, United States of America
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1DIAPPYMED SAS, ‐, Montpellier, France, 2Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France, 3University of Montpellier, Institute Of Functionnal Genomics, Inserm, Cnrs, Montpellier, France
Topic:
AS04‐Clinical Decision Support Systems/Advisors
L. De La Brosse1, P. Calmels1, T. Camalon1, M. Rehn1, P. Soulé1, N. Caleca1,
1hillo ai, Data Science, Igny, France, 2University of Montpellier, Institute Of Functionnal Genomics, Inserm, Cnrs, Montpellier, France, 3Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France
Topic:
AS04‐Clinical Decision Support Systems/Advisors
P. Soulé1, L. De La Brosse1, P. Calmels1, T. Camalon1, M. Rehn1, N. Caleca1,
1hillo ai, Data Science, Igny, France, 2University of Montpellier, Institute Of Functionnal Genomics, Inserm, Cnrs, Montpellier, France, 3Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France
The density model methodology can be improved by using a different distribution‐model and by adding a calibration step.
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1University of Exeter, College Of Medicine And Health, Exeter, United Kingdom, 2University of South Florida, Health Informatics Institute, Tampa, United States of America, 3University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America, 4University of Washington Seattle, Pacific Northwest Research Institute, Seattle, Seattle, United States of America, 5Texas Children's Hospital, Baylor College Of Medicine, Houston, United States of America
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1Novo Nordisk, Biostatistics, Aalborg, Denmark, 2Aalborg University, Health Science And Technology, Aalborg, Denmark, 3Aalborg University, Mathematical Sciences, Aalborg, Denmark, 4Aalborg University Hospital, Steno Diabetes Center North Denmark, Aalborg, Denmark, 5Novo Nordisk, Dtx Digitalization And Modelling, Søborg, Denmark, 6Aalborg University Hospital, Clinical Medicine And Department Of Endocrinology, Aalborg, Denmark, 7Novo Nordisk, Medical & Science, Søborg, Denmark
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1DarioHealth, Clinical, Caesarea, Israel, 2DarioHealth, Data, Caesarea, Israel, 3DarioHealth, Chief Medical Officer B2b, Caesarea, Israel
Topic:
AS04‐Clinical Decision Support Systems/Advisors
ETH Zurich, Department Of Biosystems Science And Engineering And Sib Swiss Institute Of Bioinformatics, Basel, Switzerland
Topic:
AS04‐Clinical Decision Support Systems/Advisors
L. Sobhi, P. Donate, C. Bowden, C. Hughes, K. Farmer,
University of Texas Health Science Center at Houston, Pediatric Endocrinology, Houston, United States of America
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1Koç University, School Of Medicine, istanbul, Turkey, 2Koc University Hospital, Pediatric Endocrinology And Diabetes, Istanbul, Turkey
Figure2: 5‐point Likert questions about the app.
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1Technical University of Denmark, Department Of Applied Mathematics And Computer Science, Kgs. Lyngby, Denmark, 2Novo Nordisk A/S, Dtx & Design Controls, Søborg, Denmark
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1universities hospitals of leicester nhs trust, Paediatric Department Of Diabetes And Endocrinology, leicester, United Kingdom, 2University Hospitals Leicester NHS Trust, Children Research And Innovation, leicester, United Kingdom, 3De Montfort University, The Design Unit, leicester, United Kingdom
Subgroup‐deapp vs control: n = 32 (n = 17 control, n = 15 deapp) control mean hba1c : 52% (109mmol/l ‐53mmol )fall in hbA1c (18 months) control vs 48% deapp( 101mmol/l‐ 52mmol/l). Clarke scores 0.3 (control) ‐1.4 (deapp). Fear of hypoglycaemia 8 (control)‐ 10 (deapp). PAID‐20 16 (control) ‐22 (deapp). Kaufmann 35 (control) ‐39 (67% post‐deapp). Bed stay = 3 days(control)vs 2 days (Deapp):
Topic:
AS04‐Clinical Decision Support Systems/Advisors
Sun Yat‐Sen University, Nursing, guangzhou, China
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1University of Padova, Department Of Information Engineering, Padova, Italy, 2University of Bern, Department Of Diabetes, Endocrinology, Nutritional Medicine And Metabolism Inselspital, Bern, Switzerland
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1DIAPPYMED SAS, ‐, Montpellier, France, 2Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France, 3University of Montpellier, Institute Of Functionnal Genomics, Inserm, Cnrs, Montpellier, France, 4Montpellier University Hospital, Department Of Medical Information, Unit Of Clinical And Epidemiological Research, Montpellier, France
Topic:
AS04‐Clinical Decision Support Systems/Advisors
Prayas Diabetes Center, Diabetology, Indore City, India
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1Hospital General de Segovia, Endocrinology And Nutrition Unit, SEGOVIA, Spain, 2Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain, Research And Development Unit, Pozuelo de Alarcón, Spain, 3Insulcloud S.L., Research And Development Unit, Madrid, Spain
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1Sud Francilien Hospital, Diabetes, Corbeil‐Essonnes, France, 2CERITD, Diabetology, Corbeil Essonne, France, 3centre hospitalier Sud francilien, Diabetes, Corbeil Essonne, France
Topic:
AS04‐Clinical Decision Support Systems/Advisors
Tribe Consulting, Diabetes Research, NEUTRAL BAY JUNCTION, Australia
Topic:
AS04‐Clinical Decision Support Systems/Advisors
University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America
Online estimation of the titration noise for each avatar enables an adaptive basal titration algorithm that lowers the hypoglycemia exposure two‐fold (0.98 [0.0–21.0] vs. 0.59 [0.0–5]) (Mean [Min–Max]) while achieving the same glycemic control (Figure).
Topic:
AS04‐Clinical Decision Support Systems/Advisors
P. Almeda‐Valdes1, N. Antonio‐Villa2, A. Garcia‐Tuomola3, M. Vidrio‐Velazquez4, L. Islas‐Ortega5, J. Bustamante‐Martínez6, A. Martínez‐Ramos Méndez7, N. De La Garza‐Hernández8, G. González‐Gálvez9, M. Valadez‐Capetillo10, K. Sánchez‐Ruiz11, C. Castillo‐Galindo12, A. Yepez‐Rodriguez13, M. Polanco‐Preza14,
1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Endocrinology And Metabolism, Metabolic Diseases Research Unit, Mexico City, Mexico, 2Universidad Nacional Autónoma de Mexico., Md/phd (pecem) Program, Facultad De Medicina, Mexico City, Mexico, 3Centro Medico ABC, Endocrinology, Mexico City, Mexico, 4Unidad de Investigacion Cardiometabolica de Occidente, Endocrinology, Guadalajara, Mexico, 5Hospital del Niño DIF Hidalgo, Endocrinología, Hidalgo, Mexico, 6Clínica DIME, Endocrinología, Nayarit, Mexico, 7Clínica Roma, Endocrinología, Mexico City, Mexico, 8CEMEDIN, Endocrinología, Monterrey, Mexico, 9Instituto Jalisciense de Investigacion en Diabetes y Obesidad S.C., Endocrinología, Guadalajara, Mexico, 10Hospital de Especialidades Del Niño y La Mujer, Endocrinología, Querétaro, Mexico, 11Clínica de Diabetes, Endocrinología, Durango, Mexico, 12Clínica EnDi, Endocrinología, Mexico City, Mexico, 13Corporativo Hospital Satelite, Internal Medicine And Endocrinology, Mexico State, Mexico, 14Hospital Civil de Guadalajara Fray Antonio Alcalde, Endocrinología, Guadalajara, Mexico, 15Clinica EnDi, Endocrinology, Mexico City, Mexico
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1diabetes care and hormone clinic, Diabetes, Ahmedabad, India, 2Diabetes care and hormone clinic, Diabetes, Ahmedabad, India
Topic:
AS04‐Clinical Decision Support Systems/Advisors
Conquer Diabetes, Diabetes, Mumbai, India
Topic:
AS05‐Glucose Sensors
Badajoz University Hospital, Endocrinology And Nutrition, Badajoz, Spain
A significant difference was found between HbA1c before the start of the device and HbA1c in the last visit (HbA1c 7.8 ± 1.3% vs HbA1c 7.4 ± 0.9 %; p = 0.043). 32 patients (68%) had a time in range 70‐180 mg/dl >50%. 18 patients (38%) had a time in range 70‐180 mg/dl >70%. 8 patients (17%) had a time <70 mg/dl <1%. Out of 47 subjects, 5 refused to initiate the prescribed device and 1 discontinued its use. Reasons for refusal were: alarm fatigue, lack of improvement or inability to understand the system. Two subjects initiated first flash/continuous glucose monitoring, and afterwards, closed‐loop systems.
Topic:
AS05‐Glucose Sensors
1University of Colorado, School Of Pharmacy, Denver, United States of America, 2Eli Lilly and Company, Diabetes, Indianapolis, United States of America, 3University of Colorado, Barbara Davis Center For Diabetes, Aurora, United States of America, 4Eli Lilly and Company, Gporwe, Indianapolis, United States of America, 5University of Colorado Anschutz Medical Campus, Skaggs School Of Pharmacy And Pharmaceutical Sciences, Aurora, United States of America
Topic:
AS05‐Glucose Sensors
1University of Colorado, Barbara Davis Center For Diabetes, Aurora, United States of America, 2University of Colorado, Barbara Davis Center For Diabetes, AURORA, United States of America, 3Imperial College London, Department Of Electrical And Electronic Engineering, London, United Kingdom, 4Imperial College London, Diabetes And Endocrinology, London, United Kingdom
Random data loss was generated by creating data gaps (1‐5 hours) and removing CGM values until the desired percentage of data loss (10‐50%) is achieved. For CGM TIR (70‐180 mg/dL), days required to cross 5% threshold of median absolute percentage error (MdAPE) by random data loss and data gaps were calculated.
Topic:
AS05‐Glucose Sensors
S. Rompicherla1, M. Kamboj2, E. Cobry3, B. Frohnert3, A. Rewers3, M. Desimone4, D. Ferro5, S. Ogburn6, B. Mccann‐Crosby7, S. Phillips8, O. Ebekozien1,
1T1D Exchange, Qi And Population Health, Boston, United States of America, 2Natiowide Children's Hospital, Endocrinology, Ohio, United States of America, 3Barbara Davis Center, Pediatrics, CO, United States of America, 4SUNY Upsatate Medical University, Endocrinology, NY, United States of America, 5Children's Mercy‐ Kansas City, Endocrinology, MO, United States of America, 6Cook Children's Hospital, Endocrinology, TX, United States of America, 7Texas Children's Hospital, Endocrinology, TX, United States of America, 8Boston Medical Center, Endocrinology, MA, United States of America
Topic:
AS05‐Glucose Sensors
1University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 2Abbott Diabetes Care, Clinical Affairs, Witney, United Kingdom, 3Abbott Diabetes Care, Medical Affairs, Wiesbaden, Germany
Topic:
AS05‐Glucose Sensors
1University of Virginia, Center For Diabetes Technology, Charlottesville, United States of America, 2University of Virginia, Nephrology, Transplant Center, Charlottesville, United States of America
Topic:
AS05‐Glucose Sensors
1Örebro University, Dept Of Medical Sciences, Örebro, Sweden, 2Region Halland, Research And Development, Halmstad, Sweden, 3Halmstad University, Center For Applied Intelligent Systems Research, Halmstad, Sweden, 4Hospital of Halland, Department Of Pediatrics, Kungssbacka, Sweden
Topic:
AS05‐Glucose Sensors
Hospital Universitario Central de Asturias, Endocrinology And Nutrition, Oviedo, Spain
Topic:
AS05‐Glucose Sensors
1Silkeborg Regional Hospital, Diagnostic Centre, Silkeborg, Denmark, 2Aarhus University, Biostatistics, Department Of Public Health, Aarhus C, Denmark
Topic:
AS05‐Glucose Sensors
Hospital General Universitario Gregorio Marañón, Endocrinology And Nutrition, Madrid, Spain
Topic:
AS05‐Glucose Sensors
Prince Sultan Military Medical City, Endocrinology, Riyadh, Saudi Arabia
Topic:
AS05‐Glucose Sensors
Vanderbilt University Medical Center, Pediatric Endocrinology, Nashville, United States of America
Topic:
AS05‐Glucose Sensors
1Abbott Diabetes Care, Global Strategic Marketing, Health Economics And Market Access, Alameda, United States of America, 2IQVIA, Health Economics, Palo Alto, United States of America, 3formerly IQVIA, Health Economics, Palo Alto, United States of America, 4Sahlgrenska University Hospital, Diabetes And Endocrinology, Goteborg, Sweden
Topic:
AS05‐Glucose Sensors
1Hull University Teaching Hospitals NHS Trust, Diabetes & Endocrinology, Hull, United Kingdom, 2Hull York Medical School, University of Hull, Department Of Academic Diabetes, Endocrinology And Metabolism, Hull, United Kingdom, 3University Hospitals of Derby and Burton, Diabetes And Endocrinology, Derby, United Kingdom, 4St Helens and Knowsley Teaching Hospitals NHS. Trust, Diabetes & Endocrinology, Prescot, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Department Of Diabetes & Endocrinology, Birmingham, United Kingdom
Topic:
AS05‐Glucose Sensors
1University of Bari Aldo Moro, Section Of Internal Medicine, Endocrinology, Andrology And Metabolic Diseases, Department Of Emergency And Organ Transplantation, Bari, Italy, 2ASST Fatebenefratelli‐Sacco, Division Of Endocrinology, Milano, Italy, 3ASS2 Bassa‐Friulana Isontina, Diabetes Unit, Monfalcone, Italy, 4G. Salesi Hospital, Department Of Women's And Children's Health, Ancona, Italy, 5University Federico II, Department Of Translational Medical Sciences, Naples, Italy, 6IRCCS Ospedale San Raffaele, San Raffaele Diabetes Research Institute, Milan, Italy, 7University of Messina, Department Of Human Pathology In Adult And Developmental Age "gaetano Barresi", Messina, Italy, 8Ospedale Maggiore di Cremona, Division Of Pediatrics, Cremona, Italy, 9University Magna Graecia, Department Of Health Science, Catanzaro, Italy
Topic:
AS05‐Glucose Sensors
Hospital Universitario de León, Endocrinología Y Nutrición, León, Spain
Topic:
AS05‐Glucose Sensors
1Dexcom, Clinical Affairs, San Diego, United States of America, 2Imperial College London, Diabetes And Endocrinology, London, United Kingdom
Topic:
AS05‐Glucose Sensors
1Poznan University of Medical Sciences, Department Of Reproduction, Poznan, Poland, 2Poznan University of Medical Sciences, Department Of Histology And Embryology, Poznan, Poland, 3Poznan University of Medical Sciences, Doctoral School, Poznan, Poland, 4Poznan University of Medical Sciences, University Hospital Of Obstetrics And Gynecology, Poznan, Poland
Topic:
AS05‐Glucose Sensors
Son Espases University Hospital, Endocrinology, PALMA DE MALLORCA, Spain
Topic:
AS05‐Glucose Sensors
S. Pasquini,
University of Verona, Medicine, Verona, Italy
Topic:
AS05‐Glucose Sensors
R. Batanero1, L. Aizpeolea1,
1University Hospital Marqués de Valdecilla, Endocrinology, Diabetes And Nutrition, Santander, Spain, 2University Hospital Marqués de Valdecilla, Clinical Analyses Laboratory, Santander, Spain
Topic:
AS05‐Glucose Sensors
Inuyama Chuo General Hospital, Diabetes, Inuyama‐city, Japan
using glucometers compliant with ISO15197:2013. Sensors where the mean absolute relative difference (MARD) could be evaluated more than nine times were included in this study.
Topic:
AS05‐Glucose Sensors
1University of Exeter, Institute Of Biomedical And Clinical Science, Exeter, United Kingdom, 2Liverpool John Moores, Research Institute For Sport And Exercise Sciences, Liverpool, United Kingdom, 3Royal Liverpool University Hospital, Department Of Diabetes/ Endocrinology And General Medicine, Liverpool, United Kingdom, 4University Hospitals Birmingham NHS Foundation Trust, Department of diabetes, Birmigham, United Kingdom, 5University of Birmingham, Institute of immunology and immunotherapy, Birmingham, United Kingdom, 6Taunton and Somerset NHS Foundation Trust, Department of diabetes, Taunton, United Kingdom
Topic:
AS05‐Glucose Sensors
1Koc University Hospital, Pediatric Endocrinology And Diabetes, Istanbul, Turkey, 2Koç University, School Of Medicine, istanbul, Turkey, 3Hacettepe University, Nutrition And Dietetics, Ankara, Turkey
Topic:
AS05‐Glucose Sensors
1HIPPOCRATION GENERAL HOSPITAL, Second Department Of Internal Medicine And Diabetes Center, Aristotle University Of Thessaloniki, THESSALONIKI, Greece, 2G.PAPANIKOLAOU GENERAL HOSPITAL, Pulmonary Department,aristotle University Of Thessaloniki, THESSALONIKI, Greece
In case 1, use of CGM revealed post prandial glucose excursions above 200mg/dl, as well as episodes of asymptomatic hypoglycemia. Fasting hyperglycemia was not detected (Figure 1). Treatment with prandial insulin was initiated. A bolus/basal ratio >60/40 and minimal between meals glucose variations in cases 2 and 3 (Figures 2, 3, respectively) are indicative of potential core role of defective first phase insulin secretion both in early and long standing CFRD.
Topic:
AS05‐Glucose Sensors
1Badajoz University Hospital, Endocrinology And Nutrition, Badajoz, Spain, 2Badajoz University Hospital, Endocrinology And Nutrition, BADAJOZ, Spain, 3Badajoz University Hospital, Paediatrics, Badajoz, Spain
At 3 months, the parameters of glucose control were as follows: sensor glucose: 168.4 ± 34.1 mg/dl, time 70‐180 mg/dl: 59.6 ± 20.8%, time <70 mg/dl: 3.3 ± 2.2%, time <54 mg/dl: 1 ± 1.4%, time >180 mg/dl: 37.3 ± 21.5%, time >250 mg/dl: 12.6 ± 12.7% and sensor use: 71.4 ± 24.4% No differences in skin reactions were found. 69% of the subjects would accept to keep using the system. Mean overall satisfaction score was 3.1 out 5.
Topic:
AS05‐Glucose Sensors
M. Rodriguez Garcia, J. Laguna, R. Wijngaard,
Hospital Clinic, Core Laboratory. Biochemistry And Molecular Genetics Department. Biomedical Diagnostic Centre, Barcelona, Spain
Topic:
AS05‐Glucose Sensors
R. Brett Mcqueen1, M. Perez‐Nieves2, G. Alonso3,
1University of Colorado Anschutz Medical Campus, Skaggs School Of Pharmacy And Pharmaceutical Sciences, Aurora, United States of America, 2Eli Lilly and Company, Diabetes, Indianapolis, United States of America, 3University of Colorado, Barbara Davis Center For Diabetes, Aurora, United States of America
Topic:
AS05‐Glucose Sensors
1Fitterfly Healthtech Pvt Ltd, Scientific Writing And Research, Navi Mumbai, India, 2Apollo Hospital, Department Of Endocrinology, Navi Mumbai, India, 3Jupiter Hospital, Department Of Endocrinology, Thane, India, 4Sree Gokulam Medical College and Research Foundation, Department Of Endocrinology, Trivandrum, India, 5Jupiter Hospital, Department Of Endocrinology, Thane West, India, 6Dr Raskar Diabetes Clinic, Department Of Diabetes, Thane, India, 7The Clinic, Department Of Diabetes, Mumbai, India, 8Kokilaben Hospital, Department Of Endocrinology, Mumbai,, India, 9Diabetes Care Clinic, Department Of Diabetes, Navi Mumbai, India, 10Asian Heart Institute, Department Of Endocrinology, Mumbai, India, 11ONGC hospital, Department Of Endocrinology, Navi Mumbai, India, 12Kevalya Hospital, Department Of Endocrinology, Thane, India, 13Shushrut Clinic, Department Of Endocrinology, Mumbai, India, 14Fitterfly Healthtech Pvt Ltd, Department Of Nutrition, Navi Mumbai, India, 15Fitterfly Healthtech Pvt Ltd, Chief Executive Officer, Navi Mumbai, India
Topic:
AS05‐Glucose Sensors
Hospital Universitario de León, Endocrinología Y Nutrición, León, Spain
Topic:
AS05‐Glucose Sensors
1University of Birmingham, College Of Medical And Dental Sciences, Birmingham, United Kingdom, 2University Hospitals Birmingham NHS Foundation Trust, Diabetes And Endocrinology, Birmingham, United Kingdom, 3Heartlands Hospital Birmingham, Diabetes And Endocrinology, Birmingham, United Kingdom
Topic:
AS05‐Glucose Sensors
Diamed Obesity SRL, Diabetes, Galati, Romania
Topic:
AS05‐Glucose Sensors
1Hospital Clínic de Barcelona, Endocrinology And Nutrition, Barcelona, Spain, 2IDIBAPS, (institut D'investigacions Biomèdiques August Pi I Sunyer), BARCELONA, Spain, 3CIBERDEM, (centro De Investigación En Red De Diabetes Y Enfermedades Metabólicas), Madrid, Spain
Topic:
AS05‐Glucose Sensors
1HUDERF, Diabetology Clinic, Brussels, Belgium, 2Hôpital Erasme, Endocrinology, Brussels, Belgium
Topic:
AS05‐Glucose Sensors
1New York Presbyterian Hospital; Columbia University School of Nursing, Neurology; Acute Care Adult Gerontology Nurse Practitioner Program, New York, United States of America, 2Columbia University, School Of Nursing, New York, United States of America
Topic:
AS05‐Glucose Sensors
Dexcom, Clinical Affairs, San Diego, United States of America
Topic:
AS05‐Glucose Sensors
Dexcom, Clinical Affairs, San Diego, United States of America
Group 2 had an abrupt rise in readings <70 mg/dL and a decrease in readings 70‐180 mg/dL on the index date, with subsequent improvement and stabilization. There were no apparent trends in Group 1 with respect to TIR or TBR.
Topic:
AS05‐Glucose Sensors
Terumo corporation, General Hospital Company, Yamanashi, Japan
Topic:
AS05‐Glucose Sensors
University of Padova, Department Of Information Engineering, Padova, Italy
Plasma glucose, insulin and C‐peptide concentrations were measured for 6 hours after each meal and used for the estimation of the reference DI with the OMM (DIMM), while CGM sensor data were employed for the calculation of DI with the sensor‐based method (DISB).
Topic:
AS05‐Glucose Sensors
1UZ Leuven ‐ KU Leuven, Endocrinology, Leuven, Belgium, 2KU Leuven ‐ University of Hasselt, Interuniversity Institute For Biostatistics And Statistical Bioinformatics, Leuven, Belgium, 3University Hospital Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Endocrinology‐diabetology‐metabolism, Antwerp, Belgium, 4Vrije Universiteit Brussel, Academic Hospital And Diabetes Research Centre, Brussels, Belgium, 5OLV Hospital Aalst, Endocrinology, Aalst, Belgium, 6Imeldaziekenhuis Bonheiden, Endocrinology, Bonheiden, Belgium, 7AZ Groeninge, Endocrinology, Kortrijk, Belgium
Topic:
AS05‐Glucose Sensors
A. Pierrard1,2, P. Verbiest1,2, Z. Mintjens1,2,
1University of Antwerp, Faculty Of Medicine And Health Sciences, Wilrijk, Belgium, 2University Hospital Antwerp, Endocrinology‐diabetology‐metabolism, Edegem, Belgium, 3University of Antwerp, Laboratory Of Experimental Medicine And Pediatrics And Member Of The Infla‐med Centre Of Excellence, Wilrijk, Belgium
Topic:
AS05‐Glucose Sensors
1University of Padova, Information Engineering (dei), Padova, Italy, 2University of Bern, Department Of Diabetes, Endocrinology, Nutritional Medicine And Metabolism Inselspital, Bern, Switzerland
Topic:
AS05‐Glucose Sensors
J. Mertens1,
1Antwerp University Hospital, Endocrinology, Diabetology And Metabolism, Edegem, Belgium, 2Antwerp University Hospital, Gastroenterology And Hepatology, Edegem, Belgium
Topic:
AS05‐Glucose Sensors
1Guys and St Thomas NHS Foundation Trust, Diabetes And Endocrinology, London, United Kingdom, 2Guys and St Thomas NHS Foundation Trust, St Johns Institute Of Dermatology, London, United Kingdom, 3King's College London, Department Of Diabetes, London, United Kingdom, 4King's Health Partners, Institute Of Diabetes, Endocrinology And Obesity, London, United Kingdom, 5Guy's and St Thomas' Hospital NHS Trust, Department Of Diabetes & Endocrinology, London, United Kingdom
Topic:
AS05‐Glucose Sensors
1Guy's and St Thomas' Hospital NHS Trust, Department Of Diabetes & Endocrinology, London, United Kingdom, 2Guys and St Thomas NHS Foundation Trust, 2. st Johns Institute Of Dermatology, London, United Kingdom, 3King's College London, Department Of Diabetes, London, United Kingdom, 4King's Health Partners, Institute Of Diabetes, Endocrinology And Obesity, London, United Kingdom
Topic:
AS05‐Glucose Sensors
1University of Copenhagen, Faculty Of Medicine, Copenhagen, Denmark, 2Procivitas Privata Gymnasium, Helsingborg, Helsingborg, Sweden, 3Lund University, Faculty Of Engineering, Lund, Sweden, 4Skane University Hospital, Dept Of Endocrinology, Lund, Sweden, 5Lund University, Clinical Sciences In Lund, Lund, Sweden
Topic:
AS05‐Glucose Sensors
1Harvard Medical School, Joslin Diabetes Center, Boston, United States of America, 2Joslin Diabetes Center, Pediatric Endocrinology, Boston, United States of America, 3Boston Children's Hospital, Endocrinology, Boston, United States of America
Topic:
AS05‐Glucose Sensors
Prayas Diabetes Center, Diabetology, Indore City, India
Topic:
AS05‐Glucose Sensors
Hospital Pedro Hispano, Matosinhos Local Health Unit, Endocrinology, Matosinhos, Portugal
Topic:
AS05‐Glucose Sensors
1Vall d'Hebron Hospital Campus, Endocrinology And Nutrition, Barcelona, Spain, 2Diabetes and Metabolism Unit, Vall D'hebron Research Institute And Ciberdem (isciii), Barcelona, Spain
Topic:
AS05‐Glucose Sensors
ICLDC Al Khaleej Al Arabi Abu Dhabi, Research Institute, Abu Dhabi, United Arab Emirates
1. 6. Glycemic Targets: Standards of Medical care in Diabetes‐2021. Diabetes Care, 2021.
2. Vigers, T., et al., cgmanalysis: An R package for descriptive analysis of continuous glucose monitor data. PLoS One, 2019.
3. Moscardó, V., et al., Updated Software for Automated Assessment of Glucose Variability and Quality of Glycemic Control in Diabetes. Diabetes Technol Ther, 2020.
Topic:
AS05‐Glucose Sensors
1Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 2Profusa, Clinical R&d, Emeryville, United States of America
Topic:
AS05‐Glucose Sensors
1Ulm University, Institute Of Epidemiology And Medical Biometry, Zibmt, Ulm, Germany, 2German Center for Diabetes Research, Dzd, München‐Neuherberg, Germany, 3Specialized Diabetes Practice, Essen, Essen, Germany, 4University of Erlangen, Department Of Internal Medicine, Erlangen, Germany, 5University Hospital Bern, Department Of Endocrinology, Diabetology And Clinical Nutrition, Bern, Switzerland, 6Landesklinikum Korneuburg Stockerau, Korneuburg Stockerau, Korneuburg Stockerau, Austria, 7Children's and Adolescent‘s Hospital „AUF DER BULT“,, Hannover, Hannover, Germany, 8Helios Clinic Schwerin, Department Of General Internal Medicine, Endocrinology And Diabetology, Schwerin, Germany, 9Institute for Pharmacology and Preventive Medicine, Cloppenburg, Cloppenburg, Germany, 10University Hospital Schleswig‐Holstein, Campus Lübeck, Lübeck, Germany
Topic:
AS05‐Glucose Sensors
1Cleveland Clinic Diabetes Center, Endocrinology And Metabolism Institute, Cleveland, United States of America, 2Close Concerns, Close Concerns, San Francisco, United States of America
Topic:
AS05‐Glucose Sensors
J. Bispham1, M. Grady2, J. Liu3, H. Nguyen3, K. Chapman3, S. Sandip Shah4,
1Evidera, Cro, Waltham, United States of America, 2LifeScan Scotland Ltd, Medical Affairs, Inverness, United Kingdom, 3T1D Exchange, T1d Exchange, Boston, United States of America, 4LifeScan Global Corporation, Marketing, Malvern, United States of America, 5LifeScan, Medical Affairs, Madrid, Spain, 6LifeScan Global Corporation, Medical Affairs, Malvern, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
S. Mitchell1, J. Hartman1, M. Grady2, H. Cameron2,
1Noom Inc., Noom Inc., New York, United States of America, 2LifeScan Scotland Ltd, Medical Affairs, Inverness, United Kingdom, 3LifeScan France, Medical Affairs, Rueil Malmaison, France, 4LifeScan Global Corporation, Medical Affairs, Malvern, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Aalborg University Hospital, Department Of Paediatrics, Aalborg, Denmark, 2Aalborg University Hospital, Steno Diabetes Center Nordjylland, Aalborg, Denmark, 3Aalborg University, Department Of Health Science And Technology, Aalborg, Denmark, 4Aalborg University Hospital, Department Of Endocrinology, Aalborg, Denmark, 5Aalborg University Hospital, Department Of Clinical Medicine, Aalborg, Denmark
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1State Medical University, Internal Medicine, Zaporozhye, Ukraine, 2Medical Academy of Postgraduating Education, Internal Medicine, Zaporozhye, Ukraine
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1NEUQUEN PROVINCIAL HOSPITAL DR EDUARDO CASTRO RENDON, Paediatrics, Neuquen, Argentina, 2NEUQUEN PROVINCIAL HOSPITAL DR EDUARDO CASTRO RENDON, Telemedicin, Neuquen, Argentina, 3PLOTTIER HOSPITAL, Nutrition, Neuquen, Argentina, 4SAN LUCAS CLINIC, Paediatrics, Neuquen, Argentina
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
P. Furtado1,
1Coimbra´s University, Sciencies And Technology, Coimbra, Portugal, 2CHUC, Endocrinology, Coimbra, Portugal
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University of Virginia, Computer Science, Charlottesville, United States of America, 2Dexcom, Data Science, San Diego, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1State Medical University, Internal Medicine, Zaporozhye, Ukraine, 2Medical Academy of Postgraduating Education, Internal Medicine, Zaporozhye, Ukraine
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Aalborg University, Department Of Health Science And Technology, Aalborg, Denmark, 2Aalborg University Hospital, Steno Diabetes Center Nordjylland, Aalborg, Denmark, 3Aalborg University Hospital, Department Of Endocrinology, Aalborg, Denmark
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
J. Hooper, M. Tanenbaum, A. Addala, A. Bonilla Ospina, E. Pang, A. Cortes, B. Leverenz, N. Arrizon‐Ruiz, C. Herrera, F. Bishop, D. Maahs,
Stanford University School of Medicine, Pediatrics, Palo Alto, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Ascensia Diabetes Care Holdings AG, Global Medical Affairs, Basel, Switzerland, 2Ascensia Diabetes Care, Global Clinical Affairs, Valhalla, United States of America, 3Ascensia Diabetes Care, Medical Affairs, Moscow, Russian Federation
with CONTOUR DIABETES App (CDA) (further “CDA system”) has been used in Russia since 2018. We evaluated HbA1c and estimated frequency of blood glucose readings (BGRs) outside of target range (OTR) in patients, who were using CDA system for 210 days in Russia.
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Asociación Mexicana de Diabetes en la Ciudad de Mexico, A.C, Education, Mexico City, Mexico, 2Medtronic, Diabetes, Mexico City, Mexico
Health team: 2 endocrinologists, 2 nutritionists, 1 educator, 2 psychologists, 1 ophthalmologist and a clinical technology specialist. First evaluation (endocrinology and nutrition) was face‐to‐face. Metabolic and anthropometric variables were obtained; follow‐up was telemedicine‐based. Before starting, a psychological and general knowledge assessment was done (to be replicated at the end, April 2022).
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
A. Kumbara1, A. Iyer1, B. Chung2, K. Leone3,
1Welldoc, Data Science, Columbia, United States of America, 2Dexcom, Population Health, San Diego, United States of America, 3Dexcom, Medical Science, San Diego, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Abbott Diabetes Care, Clinical Affairs, Alameda, United States of America, 2International Diabetes Center, Park Nicollet, Healthpartners, Minneapolis, United States of America, 3University of Leeds, Leeds Institute Of Cardiovascular And Metabolic Medicine, Leeds, United Kingdom
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
Campus Bio‐Medico, Endocrinology And Metabolic Diseases, Roma, Italy
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Ulm University of Applied Sciences, Institute For Medical Engineering And Mechatronics, Ulm, Germany, 2Diabetes Center Munich, ‐, München, Germany, 3AndroidAPS, ‐, Praha, Czech Republic
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Australian Diabetes Society, 145 Macquarie Street, Sydney, Australia, 2St Vincent's Hospital, Department Of Endocrinology And Diabetes, Fitzroy, Australia, 3University of Melbourne, Department Of Medicine, Parkville, Australia, 4National Association of Diabetes Centres, 145 Macquarie Street, Sydney, Australia
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Endocrinology Research Centre, Pediatric Endocrinology, D.Ulyanova, Russian Federation, 2Endocrinology Research Centre, Pediatric Endocrinology, D.Ulyanova, Russian Federation, 3Pirogov Russian National Research Medical University, Russian Children's Clinical Hospital, Moscow, Russian Federation
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
State University of Rio de Janeiro, Clinical Medicine, Rio de Janeiro, Brazil
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Aalborg University, Department Of Health Science And Technology, Aalborg, Denmark, 2Aalborg University, Aalborg University, Aalborg, Denmark, 3Aalborg University, Aalborg University, Aalborg Øst, Denmark, 4Aalborg University Hospital, Steno Diabetes Center Nordjylland, Aalborg, Denmark
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
Stanford University School of Medicine, Pediatrics, Palo Alto, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1McGill University Health Centre, Research Institute, Montreal, Canada, 2McGill University, School Of Human Nutrition, Sainte‐Anne‐de‐Bellevue, Canada
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Hospital Universitario San Ignacio, Endocrinology Unit, Bogota, Colombia, 2Hospital Universitario San Ignacio, Internal Medicine Department, Bogota, Colombia
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
University of Padova, Department Of Information Engineering (dei), Padova, Italy
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Fitterfly Healthtech Pvt Ltd, Scientific Writing And Research, Navi Mumbai, India, 2Bharati Hospital, Department Of Endocrinology, Haryana, India, 3Jupiter Hospital, Department Of Endocrinology, Thane West, India, 4Bombay Hospital, Department Of Endocrinology, Mumbai, India, 5Zydus Hospital, Department Of Endocrinology, Mumbai, India, 6Spectrum Clinic, Department Of Endocrinology, Thane, India, 7My Diabetes Clinic, Department Of Diabetes, Thane, India, 8Dr Malatibai Chitnis Hospital, Department Of Endocrinology, Thane, India, 9Sree Gokulam Medical College and Research Foundation, Department Of Endocrinology, Trivandrum, India, 10Global Hospitals, Department Of Endocrinology, Mumbai, India, 11Dr Nikte Clinic, Department Of Endocrinology, Mumbai, India, 12Dhriti Clinic, Department Of Diabetes, Mumbai, India, 13Fitterfly Healthtech Pvt Ltd, Department Of Nutrition, Navi Mumbai, India, 14Fitterfly healthtech Pvt ltd, Department Of Metabolic Nutrition, Navi Mumbai, India, 15Fitterfly Healthtech Pvt Ltd, Chief Executive Officer, Navi Mumbai, India
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
M. Grady1, H. Cameron1,
1LifeScan Scotland Ltd, Medical Affairs, Inverness, United Kingdom, 2LifeScan, Medical Affairs, Madrid, Spain, 3LifeScan Global Corporation, Medical Affairs, Malvern, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University of Padova, Department Of Information Engineering (dei), Padova, Italy, 2University of Bern, Department Of Diabetes, Endocrinology, Nutritional Medicine And Metabolism Inselspital, Bern, Switzerland
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Stanford University, Pediatric Endocrinology & Diabetes, Stanford, United States of America, 2University of Florida, Health Services Research, Management, And Policy, Gainesville, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University Medical Centre Ljubljana, Department Of Endocrinology, Diabetes And Metabolic Diseases, Ljubljana, Slovenia, 2Faculty of Medicine, University Of Ljubljana, Ljubljana, Slovenia
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Liva Healthcare, Operations Department, Copenhagen, Denmark, 2University of Copenhagen, Department Of Psychology, Copenhagen, Denmark
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
S. Pinkney1, A. Virani2, F. Abdulhussein2,
1BC Children's Hospital Research Institute, Pediatrics, Vancouver, Canada, 2University of British Columbia, Pediatrics, Vancouver, Canada
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University Medical Centre Ljubljana, Department Of Endocrinology, Diabetes And Metabolic Diseases, Ljubljana, Slovenia, 2Faculty of Medicine, University Of Ljubljana, Ljubljana, Slovenia
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
Portuguese Diabetes Association (APDP), Insulin Pump Department, Lisbon, Portugal
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Hospital of Halland, Department Of Pediatrics, Kungssbacka, Sweden, 2Institute of clinical sciences at Sahlgrenska Academy, Gothenburg University, Department Of Pediatrics, Gothenburg, Sweden, 3The hospital of Halland Halmstad, Department Of Pediatrics, Halmstad, Sweden
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Children's Mercy Kansas City, Pediatrics, Kansas City, United States of America, 2Children's Mercy Kansas City, Pediatric Endocrinology, Kansas City, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Penn State College of Medicine, Department Of Medicine, Division Of Endocrinology, Hershey, United States of America, 2Penn State College of Medicine, Information Services, Hershey, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Asl Na1 Centro, Uoc Medicina Interna, Dh Diabetologia, Po Dei Pellegrini, Naples, Italy, 2Federico II University, Translational Medicine, Naples, Italy, 3University Federico II, Department Of Translational Medical Sciences, Naples, Italy
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
naInzulinu.com, ‐, Zagreb, Croatia
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University Hospital of Southern Denmark, Department Of Internal Medicine, Sonderborg, Denmark, 2Odense University Hospital, Centre For Innovative Medical Technology, Odense, Denmark, 3University of Southern Denmark, Department Of Regional Health Research, Sonderborg, Denmark
The aim of this study was to explore healthcare professionals'perspectives on video consultations for type 1 diabetes patients treated with insulin pumps in the outpatient clinic.
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
V. Klimontov1,
1Research Institute of Clinical and Experimental Lymphology — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL—Branch of IC&G SB RAS), Laboratory Of Endocrinology, Novosibirsk, Russian Federation, 2Sobolev Institute of Mathematics, Siberian Branch of Russian Academy of Sciences, Laboratory Of Data Analysis, Novosibirsk, Russian Federation
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Clinica EnDi, Endocrinology, Mexico City, Mexico, 2Centro Medico ABC, Endocrinology, Mexico City, Mexico, 3Centro para la Prevención y Atención Integral del VIH/SIDA de la Ciudad de México, Computer Science, Mexico City, Mexico, 4Clinica EnDi, Education, Mexico City, Mexico, 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Endocrinology And Metabolism, Metabolic Diseases Research Unit, Mexico City, Mexico, 6Corporativo Hospital Satelite, Internal Medicine And Endocrinology, Mexico State, Mexico, 7Clinica EnDi, Nutrition, Mexico City, Mexico, 8Hospital Universitario, Universidad Autonoma de Nuevo Leon, Endocrinology, Monterrey, Mexico, 9Unidad de Investigacion Cardiometabolica de Occidente, Endocrinology, Guadalajara, Mexico, 10Universidad Nacional Autonoma de Mexico, Investigación, Mexico City, Mexico
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Sunnybrook Health Sciences Center, Department Of Medicine, Toronto , Ontario, Canada, Canada, 2Queens University, Medicine, Kingston, Canada
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Roche Diabetes Care Inc., Math Algorithms And Data Science, Indianapolis, United States of America, 2Roche Diabetes Care Inc., Strategy And Customer Solutions, Indianapolis, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
Fomin Women's Health Clinic, Endocrinology, Moscow, Russian Federation
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University of Virginia, School Of Medicine, Center For Diabetes Technology, Charlottesville, United States of America, 2University of Virginia, School Of Data Science, Charlottesville, United States of America, 3University of Virginia, Division Of Endocrinology, Charlottesville, United States of America, 4University of Virginia, Department Of Pediatrics, Charlottesville, United States of America, 5University of Virginia, Division Of Endoncrinology And Metabolism, Center For Diabetes Technology, Charlottesville, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
J.F. Merino Torres1, M. Weyland2, A. Scorsone3, A. Verhaegen4, E. Nunes Pinto5,
1Hospital Universitario y Politécnico La Fe, Endocrinology, Valencia, Spain, 2Diabetologische Praxis Dr. Puschmann, Diabetologische Praxis Dr. Puschmann, Gummersbach, Germany, 3Osp. Civico Partinico, Endocrinology, Partinico, Italy, 4University Hospital Antwerp, Endocrinology, Edegem, Belgium, 5Hospital de Cascais Dr. José de Almeida, Endocrinology, Cascais, Portugal, 6LifeScan, Medical Affairs, Madrid, Spain, 7LifeScan Scotland Ltd, Medical Affairs, Inverness, United Kingdom, 8LifeScan Global Corporation, Medical Affairs, Malvern, United States of America
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Ascensia Diabetes Care, Medical Affairs, Sydney, Australia, 2Ascensia Diabetes Care, Global Clinical Affairs, Valhalla, United States of America, 3Ascensia Diabetes Care Holdings AG, Global Medical Affairs, Basel, Switzerland
Topic:
AS07‐Insulin Pumps
1General Hospital of Pireas Tzaneio, 1st Department Of Internal Medicine And Diabetes Center, Pireas, Greece, 2Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, First Department Of Propaedeutic Internal Medicine, Athens, Greece
Topic:
AS07‐Insulin Pumps
1General Hospital of Pireas Tzaneio, 1st Department Of Internal Medicine And Diabetes Center, Pireas, Greece, 2Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, First Department Of Propaedeutic Internal Medicine, Athens, Greece
Topic:
AS07‐Insulin Pumps
1Hamad Medical Corporation, Diabetes And Endocrine, Doha, Qatar, 2Sidra Medicine, Diabetes And Endocrine, Doha, Qatar
Topic:
AS07‐Insulin Pumps
1Instituto medico rio cuarto, Endocrinology, Rio cuarto, Argentina, 2Hospital.privado, Diabetes, Cordoba, Argentina, 3CLINICA UNIVERSITARIA REINA FABIOLA , Servicio De Diabetes Y Nutricion, córdoba, Argentina, 4MAINSBLEUES, Diabetes, rafaela, Argentina, 5CEDIR, Diabetes, santa fe, Argentina, 6centro de diagnóstico cardio vascular, Diabetes, Rio cuarto, Argentina, 7Centro médico Mellitus, Diabetes, Rio cuarto, Argentina, 8Clínica de Especialidades, Diabetes, VILLA MARIA, Argentina, 9Centro Cardiometabolico, Diabetes, SANTIAGO DEL ESTERO, Argentina, 10Hospital de la Madre y el Niño, Diabetes, LA RIOJA, Argentina, 11Sanatorio Independencia, Diabetes, SANTIAGO DEL ESTERO, Argentina, 12gsbio, Diabetes, cordoba, Argentina, 13gsbio, Diabetes, rio caurto, Argentina, 14UNRC, Matematics, Rio cuarto, Argentina
Topic:
AS07‐Insulin Pumps
Ciudad Real General University Hospital, Endocrinology And Nutrition, Ciudad Real, Spain
Topic:
AS07‐Insulin Pumps
1Copenhagen University Hospital ‐ Steno Diabetes Center Copenhagen, Clinical Research, Herlev, Denmark, 2Copenhagen University Hospital ‐ Steno Diabetes Center Copenhagen, Health Promotion Research, Herlev, Denmark, 3Nordsjællands Hospital, Hillerød, Department Of Endocrinology And Nephrology, Hillerød, Denmark
Topic:
AS07‐Insulin Pumps
Hospital Pediátrico, Centro Hospitalar Universitário de Coimbra, Pediatric Endocrinology, Diabetes And Growth Unit, Coimbra, Portugal
Topic:
AS07‐Insulin Pumps
1Swansea University, Applied Sport Exercise Technology And Medicine Research Centre, Swansea, United Kingdom, 2Steno Diabetes Center Copenhagen, Diabetes Technology, Herlev, Denmark, 3Swansea University, School Of Medicine, Swansea, United Kingdom
Topic:
AS07‐Insulin Pumps
1Swansea University, Applied Sport Exercise Technology And Medicine Research Centre, Swansea, United Kingdom, 2Steno Diabetes Center Copenhagen, Diabetes Technology, Herlev, Denmark, 3Swansea University, School Of Medicine, Swansea, United Kingdom, 4Steno Diabetes Center Copenhagen, Herlev, Denmark, Clinical Research, Herlev, Denmark
Topic:
AS07‐Insulin Pumps
1Universidade de Santiago de Compostela, Psychiatry, Radiology, Public Health, Nursing And Medicine, Santiago de Compostela, Spain, 2Complexo Hospitalario Universitario de Santiago de Compostela, Department Of Endocrinology And Nutrition, Santiago de Compostela, Spain
Topic:
AS07‐Insulin Pumps
1Centro Hospitalar Universitário De Coimbra, Endocrinology, Diabetes & Metabolism, Coimbra, Portugal, 2Centro hospitalar universitário de Coimbra, Endocrinology, Coimbra, Portugal
Topic:
AS07‐Insulin Pumps
Institut für Diabetes‐Technologie, Forschungs‐ und Entwicklungsgesellschaft mbH an der Universität Ulm, Scientific Operations, Ulm, Germany
Topic:
AS07‐Insulin Pumps
1Institut für Diabetes‐Technologie, Forschungs‐ und Entwicklungsgesellschaft mbH an der Universität Ulm, Scientific Operations, Ulm, Germany, 2AMF Medical SA, Epfl Innovation Park, Ecublens, Switzerland
Topic:
AS07‐Insulin Pumps
Department of Women's and Children's Health, Azienda Ospedale Università di Padova, Padua, Italy, Pediatric Diabetes Unit, PADOVA, Italy
No hypoglycaemic episodes were observed. After two weeks: TIR 52%, TAR 48%, TBR 0%. After six months: TIR 85%, TAR 12%, TBR 4% (1% <54 mg/dl). Neurocognitive Bayley‐III scale was administered at onset and after six months with important improvements.
Topic:
AS07‐Insulin Pumps
S. Gianfrancesco,
Federico II University, Clinical Medicine And Surgery, Naples, Italy
Topic:
AS07‐Insulin Pumps
Indian Institute of Science, Centre For Product Design And Manufacturing, Bengaluru, India
In this work, we undertake in‐vitro accuracy evaluation of a novel, affordable insulin pump, designed for type‐1 diabetic patients in resource‐constrained settings.
Topic:
AS07‐Insulin Pumps
1Hospital Llerena Zafra, Endocrinology & Nutrition Department, Zafra, Spain, 2Badajoz University Hospital, Endocrinology And Nutrition, BADAJOZ, Spain, 3Badajoz University Hospital, Endocrinology And Nutrition, Badajoz, Spain
Data from analysis of glycemic control parameters are shown in Table 2.
We found statistically significant differences in the comparison of TIR between TS‐BasalIQ and TS‐ControlIQ, (p = 0.028). There were not statistically significant differences between MM640G and MM780; neither between MM780G and TS‐ControlIQ in our population of study.
Topic:
AS07‐Insulin Pumps
R. Bonfanti1, V. Castorani2,
1Instituto Scientifico H. San Raffaele Universitã Vita‐Salute, Pediatrics, Milano, Italy, 2Ospedale San Raffaele, Pediatrics, milano, Italy
Topic:
AS07‐Insulin Pumps
R. Bonfanti1, V. Castorani2, A. Rigamonti2,
1Instituto Scientifico H. San Raffaele Universitã Vita‐Salute, Pediatrics, Milano, Italy, 2Ospedale San Raffaele, Pediatrics, milano, Italy
Topic:
AS07‐Insulin Pumps
Hospital Pediátrico, Centro Hospitalar Universitário de Coimbra, Pediatric Endocrinology, Diabetes And Growth Unit, Coimbra, Portugal
Topic:
AS07‐Insulin Pumps
Campus Bio‐Medico, Endocrinology And Metabolic Diseases, Roma, Italy
Topic:
AS07‐Insulin Pumps
Hospital General Universitario Santa Lucia, Endocrinology And Nutrition, Cartagena, Spain
Topic:
AS07‐Insulin Pumps
Semmelweis University Faculty of Internal Medicine and Hematology, Dept. Of Endocrinology And Metabolism, Budapest, Hungary
Topic:
AS07‐Insulin Pumps
Hospital Universitario San Ignacio, Endocrinology Unit, Bogota, Colombia
Topic:
AS07‐Insulin Pumps
L. Lequi1,
1MAINSBLEUES, Diabetes, rafaela, Argentina, 2Clínica Universitaria Reina Fabiola, Diabetes, Córdoba, Argentina, 3Centro CODIME Buenos Aire, Diabetes, caba, Argentina, 4clinica Juan Domingo Peron. Catriel, Diabetes, Catriel, Argentina
Topic:
AS08‐New Medications for Treatment of Diabetes
1West Island Metabolic Unit, Suite 212, Pierrefonds, Canada, 2Pierrefonds Medical Center, General Medicine, Pierrefonds, Canada
Topic:
AS08‐New Medications for Treatment of Diabetes
M. Antsiferov1,
1Endocrinological Dispensary of the Mosсow, Mosсow Healthcare Department, Moscow, Russian Federation, 2Hospital of Moscowsky city, Moscow Health Care Department, Moscow, Russian Federation, 3Kuznechiki Hospital, Mosсow Healthcare Department, Moscow, Russian Federation, 4City Polyclinic №23, Mosсow Healthcare Department, Moscow, Russian Federation, 5City Polyclinic №5, Mosсow Healthcare Department, Moscow, Russian Federation, 6City Polyclinic №134, Mosсow Healthcare Department, Moscow, Russian Federation
Topic:
AS08‐New Medications for Treatment of Diabetes
1Zealand Pharma A/S, Bioanalysis & Pharmacokinetics, Søborg, Denmark, 2Certara, Strategic Consulting, Princeton, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
Scientific Centre for Family Health and Human Reproduction Problems, Department Of Personalized And Preventive Medicine, Irkutsk, Russian Federation
Topic:
AS08‐New Medications for Treatment of Diabetes
1Institute of Neuroscience, National Research Council, Padova, Italy, 2Profil, Institute For Metabolic Research, Neuss, Germany, 3Eli Lilly and Company, Diabetes Bu, Indianapolis, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
1Békés County Central Hospital, Dr Réthy Pal Member Hospital, 1st Department Of Endocrinology, Békéscsaba, Hungary, 2University of Debrecen, Department Of Internal Medicine – Division Of Endocrinology, Debrecen, Hungary, 3University of Szeged, Faculty Of Medicine, Department Of Internal Medicine, Szeged, Hungary
Topic:
AS08‐New Medications for Treatment of Diabetes
B. Pack, J. Melnick, C. Breen, R. Allen,
Eli Lilly and Company, Diabetes, Indianapolis, United States of America
Topic:
AS08‐New Medications for Treatment of Diabetes
1Fundación Santa Fe de Bogota, Endocrinology, Bogota, Colombia, 2FUNDACION SANTA FE DE BOGOTA, Endocrinologia, Bogotá, Colombia
*ID: insuline dose IU
Topic:
AS08‐New Medications for Treatment of Diabetes
SKN Diabetes and Endocrine Centre, Endocrinology And Diabetes, NAIHATI, India
Topic:
AS08‐New Medications for Treatment of Diabetes
1Ahmadu Bello University, Zaria, Nigeria, Veterinary Pathology, Zaria, Nigeria, 2Ahmadu Bello University, Zaria, Nigeria, Veterinary Physiology, Zaria, Nigeria, 3Ahmadu Bello University, Zaria, Nigeria, Biochemistry, Zaria, Nigeria
Topic:
AS08‐New Medications for Treatment of Diabetes
1National Scientific Medical Research Center, Endocrine Disturbances, Nur‐Sultan (Astana), Kazakhstan, 2National Scientific Medical Research Center, Chairman Of The Board, Nur‐Sultan (Astana), Kazakhstan, 3National Scientific Medical Research Center, Stem Cells Technology, Nur‐Sultan (Astana), Kazakhstan, 4National Scientific Medical Research Center, Clinical Laboratory, Nur‐Sultan (Astana), Kazakhstan, 5National Scientific Medical Research Center, Deputy Chairman Of The Board For Medicine And Sciens, Nur‐Sultan (Astana), Kazakhstan
Topic:
AS08‐New Medications for Treatment of Diabetes
M. Lavrador,
Centro Hospitalar Universitário de Coimbra, Endocrinology, Coimbra, Portugal
Topic:
AS08‐New Medications for Treatment of Diabetes
1Military medical academy of S. M. Kirov, Endocrinology, Saint‐Petersburg, Russian Federation, 2National Medical‐Surgical Center N.I. Pirogov, Surgery, Moscow, Russian Federation
Topic:
AS08‐New Medications for Treatment of Diabetes
Araba University Hospital ‐ Basque Country University, Peadiatric, Vitoria, Spain
Topic:
AS08‐New Medications for Treatment of Diabetes
Prince Sultan Military Medical City, Endocrinology, Riyadh, Saudi Arabia
Topic:
AS09‐New Insulin Delivery Systems: Inhaled, Transderma, Implanted Devices
K. Kaiserman1, M. Christiansen2, S. Bhavsar1, J. Ulloa3, B. Santogatta1, J. Hanna3,
1MannKind Corporation, Medical Affairs, Westlake Village, United States of America, 2Diablo Clinical Research, Endocrinology, Walnut Creek, United States of America, 3MannKind Corporation, Clinical Development, Westlake Village, United States of America, 4AMCR Institute, Endocrinology, Escondido, United States of America
Topic:
AS09‐New Insulin Delivery Systems: Inhaled, Transderma, Implanted Devices
1Karolinska Institutet, Department Of Molecular Medicine And Surgery, Solna, Sweden, 2Novo Nordisk A/S, Data Science, Søborg, Denmark, 3Novo Nordisk A/S, Digital Health, Søborg, Denmark, 4Hospital of Halland, Department Of Pediatrics, Kungssbacka, Sweden
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Philips Healthcare North America, Clinical & Medical Affair, Heor, Cambridge, United States of America, 2Philips Healthcare North America, Global Business Marketing, pittsburgh, United States of America, 3Decision Resources Group, Part of Clarivate, Consulting, Cambridge, United States of America
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Miguel Hernandez University, Clinical Medicine, San Juan de Alicante, Spain, 2Hospital Vithas and Hospital Universitario Virgen de la Macarena, Department Of Endocrinology, Sevilla, Spain, 3José Marvá Heath Care Center, Primary Care, Madrid, Spain, 4Santa Creu i Sant Pau Hospital, Department Of Endocrinology And Nutrition, Barcelona, Spain, 5Sardenya Primary Health Care Center. Biomedical Research Institute Sant Pau, Primary Care, Barcelona, Spain, 6El Campello Integrated Healthcare Center, Primary Care, Alicante, Spain, 7Galapagar Primary Care Center. RS RedGDPS Fundation, Primary Care, Galapagar, Spain, 8NTDE Health Center, Department Of Endocrinology, Sevilla, Spain, 9Merck Sharp & Dohme Spain (MSD), Medical Affairs, Madrid, Spain
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Retina Associates, LLC, Ophthalmology, Lenexa, United States of America, 2Retinal Consultants, Ophthalmology, Sacramento, United States of America, 3Genentech, Inc., Ophthalmology, South San Francisco, United States of America
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Ibn Aljazzar Hospital, Endocrinology Departement,, Kairouan, Tunisia, 2Ibn Aljazzar Hospital, Endocrinology Departement,, khniss, Tunisia
Topic:
AS10‐Devices Focused on Diabetic Preventions
Tehran university of Medical Sciences, Health Education And Health Promotion, i, Iran
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Medical Univerisy Sofia, Medical Genetics, Sofia, Bulgaria, 2SAGBAL "Dr Shterev", Endocrinology, Sofia, Bulgaria, 3Aleksandrovska hospital, Cardiology, Sofia, Bulgaria, 4Medical University Sofia, Pharmacology, Sofia, Bulgaria, 5Medical University Sofia, Clinical Laboratory, Sofia, Bulgaria
Topic:
AS10‐Devices Focused on Diabetic Preventions
H. Ranjani1,
1Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Translational Research Department, Chennai, India, 2Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Diabetology, Chennai, India, 3Imperial College London, Faculty Of Medicine, London, United Kingdom, 4Imperial College London, School Of Public Health, London, United Kingdom
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Translational Research Department, Chennai, India, 2Imperial College London, Faculty Of Medicine, London, United Kingdom, 3Imperial College London, School Of Public Health, London, United Kingdom, 4Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Diabetology, Chennai, India
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Diabetology, Chennai, India, 2Imperial College London, Faculty Of Medicine, London, United Kingdom, 3Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Translational Research Department, Chennai, India, 4Imperial College London, School Of Public Health, London, United Kingdom, 5Madras Diabetes Research Foundation, Translational Research, CHENNAI, India
Topic:
AS10‐Devices Focused on Diabetic Preventions
1Institute of medicine, the Sahlgrenska academy, University of Gothenburg, Department Of Molecular And Clinical Medicine, Gothenburg, Sweden, 2The Queen Silvia Children's hospital, the Sahlgrenska University hospital, Department Of Pediatric Clinical Physiology, Gothenburg, Sweden, 3Intitute of clinical sciences, the Sahlgrenska academy, University of Gothenburg, Department Of Pediatrics, Gothenburg, Sweden, 4Intitute of clinical sciences, Department Of Pediatrics, Gothenburg, Sweden, 5The Queen Silvia Children's hospital, the Sahlgrenska University hospital, Gothenburg, Sweden, Pediatric Heart Center, Gothenburg, Sweden
Topic:
AS10‐Devices Focused on Diabetic Preventions
L.M. Lavaysse, M. Lee, J. Hoy‐Rosas, H. Nagra, S.D. Imrisek, D. Goldner, J. Dachis,
One Drop, Outcomes Research, New York, United States of America
Topic:
AS10‐Devices Focused on Diabetic Preventions
S. Ballegaard1, N. Oersted2, B. Karpatschof3, F. Gyntelberg4, E. Eldrup1, A. Gjedde5,
1Herlev University Hospital Faculty of Health and Medical Sciences, Department Of Medicine, Endocrine Unit, Hellerup, Denmark, 2Ballegaard Stresscare, Outpatient Clinic, Hellerup, Denmark, 3Copenhagen University, Psychological Institute, copenhagen, Denmark, 4national research Center for the working environment, Occupational Medicine, copenhagen, Denmark, 5Copenhagen University, Department Of Neuroscience, Copenhagen N, Denmark
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
Helmholtz Zentrum Munich, Institute Of Translational Stem Cell Research, Munich, Germany
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
1Lund University, Clinical Sciences In Lund, Lund, Sweden, 2Skane University hospital, Dept Of Endocrinology, Lund, Sweden, 3Lund University Cancer Centre, Lund University, Lund, Sweden, 4Skane University Hospital, Department Of Surgery, Lund, Sweden
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
Scientific Centre for Family Health and Human Reproduction Problems, Department Of Personalized And Preventive Medicine, Irkutsk, Russian Federation
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
1Conquer Diabetes, Diabetes, Mumbai, India, 2Jupiter Hospital, Diabetes, Thane, India
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
1Vuk Vrhovac University Clinic, Merkur Clinical Hospital, Outpatient Department, Zagreb, Croatia, 2University of Zagreb, Statistics Department, Zagreb, Croatia
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
1University of Bern, Artorg Center For Biomedical Engineering Research, Bern, Switzerland, 2Geriatrisch Klinik St. Gallen AG, Gerontologie Medicine Resarch, St. Gallen, Switzerland, 3Bern University Hospital, Department Of Emergency Medicine, Bern, Switzerland, 4Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, Bern, Switzerland
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
1Military medical academy of S. M. Kirov, Endocrinology, Saint‐Petersburg, Russian Federation, 2National Medical‐Surgical Center N.I. Pirogov, Surgery, Moscow, Russian Federation
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
1Sandwell and West Birmingham NHS Trust, Diabetes And Endocrinology, Birmingham, United Kingdom, 2Sandwell and West Birmingham NHS Trust, Dietetics, Birmingham, United Kingdom, 3Sandwell and West Birmingham NHS Trust, Gastroenterology, Birmingham, United Kingdom, 4Sandwell and West Birmingham NHS Trust, Anaesthetics, Birmingham, United Kingdom, 5Guy's and St Thomas' NHS Foundation Trust, Diabetes, London, United Kingdom
(age 51.2 ± 7.2years, 55% male, diabetes duration 14.3(8‐20)years, BMI 41.6 ± 7.3kg/m2) attended follow‐up. During EndoBarrier treatment, mean ± SD HbA1c fell by 1.8 ± 1.8% (20.2 ± 19.7mmol/mol), from 9.1 ± 1.7 to 7.2 ± 1.0% (75.7 ± 19.0 to 55.5 ± 11.2mmol/mol)(p < 0.001), weight by 17.4 ± 9.2kg from 122.3 ± 29.4 to 104.9 ± 30.4kg(<0.001), systolic BP from 139.0 ± 14.5 to 125.4 ± 15.0mmHg(<0.001), cholesterol from 4.6 ± 1.0 to 3.8 ± 0.7mmol/L, serum alanine aminotransferase (a marker of liver fat) from 30.4 ± 17.6 to 19.0 ± 11.4U/L (p < 0.001). Median(IQR) total daily insulin dose reduced from 104(54‐162) to 20(0‐65)units(n = 27,p <0.001). 10/27(37%) insulin‐treated patients discontinued insulin. Three‐years post‐EndoBarrier, 31/42(74%) maintained most of the improvement achieved with EndoBarrier whilst 11/42(27%) reverted to baseline (Figure). Of those deteriorating all had depression and/or bereavement and/or major health problems/disability. 10/62(16%) required early EndoBarrier removal for adverse events or symptoms; all 10 fully recovered after removal and most derived significant benefit.
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
SMC Laboratories, R&d, Ota‐City, Tokyo, Japan
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
A. Buch1, S. Yeshurun2,
1Tel Aviv Sourasky Medical Center, Institute Of Endocrinology, Metabolism And Hypertension, Tel Aviv, Israel, 2Metaflow Ltd., Research Department, Tel Aviv, Israel, 3Tel‐Aviv University, The Sackler Faculty Of Medicine, Tel Aviv, Israel
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
National Medical Research Centre for Cardiology, Department Of Angiogenesis, Moscow, Russian Federation
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
P. Kanehl1, L. Jones2,
1Oviva AG, Data Science, Potsdam, Germany, 2Oviva AG, Science, Potsdam, Germany
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
1University of Bern, Artorg Center For Biomedical Engineering Research, Bern, Switzerland, 2University of Zurich, Epidemiology, Biostatistics And Prevention Institute (ebpi), Zurich, Switzerland, 3Oviva S.A., Oviva, Altendorf, Switzerland
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
Z. Hadj Ali, S. Mokni, Y. Htira, F. Ben Slama,
National Institute of Nutition, Section C, bab saadoun, Tunisia
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
N. Evdokimova, A. Pochlebkina, E. Milner, U. Petrenko,
St. Petersburg State Pediatric University, Propedutics Childhood Disease, St. Petersburg, Russian Federation
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
Hospital Universitario San Ignacio, Endocrinology Unit, Bogota, Colombia
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1Tampere University, Faculty Of Medicine And Health Technology, Tampere, Finland, 2Tampere University Hospital, Department Of Internal Medicine, Tampere, Finland, 3Tampere University, Faculty Of Social Sciences, Tampere, Finland
balance (OR 0.46; 95% CI 0.28–0.81). Intermittent glucose monitoring with multiple daily injections (IGM+MDI) and continuous subcutaneous insulin infusion (CSII) with glucose sensor (IGM or continuous glucose monitoring, CGM; CSII+sensor) were independently associated with poor glycaemic control compared to sensor‐augmented or hybrid closed‐loop pump (SAP/HCL) which yielded the best results.
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
Inuyama Chuo General Hospital, Diabetes, Inuyama‐city, Japan
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
M. Ortiz‐Espejo1, R. Batanero2,
1University Hospital Marqués de Valdecilla, Clinical Analyses Laboratory, SANTANDER, Spain, 2University Hospital Marqués de Valdecilla, Endocrinology, Diabetes And Nutrition, SANTANDER, Spain, 3University Hospital Marqués de Valdecilla, Hematology, Santander, Spain, 4University Hospital Marqués de Valdecilla, Endocrinology, Diabetes And Nutrition, Santander, Spain
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1Dr Makkar's Diabetes and Obesity Centre, Diabetes, DELHI, India, 2Central Delhi Diabetes Centre, Diabetes, Delhi, India, 3North Delhi Diabetes Centre, Diabetes, Delhi, India
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
Inuyama Chuo General Hospital, Diabetes, Inuyama‐city, Japan
Pattern 1 was selected for achieving the following: Patients with low HbA1c had low TIR; “The ratio of time‐below‐range (<70 mg/dL) to time‐above‐range (>180 mg/dL)” (TBR <70/TAR >180) negatively correlated to HbA1c. Pattern 2 was selected to realize that “TBR <70/TAR >180 did not correlate to HbA1c.
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1The Chinese University of Hong Kong, Department Of Medicine And Therapeutics, Hong Kong, Hong Kong PRC, 2The Chinese University of Hong Kong, Li Ka Shing Institute Of Health Science, Hong Kong, Hong Kong PRC, 3The Chinese University of Hong Kong, Phase 1 Clinical Trial Centre, Hong Kong, Hong Kong PRC
with lower rates of nocturnal hypoglycemia. Dynamic glucose profiles may reveal between‐group temporal differences not apparent from CGM metrics. We used functional data analysis (FDA) to compare changes in 24 hour CGM profiles in FGM vs SMBG groups.
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
Symbiosis International (Deemed) University, Symbiosis Institute Of Health Sciences, Nutrition And Dietetics, Pune, India
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
Queens Hospital, Diabetes And Endocrinology, LONDON, United Kingdom
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1King Abdulaziz medical city, Family Medicine, jeddah, Saudi Arabia, 2King Saud bin Abdulaziz University, Family Medicine, Jeddah, Saudi Arabia
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
Research Institute of Clinical and Experimental Lymphology — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (RICEL—Branch of IC&G SB RAS), Laboratory Of Endocrinology, Novosibirsk, Russian Federation
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1diabetes care and hormone clinic, Diabetes, Ahmedabad, India, 2Diacare Diabetes & Hormone Clinic, Diabetes, Ahmedabad, India
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1Faculty Of Medicine, University Of Thessaly, Department Of Endocrinology And Metabolic Diseases, Larisa, Greece, 2Centre for Research and Technology Hellas, Information Technologies Institute, Thermi, Thessaloniki, Greece
Logistic regression was performed, using age, sex, SOFA, OASIS and GV during ICU admission (thresholded at 0.5 for high) as predictors, and death in ICU as the target. The study protocol was approved by the respective Institutional Review Boards.
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
University Hospital Birmingham, Department Of Paediatrics., Birmingham, United Kingdom
Topic:
AS14‐Human factor in the use of diabetes technology
Insulet Corporation, Clinical Department, Acton, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
Imperial College London, Electrical And Electronic Engineering, London, United Kingdom
Topic:
AS14‐Human factor in the use of diabetes technology
1Eli Lilly and Company, Gporwe, Indianapolis, United States of America, 2T1D Exchange, T1d Exchange, Boston, United States of America, 3Eli Lilly and Company, Value, Evidence, And Outcomes, Indianapolis, United States of America, 4Pediatric Endocrinology and Diabetes Specialists, Pediatrics, Charlotte, United States of America, 5Eli Lilly and Company, Diabetes Medical Affairs, Indianapolis, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1The diaTribe Foundation, Diabetes Education, San Francsico, United States of America, 2dQ&A Market Research Inc., Diabetes Research, San Francisco, United States of America, 3University Hospitals Leuven, Endocrinology, Leuven, Belgium
Topic:
AS14‐Human factor in the use of diabetes technology
I. Crisci, F. Baccetti, M. Mori,
ATNO Massa Carrara District, Centro Polispecialistico Monterosso, Carrara, Italy
Topic:
AS14‐Human factor in the use of diabetes technology
K. Cossen1,
1Children Hospital of Atlanta, Endocrinology, Atlanta, United States of America, 2T1D Exchange, Qi And Population Health, Boston, United States of America, 3Cincinnati Children Hospital, Endocrinology, Cincinnati, United States of America, 4SUNY Upstate Medical University, Pediatric Endocrinology, Syracuse, United States of America, 5University of Alabama at Birmingham, Endocrinology, Birmingham, United States of America, 6Albert Einstein College of Medicine, Endocrinology, Bronx, United States of America, 7University of Tennessee, Endocrinology, Nashville, United States of America, 8Nationwide Children Hospital, Endocrinology, Columbus, United States of America, 9Mount Sinai Hospital, Endocrinology, New York, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
O. Odugbesan1, A. Addala2, K. Gandhi3, N. Rioles1, N. Hawa Yayah Jones4, R. Izquierdo5, K. Cossen6, J. Schmitt7, S. Agarwal8, G. Nelson9, S. Dei‐Tutu10, D. Maahs2,
1T1D Exchange, Qi And Population Health, Boston, United States of America, 2Stanford University, Endocrinology, Stanford, United States of America, 3Nationwide Children Hospital, Endocrinology, Columbus, United States of America, 4Cincinnati Children's Hospital, Endocrinology, OH, United States of America, 5SUNY UPSTATE MEDICAL UNIVERSITY, Endocrinology, SY, United States of America, 6Children Hospital of Atlanta, Endocrinology, Atlanta, United States of America, 7University of Alabama at Birmingham, Endocrinology, Birmingham, United States of America, 8Albert Einstein College of Medicine, Endocrinology, Bronx, United States of America, 9University of Tennessee, Endocrinology, Nashville, United States of America, 10Texas Children Hospital, Endocrinology, Houston, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
Children's Natonal Hospital, Endocrinology, washington, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
E. Ye,
dQ&A Market Research, Inc., Patient And Outcomes Research, San Francisco, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
dQ&A Market Research Inc., Diabetes Research, San Francisco, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1Ann & Robert H. Lurie Children's Hospital of Chicago, Department Of Psychiatry And Behavioral Health, Chicago, United States of America, 2Johns Hopkins All Children's Hospital, Department Of Psychiatry, St. Petersburg, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1Barbara Davis Center, Pediatric Endocrinology, Denver, United States of America, 2Barbara Davis Center, Pediatric Endocrinology, Aurora, United States of America, 3University of Colorado Anschutz Medical Campus, College Of Nursing, aurora, United States of America, 4University of Colorado Anschutz Medical Campus, Barbara Davis Center For Diabetes, Aurora, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1The diaTribe Foundation, Diabetes Education, San Francsico, United States of America, 2dQ&A Market Research Inc., Diabetes Research, San Francisco, United States of America, 3University Hospitals Leuven, Endocrinology, Leuven, Belgium
Topic:
AS14‐Human factor in the use of diabetes technology
Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany
Topic:
AS14‐Human factor in the use of diabetes technology
1Hospital Universitario Son Llàtzer. Health Research Institute of the Balearic Islands (IdISBa) ., Endocrinology And Nutrition, Palma, Spain, 2Hospital Ca'n Misses, 2endocrinology And Nutrition Department, Eivissa, Spain, 3Son Espases University Hospital, Endocrinology, PALMA DE MALLORCA, Spain
Topic:
AS14‐Human factor in the use of diabetes technology
1Forschungsinstitut der Diabetes‐Akademie Bad Mergentheim (FIDAM), Universität Bamberg, Diabetes‐zentrum Mergentheim, Bamberg, Germany, 2Centre Hospitalier Sud Francilien, Université Paris‐Saclay, Diabetology Department, Paris, France, 3Somerset NHS Foundation Trust, Taunton, Somerset, United Kingdom, 4Carenity, 1 Rue De Stockholm, Paris, France, 5Sanofi, General Medicines, Paris, France
Topic:
AS14‐Human factor in the use of diabetes technology
1Aalborg university, Health Science And Technology, Aalborg Ø, Denmark, 2Aalborg University, Health Science And Technology, Aalborg Ø, Denmark, 3Aalborg University Hospital, Steno Diabetes Center Nordjylland, Aalborg, Denmark, 4Aalborg University Hospital, Department Of Clinical Medicine, Aalborg, Denmark, 5Aalborg University, Department Of Health Science And Technology, Aalborg, Denmark
Topic:
AS14‐Human factor in the use of diabetes technology
Pace University, Graduate Studies, Pleasanville, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1dQ&A Market Research Inc., Diabetes Research, San Francisco, United States of America, 2Close Concerns, Diabetes Technology, San Francisco, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
K. Shankar,
Dexcom, Inc., Data Science, San Diego, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1Fitterfly Health Tech Pvt Ltd, Department Of Psychology & Wellbeing, Navi Mumbai, India, 2Jupiter Hospital, Department Of Endocrinology, Thane West, India, 3Dr Raskar Diabetes Clinic, Department Of Diabetes, Thane, India, 4Jupiter Hospital, Department Of Diabetes, Thane, India, 5Diabecare Diabetes & Thyroid Clinic, Department Of Endocrinology, Navi Mumbai, India, 6Private Clinic, Department Of Diabetes, Mumbai, India, 7My Diabetes Clinic, Department Of Diabetes, Thane, India, 8Apollo Hospital, Department Of Endocrinology, Navi Mumbai, India, 9Fitterfly Healthtech Pvt Ltd, Department Of Nutrition, Navi Mumbai, India
Topic:
AS14‐Human factor in the use of diabetes technology
1University of Padova, Department Of Information Engineering, Padova, Italy, 2University of Padova, Department Of Woman And Child's Health, Padova, Italy, 3Becton, Dickinson and Company, Medical Affairs, Eysins, Switzerland
Topic:
AS14‐Human factor in the use of diabetes technology
1Fitterfly Health Tech Pvt Ltd, Department Of Psychology & Wellbeing, Navi Mumbai, India, 2Fitterfly Health Tech Pvt Ltd, Department Of Nutrition, Navi Mumbai, India, 3De Care Clinic, Department Of Diabetes, Thane, India, 4Diabetes Care Clinic, Department Of Diabetes, Navi Mumbai, India, 5Dr Sarwate Diabetes Control & footcare Centre, Department Of Diabetes, Thane, India, 6Diab Connect Clinic, Department Of Diabetes, Mumbai, India, 7The Clinic, Department Of Diabetes, Mumbai, India, 8Bharati Hospital, Department Of Endocrinology, Haryana, India
Topic:
AS14‐Human factor in the use of diabetes technology
1Department of Women's and Children's Health, Azienda Ospedale Università di Padova, Padua, Italy, Pediatric Diabetes Unit, PADOVA, Italy, 2University of Padova, Department Of General Psychology, Padova, Italy
Topic:
AS14‐Human factor in the use of diabetes technology
1Prayas Diabetes Center, Diabetology, Indore City, India, 2Samarpan Clinic, Diabetology, Omerga, India
Topic:
AS14‐Human factor in the use of diabetes technology
J. Madrid‐Valero1,
1University of Alicante, Department Of Health Psychology, Faculty Of Health Sciences, Alicante, Spain, 2Goldsmiths, University of London, Department Of Psychology, London, United Kingdom, 3University of Cambridge, Wellcome‐mrc Institute Of Metabolic Science‐metabolic Research Laboratories And Medical Research Council Metabolic Diseases Unit, Cambridge, United Kingdom, 4University of Cambridge, Department Of Paediatrics, Cambridge, United Kingdom, 5Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes And Endocrine Clinic, Cambridge, United Kingdom, 6Centre Hospitalier de Luxembourg, Deccp, Clinique Pédiatrique, Luxembourg, Luxembourg, 7UZ‐VUB, Department Of Paediatric Endocrinology, Brussels, Belgium, 8Leeds Children's Hospital, Department Of Paediatric Diabetes, Leeds, United Kingdom, 9Jaeb Center for Health Research, Jchr, Tampa, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1UiT The Arctic University of Norway, Department Of Community Medicine, Tromsø, Norway, 2UiT The Arctic University of Norway, Department Of Health And Caring Sciences, Tromsø, Norway, 3UiT The Arctic University of Norway, Department Of Computer Science, Tromsø, Norway
Topic:
AS14‐Human factor in the use of diabetes technology
J. Stevenson1,
1dQ&A Market Research Inc., Diabetes Research, San Francisco, United States of America, 2Close Concerns, Diabetes Technology, San Francisco, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
1Capillary Biomedical Inc, Capbio, Irvine, United States of America, 2Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria
Topic:
AS14‐Human factor in the use of diabetes technology
C. Fallon1, E. Jones1,2, N. Oliver1,2, M. Reddy1,2,
1Imperial College London, Department Of Metabolism, Digestion And Reproduction, London, United Kingdom, 2Imperial College Healthcare NHS Trust, Department Of Diabetes And Endocrinology, London, United Kingdom
Topic:
AS14‐Human factor in the use of diabetes technology
IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Pediatrics, Bologna, Italy
Topic:
AS14‐Human factor in the use of diabetes technology
S. Painter1, R. James2,
1Teladoc Health, Clinical Research And Analytics, Purchase, United States of America, 2Teladoc Health, Clinical Research And Analytics, Mountain View, United States of America, 3University of California, Department Of Medicine, San Francisco, United States of America, 4Teladoc Health, International Case Manager, Barcelona, Spain, 5Duke University, School Of Medicine, Durham, United States of America
Members had a mean change in hA1c of 0.13% (SD 0.70) and eA1c of 0.01% (0.64%). Figure 1 shows similar hA1c and eA1c changes by Fall 2020 A1c value. A strong, positive correlation was shown between eA1c and hA1c (r2 = 0.69).
Topic:
AS14‐Human factor in the use of diabetes technology
F. Mena‐Salas, N. Tapia, M.T. Onetto,
Universidad Católica de Chile, Department Of Nutrition, Diabetes And Metabolism, School Of Medicine., santiago, Chile
Topic:
AS14‐Human factor in the use of diabetes technology
1Royal Manchester Children's Hospital, Dept Paediatric Endocrinology, Manchester, United Kingdom, 2University of Manchester, Department Of Computer Science, Manchester, United Kingdom, 3University of Manchester, Facultyof Biology, Medicine And Health, Manchester, United Kingdom, 4University of Manchester, Faculty Of Biology, Medicine And Health, Manchester, United Kingdom
Topic:
AS14‐Human factor in the use of diabetes technology
The Ohio State University, Internal Medicine/division Of Endocrinology, Diabetes, And Metabolism, Columbus, United States of America
Topic:
AS14‐Human factor in the use of diabetes technology
V. Glocker1, S. Bachmann1,2, M. Hess1,2, U. Zumsteg1,2, G. Szinnai1,2,
1University Children's Hospital Basel, Pediatric Endocrinology And Diabetology, Basel, Switzerland, 2University of Basel, Department Of Clinical Research, Basel, Switzerland
Topic:
AS14‐Human factor in the use of diabetes technology
1Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany, 2Science Consulting in Diabetes GmbH, Profil Neuss, Neuss, Germany
Topic:
AS14‐Human factor in the use of diabetes technology
1Science Consulting in Diabetes GmbH, Profil Neuss, Neuss, Germany, 2Research Institute Diabetes‐Academy Bad Mergentheim, Fidam, Bad Mergentheim, Germany
Topic:
AS15‐Trials in progress
1First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Department Of Endocrinology, Moscow, Russian Federation, 2"CardioQVARK", "cardioqvark", Moscow, Russian Federation
Topic:
AS15‐Trials in progress
1Sheba Medical Center, Edmond and Lily Safra Children's Hospital, Pediatric Endocrinolgy, Ramat Gan, Israel, 2Sheba Medical Center, Edmond and Lily Safra Children's Hospital, Pediatric Endocrinolgy, Ramat gan, Israel, 3The Hebrew University of Jerusalem, Institute Of Biochemistry, Food Science And Nutrition, Robert H. Smith Faculty Of Agriculture, Food And Environment, Rehovot, Israel
Topic:
AS15‐Trials in progress
1University of Southern Denmark, Department Of Psychology, Odense, Denmark, 2King's College London,, Department Of Diabetes, School Of Life Course Sciences, Faculty Of Life Sciences And Medicine, London, United Kingdom, 3Radboud University Medical Centre, Radboud Institute for Health Sciences, Department Of Medical Psychology, Nijmegen, Netherlands, 4Tilburg University, Department Of Medical And Clinical Psychology, Tilburg, Netherlands, 5National treatment and research center for children, adolescents and adults with type 1 diabetes, Diabeter, Rotterdam, Netherlands, 6University of Sheffield, School Of Health And Related Research (scharr), University Of Sheffield, Sheffield, United Kingdom, 7Medical University of Graz, Division Of Endocrinology And Diabetology, Graz, Austria, 8Novo Nordisk A/S, Digital Therapeutics, Scientific Modelling, Søborg, Denmark, 9University of Duisburg‐Essen, . Department Of Clinical Psychology, Essen, Germany, 10University of Sheffield, Department Of Oncology And Metabolism, Sheffield, United Kingdom, 11Nordsjællands Hospital, Hillerød, Department Of Endocrinology And Nephrology, Hillerød, Denmark, 12University of Dundee, Systems Medicine, School Of Medicine, Dundee, United Kingdom, 13Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France, 14University of Cambridge, Wellcome Trust‐mrc Institute Of Metabolic Science, Cambridge, United Kingdom, 15Radboud University Medical Centre, Department Of Internal Medicine, Nijmegen, Netherlands, 16Maastricht University Medical Centre, . Department Of Internal Medicine, Division Of Endocrinology And Metabolic Disease, Maastricht, Netherlands, 17Maastricht University, Carim School For Cardiovascular Diseas, Maastricht, Netherlands, 18Deakin University, School Of Psychology, Geelong, Australia, 19Diabetes Victoria, The Australian Centre For Behavioural Research In Diabetes, Melbourne, Australia, 20Steno Diabetes Center Odense (SDCO), Steno Diabetes Center Odense (sdco), Odense, Denmark
Topic:
AS15‐Trials in progress
Copenhagen University Hospital ‐Steno Diabetes Center Copenhagen, Clinical Research, Herlev, Denmark
Topic:
AS15‐Trials in progress
Amsterdam University Medical Centers, Department Of Medical Psychology, Amsterdam, Netherlands
Topic:
AS15‐Trials in progress
1Medical University of Graz, Internal Medicine, Div. Of Endocrinology And Diabetology, Graz, Austria, 2University of Bayreuth, Exercise Physiology & Metabolism, Institute Of Sports Science, Bayreuth, Germany, 3Medical University of Graz, Clinical Division Of Cardiology, Graz, Austria
Topic:
AS15‐Trials in progress
1National and Kapodistrian University of Athens, Medical School, "Aghia Sophia" Children' s Hospital, First Department Of Pediatrics, Division Of Endocrinology, Diabetes And Metabolism, Athens, Greece, 2National Technical University of Athens,, School Of Electrical And Computer Engineering, Athens, Greece, 3UBITECH, Research And Development Department, Chalandri, Greece, 4Inspiring Earth, Pegneon, Athens, Greece
Topic:
AS15‐Trials in progress
1Institute of clinical sciences at Sahlgrenska Academy, Gothenburg University, Department Of Pediatrics, Gothenburg, Sweden, 2Hospital of Halland, Department Of Pediatrics, Kungsbacka, Sweden
Topic:
AS15‐Trials in progress
1Antwerp University Hospital, Department Of Endocrinology, Diabetology And Metabolism, Edegem, Belgium, 2University of Antwerp, Laboratory Of Experimental Medicine And Pediatrics And Member Of The Infla‐med Centre Of Excellence, Wilrijk, Belgium, 3Indigo Diabetes n.v., Medical Devices, Gent, Belgium, 4Montpellier University Hospital, Endocrinology, Diabetes, Nutrition, Montpellier, France, 5University of Montpellier, Institute Of Functional Genomics, Montpellier, France, 6Montpellier University Hospital, Department Of Endocrinology, Diabetes, Nutrition, Montpellier, France, 7University of Montpellier, Institute Of Functionnal Genomics, Inserm, Cnrs, Montpellier, France, 8Campus Bio‐Medico, Endocrinology And Metabolic Diseases, Roma, Italy, 9Antwerp University, Medicine & Health Science, Wilrijk, Belgium
Topic:
AS16‐COVID‐19 and Diabetes
Sidra Medicine, Diabetes And Endocrine, Doha, Qatar
Topic:
AS16‐COVID‐19 and Diabetes
R. Gowen,
dQ&A Market Research, Patient And Outcomes Research, San Francisco, United States of America
Topic:
AS16‐COVID‐19 and Diabetes
S. Andrikopoulos1,
1Australian Diabetes Society, 145 Macquarie Street, Sydney, Australia, 2National Association of Diabetes Centres, 145 Macquarie Street, Sydney, Australia
Topic:
AS16‐COVID‐19 and Diabetes
G. Cornadó1, C. Martín‐Polo2, E. Queral‐Martínez2, D. Patricio‐Peña2,
1Institut Català de la Salut, Assir (sexual And Reproductive Health Care), Reus, Spain, 2Institut Català de la Salut, Assir (sexual And Reproductive Health Care), Tarragona, Spain, 3IDIAP Jordi Gol, Primary Care, Tarragona, Spain, 4Institut Català de la Salut, Primary Care. Abs "sant Pere Centre"‐reus‐1, Reus, Spain
Topic:
AS16‐COVID‐19 and Diabetes
1Virgen del Rocío University Hospital, Department Of Endocrinology And Nutrition, Seville, Spain, 2University of Leicester, Leicester General Hospital, 1. leicester Diabetes Centre – Bloom, Leicester, United Kingdom, 3Founder, ééndiabetes foundation, ééndiabetes Foundation, Netherlands, Netherlands, 4Founder of Digital Health Groupe and German Institute of Telemedicine, Founder Of Digital Health Groupe And German Institute Of Telemedicine, Frankfurt, Germany, 5Universita Cattolica del Sacro Cuore, School Of Healthcare Systems, Economics And Management, Roma, Italy, 6Hôpital Henri Mondor, Ap‐hp Santé Publique, Creteil, France, 7Faculty of Health Sciences, University of Southern Denmark, Danish Centre For Health Economics (dache), Denmark, Denmark
Topic:
AS16‐COVID‐19 and Diabetes
1Clinic Hietzing, Vienna Health Care Group, 3rd Department Of Medicine Iii And Karl Landsteiner Institute For Metabolic Diseases And Nephrology, Vienna, Austria, 2Clinic Hietzing, Vienna Health Care Group, Department Of Pneumology, Wien, Austria
Topic:
AS16‐COVID‐19 and Diabetes
1University Hospital Antwerp, Pediatric Endocrinology, Edegem, Belgium, 2University Hospital Antwerp, Pediatrics, Edegem, Belgium, 3University of Antwerp (UA), Faculty of Medicine & Health Science, Laboratory Of Experimental Medicine And Pediatrics (lemp), Edegem, Belgium
Topic:
AS16‐COVID‐19 and Diabetes
1Fundación Santa Fe de Bogota, Endocrinology, Bogota, Colombia, 2FUNDACION SANTA FE DE BOGOTA, Endocrinologia, Bogotá, Colombia
Topic:
AS16‐COVID‐19 and Diabetes
1Cruces University Hospital, Endocrinology And Nutrition, Bilbao, Spain, 2Cruces University Hospital, Endocrinology, Bilbao, Spain, 3Virgen del Rocío University Hospital, Endocrinology And Nutrition, Seville, Spain
Topic:
AS16‐COVID‐19 and Diabetes
1Ibn Aljazzar Hospital, Endocrinology Departement,, Kairouan, Tunisia, 2Ibn Aljazzar Hospital, Endocrinology Departement,, khniss, Tunisia
Topic:
AS16‐COVID‐19 and Diabetes
NPJSC «Karaganda Medical University», Internal Medicine, Karaganda, Kazakhstan
Topic:
AS16‐COVID‐19 and Diabetes
1Medical University Varna, Pediatrics, Varna, Bulgaria, 2UMHAT St Marina, Pediatrics, Varna, Bulgaria, 3UMHAT St Marina, Clinical Laboratory, Varna, Bulgaria, 4Medical University Varna, Clinical Laboratory, Varna, Bulgaria
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Luxembourg Institute of Health, Department Of Population Health, LUXEMBOURG, Luxembourg, 2Luxembourg Institute of Health, Department Of Population Health, Deep Digital Phenotyping Research Unit, LUXEMBOURG, Luxembourg
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Oregon Health & Science University, Biomedical Engineering, Portland, United States of America, 2JAEB Center for Health Research, Clinical Research, Tampa, United States of America, 3Jaeb Center for Health Research, N/a, Tampa, United States of America, 4Oregon Health & Science University, Endocrinology, Portland, United States of America, 5Children's Mercy Kansas City, Pediatric Endocrinology, Kansas City, United States of America, 6Harvard University, John A. Paulson School Of Engineering And Applied Sciences, Cambridge, United States of America, 7Louisiana State University, Pennington Biomedical Research Center, Baton Rouge, United States of America, 8University of Pennsylvania, Perelman School of Medicine, Rodebaugh Diabetes Center, Philadelphia, United States of America, 9Nemours Children's Health System, Nemours Center For Healthcare Delivery Science, Jacksonville, United States of America, 10York University, School Of Kinesiology And Health Science, Toronto, Canada
Topic:
AS17‐Big data and artificial intelligence based decision support systems
GluCare Integrated Diabetes Center, Diabetes, DUBAI, United Arab Emirates
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Osaka University, Human Sciences, Suita City, Osaka, Japan, 2Osaka University, Health And Counseling Center, Toyonaka City, Osaka, Japan
Diabetes was defined as fasting plasma glucose of ≥126 mg/dL or HbA1c of ≥6.5%, and self‐report. Models were developed using LightGBM and logistic regression. Their reliability was measured in expected calibration error (ECE), Negative log‐likelihood(logloss), and reliability diagram. Also, we analyzed their reliability while changing the sample size for training.
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Imperial College London, Computing, London, United Kingdom, 2Imperial College London, Department Of Electrical And Electronic Engineering, London, United Kingdom, 3Imperial College London, Diabetes And Endocrinology, London, United Kingdom
Topic:
AS17‐Big data and artificial intelligence based decision support systems
S. Di1,2, J. Petch2,3,4,5,
1University of Toronto, Dalla Lana School Of Public Health, Toronto, Canada, 2Hamilton Health Sciences, Centre For Data Science And Digital Health, Hamilton, Canada, 3University of Toronto, Institute Of Health Policy, Management And Evaluation, Toronto, Canada, 4McMaster University, Department Of Medicine, Faculty Of Health Sciences, Hamilton, Canada, 5Hamilton Health Sciences, Population Health Research Institute, Hamilton, Canada, 6McMaster University, School Of Nursing, Hamilton, Canada
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Nara Institute of Science and Technology, Graduate School Of Science And Technology, Nara, Japan, 2Suntory Global Innovation Center Limited, Research Institute, Kyoto, Japan, 3Japan Business Division, Suntory Beverage & Food Limited, Development & Design Department, Kanagawa, Japan, 4Suntory Holdings Limited, Research Planning Department, Tokyo, Japan, 5Keio University School of Medicine, Department Of Biochemistry, Tokyo, Japan, 6Nara Institute of Science and Technology, Data Science Center, Nara, Japan
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1University of Southern California, Occupational Science And Occupational Therapy, Los Angeles, United States of America, 2University of Southern California, Center For Economic And Social Research, LOS ANGELES, United States of America, 3University of Southern California, Keck School of Medicine, Medicine, Los Angeles, United States of America, 4Albert Einstein College of Medicine, Department Of Medicine (endocrinology), Bronx, United States of America, 5Yeshiva University, Department Of Psychology, Bronx, United States of America
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Norwegian University of Science and Technology, Department Of Electronics System, Trondheim, Norway, 2Norwegian University of Science and Technology, Department Of Engineering Cybernetics, Trondheim, Norway
Topic:
AS17‐Big data and artificial intelligence based decision support systems
D. Haldimann,
SNAQ AG, Snaq Ag, Winterthur, Switzerland
Topic:
AS17‐Big data and artificial intelligence based decision support systems
J. Petch1,2,3,4,
1University of Toronto, Institute Of Health Policy, Management And Evaluation, Toronto, Canada, 2Hamilton Health Sciences, Centre For Data Science And Digital Health, Hamilton, Canada, 3McMaster University, Department Of Medicine, Faculty Of Health Sciences, Hamilton, Canada, 4Hamilton Health Sciences, Population Health Research Institute, Hamilton, Canada, 5Massachusetts Institute of Technology, Institute For Medical Engineering And Science, Boston, United States of America, 6University of Tuebingen, International Max Planck Research School (imprs) For Intelligent Systems (is), Tübingen, Germany
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Imperial College London, Centre For Bio‐inspired Technology, Electrical And Electronic Engineering, London, United Kingdom, 2University College London, Institute Of Health Informatics, London, United Kingdom
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Digital Diabetes Analytics Sweden AB, ., Stockholm, Sweden, 2Uppsala University, 2. department Of Women's And Children's Health, Uppsala, Sweden, 3Diabetes Center Berne, ., Bern, Switzerland, 4Uppsala University, Department Of Medical Cell Biology, Uppsala, Sweden, 5Uppsala University, Department Of Medical Sciences, Uppsala, Sweden, 6Uppsala University, Science For Life Laboratory, Department Of Medical Sciences, Uppsala, Sweden, 7Uppsala University, Science For Life Laboratory, Department Of Medical Cell Biology, Uppsala, Sweden
Topic:
AS17‐Big data and artificial intelligence based decision support systems
Hospital Dona Estefânia, Pediatric Endocrinology, Lisboa, Portugal
Topic:
AS17‐Big data and artificial intelligence based decision support systems
G. Tabella,
Norwegian University of Science and Technology, Department Of Electronics System, Trondheim, Norway
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Oregon Health and Sciences University, Biomedical Engineering, Portland, United States of America, 2Oregon Health and Sciences University, Endocrinology, Portland, United States of America
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Twin Health, Diabetes, MOUNTAIN VIEW, United States of America, 2Children's Hospital Los Angeles, Diabetes, Los Angeles, United States of America, 3Twin Health, Diabetes, Bangalore, India
Topic:
AS17‐Big data and artificial intelligence based decision support systems
J. Alvarado Díaz1, J. Manuel Velasco1, M. Botella2, E. Maqueda3, F. Fernández De Vega4,
1Complutense University of Madrid, Department Of Computer Architecture And Automatics, Madrid, Spain, 2Hospital Universitario Príncipe de Asturias, Endocrinology And Nutrition Service, Alcalá de Henares, Spain, 3Hospital Virgen de la Salud, Endocrinology And Nutrition Service, Toledo, Spain, 4Universidad de Extremadura, Departamento De Tecnología De Los Computadores Y De Las Comunicaciones, Mérida, Spain
Topic:
AS17‐Big data and artificial intelligence based decision support systems
Fomin Women's Health Clinic, Endocrinology, Moscow, Russian Federation
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Roche Diabetes Care Inc., Math Algorithms And Data Science, Indianapolis, United States of America, 2Genentech/Roche, Pharma Informatics Phc, San Francisco, United States of America, 3F. Hoffmann‐La Roche, Product & Service Management Chapter, Basel, Switzerland, 4Roche Diabetes Care Inc., Strategy And Customer Solutions, Indianapolis, United States of America, 5F. Hoffmann‐La Roche, Integrative Neuroscience And Medical Practicescience, Basel, Switzerland
Topic:
AS11‐Advanced Medical Technologies to Be Used in Hospitals
1Boston Scientific, Galway, Ireland, Research And Development Department, Galway, Ireland, 2Eberhard Karls University Tübingen, Department Of Biomedical Engineering, Tübingen, Germany, 3Anatomy and Regenerative Medicine Institute (REMEDI), National University Of Ireland Galway, Galway, Ireland, 4University of Tuebingen, Cluster Of Excellence Ifit (exc 2180) “image‐guided And Functionally Instructed Tumor Therapies, Tübingen, Germany, 5Natural and Medical Sciences Institute (NMI) at the University of Tübingen, Natural And Medical Sciences Institute, Reutlingen, Germany, 6David Geffen School of Medicine at UCLA, Department Of Medicine/cardiology, Cardiovascular Research Laboratories, Los Angeles, United States of America
Topic:
AS16‐COVID‐19 and Diabetes
Osp. Civico Partinico, Endocrinology, Partinico, Italy
Topic:
AS01‐Closed‐loop System and Algorithm
V. Balla1, J. Eroukhmanoff1, K. Ly Sall1, P. Huynh1, A. Daoudi1, A. Pochat1, C. Petit1, D. Dardari1, M. Lejeune1, A. Penfornis2,
1Sud Francilien Hospital, Diabetes, Corbeil‐Essonnes, France, 2Sud Francilien Hospital‐ Paris‐Saclay University, Diabetes, Corbeil‐Essonnes, France
Topic:
AS03‐Artificial Pancreas
M. Jaloli,
University of Houston, Mechanical Engineering, Houston, United States of America
ATTD 2022 Read by Title
Topic:
AS01‐Closed‐loop System and Algorithm
Endocrinology and Diabetes Unit, ASL Salerno, Salerno, Italy., Asl Salerno, Cava De' Tirreni ‐ Salerno (SA), Italy
Topic:
AS01‐Closed‐loop System and Algorithm
1Pontificia Universidad Católica de Chile, Departamento De Nutrición, Diabetes Y Metabolismo, santiago, Chile, 2Pontificia Universidad Católica de Chile, Escuela De Medicina, Santiago, Chile
Topic:
AS02‐New Insulin Analogues
Hospital Regional de Málaga, Endocrinology, Málaga, Spain
Topic:
AS04‐Clinical Decision Support Systems/Advisors
Sun Yat‐Sen University, Nursing, guangzhou, China
Topic:
AS04‐Clinical Decision Support Systems/Advisors
1Penn State College of Medicine, Medicine/endocrinology, Hershey, United States of America, 2Penn State College of Medicine, Medicine, Hershey, United States of America
Topic:
AS05‐Glucose Sensors
1Mount Sinai Medical Center, Internal Medicine, Miami, United States of America, 2Mount Sinai Medical Center, Diabetes, Endocrinology And Metabolism, Miami, United States of America
Topic:
AS05‐Glucose Sensors
1AMCR Institute, Ceo, Escondido, United States of America, 2PKvitality SAS, R&d, Danvers, United States of America, 3PKvitality SAS, Clinical Affairs, Paris, France, 4PKvitality SAS, Ceo, Paris, France
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
M. Baretić1,2,
1University of Zagreb, School Of Medicine, Zagreb, Croatia, 2University Hospital Centre Zagreb, Department Of Endocrinology And Diabetes, Zagreb, Croatia, 3University of Zagreb ‐ Faculty of Humanities and Social Sciences, Department Of Information And Communication Sciences, Zagreb, Croatia, 4Private General Practitioner's Office, General Practice, Zagreb, Croatia, 5Faculty of Economics in Zagreb, Department Of Informatics, Zagreb, Croatia
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1King's College London, Diabetes, London, United Kingdom, 2King's College Hospital, Diabetes, London, United Kingdom, 3Living With, Healthtech Development, London, United Kingdom, 4King's College London, Methodologies, London, United Kingdom, 5King's College London, Psychiatry, London, United Kingdom
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University of British Columbia, Pediatrics, Vancouver, Canada, 2University of Victoria, Health Information Science, Victoria, Canada
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1Scuola Superiore Sant'Anna, Management, Pisa, Italy, 2USL Toscana Centro, Nursing, Firenze, Italy, 3Università degli Studi di Firenze, Dinfo, Firenze, Italy, 4PIN, Pin, Prato, Italy
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
Uppsala University, Department Of Medical Sciences, Uppsala, Sweden
Topic:
AS06‐Informatics in the Service of Medicine; Telemedicine, Software and other Technologies
1University Hospital of Southern Denmark, Department Of Internal Medicine, Sonderborg, Denmark, 2Odense University Hospital, Centre For Innovative Medical Technology, Odense, Denmark, 3University of Southern Denmark, Department Of Regional Health Research, Sonderborg, Denmark
Topic:
AS07‐Insulin Pumps
Comprehensive Diabetes Centre, Diabetology, Nairobi, Kenya
Topic:
AS08‐New Medications for Treatment of Diabetes
Gold Coast University Hospital, Endocrinology, Southport, Australia
Topic:
AS08‐New Medications for Treatment of Diabetes
Scientific Centre for Family Health and Human Reproduction Problems, Department Of Personalized And Preventive Medicine, Irkutsk, Russian Federation
Topic:
AS10‐Devices Focused on Diabetic Preventions
University Hospital, Endocrinology‐internal Medicine, Monastir, Tunisia
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
1Privolzhsky research medical university, Institute Of Biomedical Technologies, Nizhny Novgorod, Russian Federation, 2Privolzhsky research medical university, Department Of Faculty Surgery And Transplantology, Nizhny Novgorod, Russian Federation, 3N.A. Semashko Nizhny Novgorod Regional Clinical Hospital, Abdominal Surgery Center, Nizhny Novgorod, Russian Federation, 4Lobachevsky State University of Nizhny Novgorod, Institute Of Biology And Biomedicine, Nizhny Novgorod, Russian Federation
Topic:
AS12‐New Technologies for Treating Obesity and Preventing Related Diabetes
National Medical Research Centre for Cardiology, Department Of Angiogenesis, Moscow, Russian Federation
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
King George's Medical University, Physiology, Lucknow, India
Topic:
AS13‐Blood Glucose Monitoring and Glycemic Control in the Hospitals
1University of Cantabria/IDIVAL, Health Economics And Health Services Management Research Group, Idival & Departament Of Business And Management, Santander, Spain, 2University of Cantabria/IDIVAL, Health Economics And Health Services Management Research Group, Idival & Departament Of Economics, Santander, Spain, 3University Hospital Marques de Valdecilla, Head Of The Department Of Endocrinology, Santander, Spain, 4IDIVAL, Health Economics And Health Services Management Research Group, Santander, Spain, 5Servicio Cantabro de Salud, Head Of The Department Of Pharmacology Management Service, Santander, Spain
Topic:
AS14‐Human factor in the use of diabetes technology
Academic Primary Health Care Centre, Region Stockholm and Karolinska Institutet, Family Medicine And Primary Health Care, Stockholm, Sweden
Topic:
AS14‐Human factor in the use of diabetes technology
Città della Salute e della Scienza, Dipartimento Di Scienze Pubbliche E Pediatriche, Torino, Italy
Topic:
AS14‐Human factor in the use of diabetes technology
Universidad Católica de Chile, Department Of Nutrition, Diabetes And Metabolism, School Of Medicine., santiago, Chile
Topic:
AS17‐Big data and artificial intelligence based decision support systems
1Imperial College London, Centre For Bio‐inspired Technology, Electrical And Electronic Engineering, London, United Kingdom, 2University College London, Institute Of Health Informatics, London, United Kingdom
Topic:
AS17‐Big data and artificial intelligence based decision support systems
J. Noguer1,
1Universitat de Girona, Electric, Electronic And Automatic Engineering, Girona, Spain, 2University of Girona, Institute Of Informatics And Applications, Girona, Spain